var title_f24_12_24768="ICE mitral stenosis 2";
var content_f24_12_24768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    ICE mitral stenosis 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 203px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intracardiac examination shows a severely deformed mitral valve with extreme thickening of valve leaflets and subvalvular apparatus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24768=[""].join("\n");
var outline_f24_12_24768=null;
var title_f24_12_24769="Large septated fetal cystic hygroma with hydrops";
var content_f24_12_24769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial image of the fetal head of an early second trimester fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surrounding the fetal cranium is a large septated cystic hygroma. The fluid extends beyond the nuchal region and diffusely involves the skin throughout the fetus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24769=[""].join("\n");
var outline_f24_12_24769=null;
var title_f24_12_24770="Modified Martius fat pad graft4";
var content_f24_12_24770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Modified Martius fat pad graft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The graft is secured at its edges with interrupted sutures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24770=[""].join("\n");
var outline_f24_12_24770=null;
var title_f24_12_24771="Empyema with calcifications";
var content_f24_12_24771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Empyema with calcifications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Empyema due to previous pneumothorax therapy for cavitary tuberculosis. Left: Chest radiograph shows large right sided pleural mass with a sharp border towards the lung and obtuse angles of interface towards the chest wall. Slight caudad \"drooping\" is visible. Pleural calcifications are present. The lateral costophrenic sulcus is obscured. Right: CT scan shows a large loculated collection of liquid in the right hemithorax with obvious calcifications of the visceral and parietal pleura. Restrictive changes are evident and account for the small size of the right hemithorax. The thickness of the extrapleural fat in the posterolateral aspect of the right hemithorax is increased when compared to the left side. This compensates for the low lung volume on the right side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24771=[""].join("\n");
var outline_f24_12_24771=null;
var title_f24_12_24772="Atopic dermatitis infantile I";
var content_f24_12_24772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77457%7EPI%2F57650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77457%7EPI%2F57650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis: infantile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent erythema, microvesiculation, scaling, and crusting on the face, with similar involvement (to a lesser degree) on the trunk and arms. The facial involvement is more severe due to easier access to scratching; the baby is squeezing the breast skin to relieve the intense pruritus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright &copy; McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis on the backs of the knees",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 218px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atopic dermatitis often affects the crease of the skin where the leg bends.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24772=[""].join("\n");
var outline_f24_12_24772=null;
var title_f24_12_24773="CPA radiographs";
var content_f24_12_24773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Chronic pulmonary aspergillosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 472px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Chest radiograph in 1969 in a patient aged 24 with asthma with bronchiectasis showing mild left mid zone shadows consistent with bronchiectasis and a small area of opacification in the left base, with left apical scarring. New streaky shadowing is projected over the left heart border.",
"    <br>",
"     (B) Chest radiograph in same patient in 1981 (aged 36) following first radiological feature of ABPA (clearance of the left upper lobe shadowing after physiotherapy and corticosteroids). Compared with 1969, there is now extensive bronchiectasis in the left lower and right lower lobes.",
"     <br>",
"      (C) Chest radiograph in same patient in 1985 (aged 40), with first clue of chronic cavitary pulmonary aspergillosis. The chest radiograph shows development of right upper pleural thickening with further volume loss, without extensive fibrotic disease. There is more obvious new cavity formation in the left upper lobe with unchanged thickened bronchi in the left mid zone. A mild scoliosis has developed.",
"      <br>",
"       (D) Chest radiograph in same patient in 1995 (aged 50), showing interval development of scoliosis with bilateral upper lobe pleural thickening, worse on the right, with cavities in the left upper lobe and fullness of the right upper mediastinum. The features of central bronchiectasis, so characteristic of ABPA, are very prominent. She is significantly disabled by her disease now.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: The Aspergillus Website (file://www.aspergillus.org.uk/). Copyright &copy; 2010.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24773=[""].join("\n");
var outline_f24_12_24773=null;
var title_f24_12_24774="Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)";
var content_f24_12_24774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24774/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24774/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24774/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24774/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24774/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24774/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/12/24774/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Yersinia includes 11 species, 3 of which are important human pathogens: Yersinia pestis, Yersinia enterocolitica and Yersinia pseudotuberculosis. The yersinioses are zoonotic infections of domestic and wild animals; humans are considered incidental hosts that do not contribute to the natural disease cycle.",
"   </p>",
"   <p>",
"    Y. pestis causes plague and is transmitted by fleas. The most common clinical manifestation is acute febrile lymphadenitis, called bubonic plague. Less common forms include septicemia, pneumonia, pharyngeal and meningeal plague.",
"   </p>",
"   <p>",
"    The epidemiology, microbiology and pathogenesis of Yersinia pestis will be reviewed here. The clinical manifestations, diagnosis, and treatment of Yersinia pestis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to other Yersinia species are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31062?source=see_link\">",
"     \"Epidemiology of yersiniosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22373?source=see_link\">",
"     \"Microbiology and pathogenesis of Yersinia infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32885?source=see_link\">",
"     \"Treatment and prevention of Yersinia enterocolitica and Yersinia pseudotuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28585734\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major plague pandemics have been recorded in human history: in the 6th century, in the 14th century (known as the &lsquo;Black Death,&rsquo; which killed up to one-third of the European population or an estimated 17 to 28 million people [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/1\">",
"     1",
"    </a>",
"    ]), and at the end of 19th century following the spread of infection from China [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2\">",
"     2",
"    </a>",
"    ]. The plague bacillus was isolated during the third pandemic by Alexandre Yersin in 1894 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/3\">",
"     3",
"    </a>",
"    ]. Over the ensuing 20 years, Y. pestis spread via rats on steamships to port cities on all inhabited continents, including North America. The infection spread to various species of wild rodents, becoming entrenched in rural areas of the Americas, Africa and Asia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23343596\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plague is primarily a zoonotic infection of rodents and wild and domestic animals and is transmitted by fleas; humans are considered incidental hosts that do not contribute to the natural disease cycle. Enzootic plague is maintained in nature through flea-borne transmission between partially resistant rodents (enzootic or maintenance hosts). Intermittently infection may spread to more susceptible animals which function as epizootic or amplifying hosts. In such cases these more susceptible hosts may die in large numbers in an epidemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23343795\">",
"    <span class=\"h2\">",
"     Geographic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Areas of enzootic plague area include North America (mainly the southwestern United States and Pacific coastal area), the former Soviet Union, and foci in Africa, Asia, and South America (",
"    <a class=\"graphic graphic_figure graphicRef78203 \" href=\"UTD.htm?19/55/20341\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Between 1989 and 2003, 25 countries reported a total of 38,310 cases and 2845 deaths (7 percent fatality rate) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In 2000 and 2001, more than 95 percent of reported cases were from Africa, including approximately 40 percent from Madagascar [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/4\">",
"     4",
"    </a>",
"    ]. Outbreaks of human plague, with numbers of cases ranging from 100 to more than 1000, have occurred since 1992 in Zaire, Peru, and India [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/3\">",
"     3",
"    </a>",
"    ]. Plague reappeared in 1994 in Malawi, Mozambique, and India, raising concern that the disease may reemerge as a significant worldwide public health hazard [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. An increase in bubonic cases was noted in Uganda in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/9\">",
"     9",
"    </a>",
"    ]. These incidence data may be underestimates because diagnostic facilities and surveillance systems are inadequate in many areas of the world where plague is endemic or occurs in focal outbreaks. &nbsp;",
"   </p>",
"   <p>",
"    In the United States, plague is endemic in all of the western states and has extended north and east over the years. Ninety percent of human cases in the United States have occurred in four states: Arizona, California, Colorado, and New Mexico. Human disease has also been reported from Texas and Oklahoma and Oregon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In addition, animal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flea plague has been identified in western North Dakota and Nebraska.",
"   </p>",
"   <p>",
"    The rate of plague in the United States is low, probably because the affected areas are rural and largely uninhabited. Between 1987 and 2001, 125 cases were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. In 2006, a total of 13 human plague cases were reported among residents of four states: New Mexico, Colorado, California, and Texas; two cases were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23343802\">",
"    <span class=\"h2\">",
"     Routes of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans acquire plague via bites of rodent fleas, scratches or bites from infected domestic cats, direct handling of infected animal tissues, inhalation of respiratory secretions from infected animals, inhalation of aerosolized droplets from infected humans, or by laboratory exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2,10,13-15\">",
"     2,10,13-15",
"    </a>",
"    ]. Flea bites are the most common route of transmission of plague to humans, followed by contact with infected animals. In about 14 percent of cases, the source of infection is unknown.",
"   </p>",
"   <p>",
"    Animals acquire plague via bites of rodent fleas and ingestion of contaminated animal tissues. More than 200 mammalian species have been reported to be infected with Y. pestis, including squirrels, prairie dogs, rabbits, field mice, chipmunks, rats, bobcats, domestic cats, and camels. Rodents are the most important hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Domestic cats are important in the modern transmission of plague. Between 1977 and 1998, 23 human cases of plague associated with cats were reported by the US Centers for Disease Control and Prevention (CDC) from eight western states, representing 8 percent of the reported cases of plague during that time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/16\">",
"     16",
"    </a>",
"    ]. The incidence of infection did not increase during the summer months, unlike cases of plague associated with fleas. Inhalation was found to be more common as a route of acquisition involving cats than in other cases of plague. Approximately 25 percent of the cases resulting from contact with cats occurred among veterinarians and their assistants [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. Contact with fleas from household canine pets has also been implicated in human infection with Y. pestis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/11,17\">",
"     11,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 30 species of fleas are proven vectors of plague [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. The most efficient flea vector is Xenopsylla cheopis, the oriental rat flea; different flea vectors may be important in different regions. The most important flea vector in North America is Oropsylla montana [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plague could be used as a bioterrorism agent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Y. pestis is a gram-negative coccobacillus that exhibits bipolar staining with Giemsa, Wright&rsquo;s, or Wayson staining (",
"    <a class=\"graphic graphic_picture graphicRef81633 \" href=\"UTD.htm?33/15/34037\">",
"     picture 1",
"    </a>",
"    ). It grows aerobically on most culture media, including blood agar and MacConkey agar. Commercial automated laboratory identification systems may incorrectly identify Y. pestis as other species (eg, Acinetobacter or Pseudomonas) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/11\">",
"     11",
"    </a>",
"    ]. Laboratory technicians should be alerted regarding cases of suspected plague, as transmission can occur via laboratory exposure.",
"   </p>",
"   <p>",
"    Genetic studies indicate that Y. pestis evolved from the enteric pathogen Y. pseudotuberculosis shortly before the first known pandemics of human plague [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. This transition from an enteric to a flea-borne pathogen was made possible by the acquisition of two unique plasmids, coupled with the inactivation of genes required for survival in the mammalian gut [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2,5,23,24\">",
"     2,5,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three distinct biovars of the Y. pestis clone, Antiqua, Medievalis, and Orientalis, have been described, and a fourth biotype (Microtus) has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. These biovars appear to have emerged before any recorded epidemics. Genotyping performed on dental pulp from the remains of eight individuals who probably died in the first and second pandemics (6",
"    <sup>",
"     th",
"    </sup>",
"    century and 14",
"    <sup>",
"     th",
"    </sup>",
"    century respectively) identified sequences that matched those of the biovar Orientalis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of plague consists of two components: transmission of infection from fleas to the mammalian host, and the host response to infection.",
"   </p>",
"   <p>",
"    Fleas become infected by feeding on a bacteremic host. Y. pestis colonizes the flea midgut, replicates, and creates a blockage of the flea intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/24,27\">",
"     24,27",
"    </a>",
"    ]. Starved of sustenance, &ldquo;blocked&rdquo; fleas feed aggressively, regurgitating bacteria into the bite wound at each feed attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/3,28\">",
"     3,28",
"    </a>",
"    ]. It has been estimated the minimum infectious dose for mammals is less than 10 organisms by the subcutaneous route [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The invading organisms are carried via lymphatics to the regional lymph nodes, where they initiate an intense inflammatory reaction, creating a bubo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2\">",
"     2",
"    </a>",
"    ]. Survival and replication within macrophages is probably of greatest importance in the early stages of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/29\">",
"     29",
"    </a>",
"    ]. After dissemination, necrotic foci containing extracellular Y. pestis form and progressively increase in size [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This progressive extracellular course is facilitated by impairment of local immune cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacteremia is common and can lead to sepsis, pneumonia, and hemorrhagic lesions in various organs. In the absence of therapy, plague sepsis and endotoxemia lead to release of proinflammatory mediators. The resulting systemic inflammatory response syndrome may lead to disseminated intravascular coagulation, bleeding, organ failure, and shock [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/31\">",
"     31",
"    </a>",
"    ]. Affected tissues contain inflamed microvasculature occluded by fibrin thrombi, resulting in necrosis and hemorrhage. Purpuric skin lesions arise on the extremities and trunk; they begin with erythema and subsequently change to a dark purple, and in patients who survive, eventually slough. Gangrene can occur at the tips of the fingers, toes, ears and nose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24774/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22398451\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Yersinia pestis causes plague and is transmitted by fleas; it is a zoonotic infection of domestic and wild animals. Humans are considered incidental hosts that do not contribute to the natural disease cycle. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Areas of enzootic plague area include North America (mainly the southwestern United States and Pacific coastal area), the former Soviet Union, and foci in Africa, Asia, and South America (",
"      <a class=\"graphic graphic_figure graphicRef78203 \" href=\"UTD.htm?19/55/20341\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23343795\">",
"       'Geographic distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humans acquire plague via bites of rodent fleas, scratches or bites from infected domestic cats, direct handling of infected animal tissues, inhalation of respiratory secretions from infected animals, inhalation of aerosolized droplets from infected humans, or by laboratory exposure. (See",
"      <a class=\"local\" href=\"#H23343802\">",
"       'Routes of transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Y. pestis is a gram-negative coccobacillus that exhibits bipolar staining with Giemsa, Wright&rsquo;s, or Wayson staining. It grows aerobically on most culture media, including blood agar and MacConkey agar. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of plague consists of two components: transmission of infection from fleas to the mammalian host, and the host response to infection. It has been estimated the minimum infectious dose for mammals is less than 10 organisms by the subcutaneous route. The invading organisms are carried via lymphatics to the regional lymph nodes, where they initiate an intense inflammatory reaction, creating a bubo. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacteremia is common and can lead to sepsis, pneumonia, and hemorrhagic lesions in various organs. In the absence of therapy, plague sepsis and endotoxemia lead to release of proinflammatory mediators. The resulting systemic inflammatory response syndrome may lead to disseminated intravascular coagulation, bleeding, organ failure, and shock. Purpuric skin lesions can arise on the extremities and trunk. Gangrene can occur at the tips of the fingers, toes, ears and nose. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Drancourt M, Raoult D. Past plague. In: Paleomicrobiology: Past Human Infections, Raoult D, Drancourt M.  (Eds), Springer-Verlag, Berlin Heidelberg 2008. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/2\">",
"      Prentice MB, Rahalison L. Plague. Lancet 2007; 369:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/3\">",
"      Perry RD, Fetherston JD. Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev 1997; 10:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/4\">",
"      Human plague in 2000 and 2001. Wkly Epidemiol Rec 2003; 78:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/5\">",
"      Zhou D, Han Y, Yang R. Molecular and physiological insights into plague transmission, virulence and etiology. Microbes Infect 2006; 8:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/6\">",
"      Butler T. Yersinia infections: centennial of the discovery of the plague bacillus. Clin Infect Dis 1994; 19:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/7\">",
"      Campbell GL, Hughes JM. Plague in India: a new warning from an old nemesis. Ann Intern Med 1995; 122:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/8\">",
"      Human plague in 1994. Wkly Epidemiol Rec 1996; 71:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Bubonic and pneumonic plague - Uganda, 2006. MMWR Morb Mortal Wkly Rep 2009; 58:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Human plague--United States, 1993-1994. MMWR Morb Mortal Wkly Rep 1994; 43:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: two cases of human plague--Oregon, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Human plague--four states, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/13\">",
"      Crook LD, Tempest B. Plague. A clinical review of 27 cases. Arch Intern Med 1992; 152:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/14\">",
"      Weniger BG, Warren AJ, Forseth V, et al. Human bubonic plague transmitted by a domestic cat scratch. JAMA 1984; 251:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Fatal laboratory-acquired infection with an attenuated Yersinia pestis Strain--Chicago, Illinois, 2009. MMWR Morb Mortal Wkly Rep 2011; 60:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/16\">",
"      Gage KL, Dennis DT, Orloski KA, et al. Cases of cat-associated human plague in the Western US, 1977-1998. Clin Infect Dis 2000; 30:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/17\">",
"      Wang H, Cui Y, Wang Z, et al. A dog-associated primary pneumonic plague in Qinghai Province, China. Clin Infect Dis 2011; 52:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/18\">",
"      Laudisoit A, Leirs H, Makundi RH, et al. Plague and the human flea, Tanzania. Emerg Infect Dis 2007; 13:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/19\">",
"      Gage KL, Lance SE, Dennis DT, Montenieri JA. Human plague in the United States: A review of cases from 1988-1992 with comments on the likelihood of increased plague activity. Border Epidemiol Bull 1992; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/20\">",
"      Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/21\">",
"      Achtman M, Zurth K, Morelli G, et al. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc Natl Acad Sci U S A 1999; 96:14043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/22\">",
"      Achtman M, Morelli G, Zhu P, et al. Microevolution and history of the plague bacillus, Yersinia pestis. Proc Natl Acad Sci U S A 2004; 101:17837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/23\">",
"      Chain PS, Carniel E, Larimer FW, et al. Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis. Proc Natl Acad Sci U S A 2004; 101:13826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/24\">",
"      Hinnebusch BJ. The evolution of flea-borne transmission in Yersinia pestis. Curr Issues Mol Biol 2005; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/25\">",
"      Zhou D, Tong Z, Song Y, et al. Genetics of metabolic variations between Yersinia pestis biovars and the proposal of a new biovar, microtus. J Bacteriol 2004; 186:5147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/26\">",
"      Drancourt M, Roux V, Dang LV, et al. Genotyping, Orientalis-like Yersinia pestis, and plague pandemics. Emerg Infect Dis 2004; 10:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/27\">",
"      Hinnebusch BJ, Rudolph AE, Cherepanov P, et al. Role of Yersinia murine toxin in survival of Yersinia pestis in the midgut of the flea vector. Science 2002; 296:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/28\">",
"      Hinnebusch BJ, Perry RD, Schwan TG. Role of the Yersinia pestis hemin storage (hms) locus in the transmission of plague by fleas. Science 1996; 273:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/29\">",
"      Pujol C, Bliska JB. Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae. Clin Immunol 2005; 114:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/30\">",
"      Marketon MM, DePaolo RW, DeBord KL, et al. Plague bacteria target immune cells during infection. Science 2005; 309:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24774/abstract/31\">",
"      Butler T. A clinical study of bubonic plague. Observations of the 1970 Vietnam epidemic with emphasis on coagulation studies, skin histology and electrocardiograms. Am J Med 1972; 53:268.",
"     </a>",
"    </li>",
"    <li>",
"     David T. Dennis, Paul S. Mead. Yersinia Species, Including Plague. In: Principles and Pracitce of Infectious Diseases, seventh, Gerald L. Mandell, John E. Bennett, Raphael Dolin.  (Eds), Elsevier, Philadelphia 2010. p.2943.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3143 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24774=[""].join("\n");
var outline_f24_12_24774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22398451\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28585734\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23343596\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23343795\">",
"      Geographic distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23343802\">",
"      Routes of transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22398451\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3143|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/55/20341\" title=\"figure 1\">",
"      Global distribution of plague",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3143|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/15/34037\" title=\"picture 1\">",
"      Bipolar stain of Yersinia pestis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31062?source=related_link\">",
"      Epidemiology of yersiniosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22373?source=related_link\">",
"      Microbiology and pathogenesis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32885?source=related_link\">",
"      Treatment and prevention of Yersinia enterocolitica and Yersinia pseudotuberculosis infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_12_24775="PLAX view of nonclassic MVP";
var content_f24_12_24775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1166px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83602/PLAX_nonclassic_MVP_video.mp4?title=PLAX+view+of+nonclassic+MVP\" style=\"width:512px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Parasternal long-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 354px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFiAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VUZPFO2H2oj+9+FSUAR7D7UbD7VJRQBHsPtRsPtUlFAEew+1Gw+1SUUAR7D6ijYfapKKAI9h9qNh9qkooAj2H2o2H2qSigCPYfajYfapKKAI9h9qNh9qkooAj2H2o2H2qSigCPYfajYfapKKAI9h9qNh9qkooAj2H2o2H1FSUUAR7D7UbD6ipKKAI9h9qNh9qkooAj2H2o2H2qSigCPYfUUbD7VJRQBHsPtRsPtUlFAEew+1Gw+1SUUAR7D7UbD7VJRQBHsPtRsPtUlFAEew+oo2H2qSigCPYfajYfapKKAI9h9qNh9RUlFAEew+1Gw+1SUUAR7D7UbD7VJRQBHsPtRsPtUlFAEew+1Gw+1SUUAR7D7UbD6ipKKAI9h9qNh9qkooAj2H2o2H2qSigCPYfakKkDmpaZJ0oAjooooAfH978KmijeaVI4kZ5HIVUUZLE9AB61DH96tfwt/yM2kf9fkP/oYoA0bjwH4vtfK+0+Fdfh82QRR+Zp0y73PRRleScHgVm65oGsaDLFHruk6hpskoLRreWzwlwOpAYDIr2jTJtGk/ahjTTrDUYL9fEtz9omnvklikPmSZ2RiFSmTyMu2Bxz1rkvFjW1/8J9HbwnDcDQrC9le/hu5xPcWt1KFC7mCqPKZUG0hQN24HnGQDhdJ8P6zrMNxNpGk6hfxW4zM9rbPKsQxnLFQcdD1q3pPg3xPrFkl5pHhzWr+zckLPa2MssbEHBwyqQcHivSPhY/8AbOg+HrPytd09NB1h799SsrVXtPmEZJuJWdBEVEfDfN8rEBTwDjWNzY2/iLxd48gRVsra+m/saMrgPdSuzRED0jTMh9CqA/eoA89uNMv7ZIHubG6hSdmSFpImUSMrbWC5HJB4IHQ8VHe2lzYXc1pfW81tdQsUkhmQo6MOoZTyD7GvV3udGX4ffDhtdsNTvZ3uL0xva36W4U/aVzuDQyFucdCK7nUdL1mLxT8QNdj8Mwa9ZR6tc29jZDQob17i5Y8s8hiaRYoxg43AFsAfxUAfNFFK+d7bhhs8jGMfhSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVd0ayF/qUNu5ZYycyMvUKOv49vxroPGXgrUPDLsdQtbizUgMolKyRnP8KypwT7ELQByVFH05ooAKKKKACiiigAooooAKKKKACiiigAoqxY2wupxH5gjOMj5WYsfQAAkmtG/0qO3tZtqTpc2+13EhGXjJwW2j7uDt4yfve1AGNRRW/p3g7X9Q0w6jbaXcmwAJFw67UbHoT1ppN7AYFFSTwyW8zRTxtHIvBVhgio6QBRRRQAUUUUAFFFFABRRRQACir1zqt3c6TZaZM8bWdk8jwKIkDKXILZcDcQcDgk47YqjQAUUUUAFe5eHvDHhzXvht4UF/Fa2V3YpPq17cqqpJd2SXMiTIW4LOAsWzOepArw2rt5ql5e6fp9lczb7WwR47ZNoHlqzl2GQMnLMTznrQB6z47vrDS/ite2+m2PhfRbK/tbGbzL7SluILQG2SRgkYjcDcWwSEznHK8muE+K1lBp3xE122s7AafapcEw24IIVGAZWGCQAwIYAE4DAUieP/ABEt1cXEl1a3DzpAki3Wn286EQpsiIR4yoKrxuAz155NYGr6leaxqdzqGqXElze3DmSWWQ5LMf8APToO1AFSmSfd/Gn0yT7v40AR0UUUAPj+8fpUlRx/e/CpKAN7xX4WvvDA0z+0J7CY6hbfaojZ3K3CBfMePBdMoTlD90ke+cgWde8D6zoeh6LqWoRxr/azvHBaqSZ1KhCN6Y+UsJEIGc4PQcV0niDVtK0i38EXukavomvXehW/2eWze2uvLd/tE8wYiSKMMgDqPvBs9sc10ek/E/Q/L8JXeoadawX1trF5eXjWxupZYBIkYEymaVgzFssQST+7GNueQDzF/BXipL5LJ/DOtrePH5ywGwlEjJuC7gu3O3cyjPTJA71FfeEvEen2lxdX/h/V7W1tmCTzTWUiJExxgMxXAPI4PqK6+x1LTfD2neJbdPGA1aS/0me2g8iK5VFke6t3K5kRSGdEctxjjG4k1NL4v06W5/e6jI8A8IjSgGSQgXAiAEeMf3wOemRnNAHl9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFBoA9I+A/hyXxD413b0W0s4/NnV32iUZG1M+7YP4V7x421q2soQG8iPUoT81rewrmdR2ViMP8AQ1558P8Aw7q/hTw3H9qtruxu9SxcJJ9n3Erj5QCeOmDg1r3OsXkQaPxRZzYxiJprcPDJ9CeVNbRVkZt3ZJP4f8L+PUgit/CMdnfSDL3Fg4gkRu+5M7W/KuU1n9n3WYrgppF9BcYyPLm+V/bgf4fnXUW1rJdXMWpaYktncLwZodu4AexOCK7zw740t4m8rUpIdQuAOZhlnH4djRyphdnzjq/wa8d6YHZtCmuY06tbMJP/AB3736VxF5pWo2TlLzT7y3YdRLCy/wAxX25deJ7bVoltg9yQfuTmInH0bjB+tL/aj29ubWPxE9yX4KXkaIVGP7wGSPzqeQfMfCuR3NGR6ivrDU/B+q6tq0qwX+gXMQ5Mc1smRkdywH515VrXhSTR/EEgu7eG6YE7obW0V1x6qBxS5B8x5JketGR6ivb9N07wzNNGtjoE93cOcPBNGqbT3+Xr+tdlaeGPDpuBdR2Wmaa0IBaMw4I+p5Bo5A5j5hVGZSyozKOpAJArRtdA1a6jaSHT7jy1+87rtA/E19B61eQ28u7SJpLktxnygkY/3QBzUd8qLoonlMkV3gks+QiD1O7j8hT9mLmPCk8L3/2d55Qqxp12AuT9McfrVqz0iwNh5m2e5ugfmVnCKo+g5/M132piPVdP/wCJW0l9cLwXkIhiUY64HJrh2R7Sdo761QbDynVXPuKOVIady1DZLayK9kUEkg4gilBCD1dh/KqGqLLFHcKkbxzkMDIvG5SMMuPQitKDUmuL2KK6MNnGn3I4IRuP+fU0zXGtrdZJWkknlf5QWPyIPdu5+lDA4+wEDX1sLri3MiiT/dzzX194R1bT7vRbpdStIp4YvJtre0CAsqbGB2cjbzglua+P7mMRTMqsGXqDjqK6bQvH2u6JbeVZzxHau1Hkj3Oo9j3/ABz0q6U4xTUiZxbs0b3xs0yLTNS0+I/8fJjbcOvyZ4yfXOa82q3q2pXmr6hNe6jO9xdSnLyN3/wFVKzqT55ORUVyqwUUUVBQUUUUAFFFFABRRRQAUUUUAFFFX722tY9OsZLdrtrp1Y3ayw7Y423HZsbPzArgnOOaAKFFemWPg7RbnwNZ6nYWd7rOpGxmu7+O0120iaz2SOuTamJpSoUIxOejdRXmdAH6R/Cgf8Wu8Hf9gaz/APRCV8C/Ff8A5Kl4x/7DN5/6Pevvv4Uf8kt8Hf8AYGs//RCV8C/Ff/kqXjH/ALDN5/6PegDlaZJ0p9Mk+7+NAEdFFFAD4/vfhUlRx/eqeGKSeaOKFGeWRgiqvJJJwAKAGUV1Op+APEmmyWqXVhGTcXa2CeTdwzBbhukTlHIjf/ZfB/Kk1zwH4h0Wwub29tLeS1tZfIuZLS9guhbvnG2TynbYc8fNjnigDl6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACrWl25udQgjAyN25gemByaq10vg+W2tRPPcRpMzfJ5ZJU49Qe1NK7Bnvlp8b7/wDsdLTVLGK/iVdhLoQR2B3L/OsXWPijO9pJatbWd5YSD/VStuljHscfMK4K01WBAy2sUyqeDls49jj+dJHM1q5uneUxA9Rhtv1IH8xWlyLGvpMtnNcrcaQbiJmOfJYgoD6DOPyr17wbqvhvRxHceJdMuILl/uuYFaN/+BL/AFrwvStT8MzXRXVf7QIc8tC2QPfArfvryPT7dDod9dSaaRlre5JIP03A00Jo+k4bnQvEU0baPG1s+fuSsY1kHqOcGuY8a+CtXt53utFsp4053Mjoce+K8v8AD3iKC+US6Y0FpcR/ejnm2o/4YwD9K62z8aeIYpAlrrVu4JCtaLmf8h1p+gjpfDskVxZra3usw3Eyn50njDke2Mf1rG8X6LZyXKXHhm7me4TiaOzhwvvu716doPhG21nTFu9WluGlmXpGv2fH5c1ia34HtbWT7PpyXti8hx9pSU5f2Z+TRdXsFjw/xSLYTw74rj7Uv39zkJ+PQj86yjq+n2q/ZYtTuPPl6wFvNjX6EHj8a9G8XeC7jT7fYzWN3F/FNdXBlb8jXmuu+Eljt2ezcIGHzqmAD+nFAECeJbvRVkDGG8jI+7cMCB9CKlGsWut2W+aysbUHh7iaViF/3E6/nXMGzi0SIlprNpjyIkXzH/HsKqC7GpK6HTGQnrMr4bH8qm5VjTu9QhUrbaXqgW3zhhArb2P1NZOpW0+nXCSCVJGJyBOx498dzWr4b8N6nqVwIdGWSKNRlneVcjt2r6Q+FfwW0DTIk1bxAg1TUXG5UkZpFX6qe9DA8I8KeE9b191ktbSe7eUY8zyTj8DjAHvXrPhH4Axrdx3XitJLi4IBSGNhsjHufWvoGKBHaOBLZ4LaMcKBsX8hT7vWdPtCVluoQ4GdoYE//WpX7AfO/wC0r8KLG1+H1vrWgWUUNzpLZufKQ7pYWIBJP+ycH6Zr5Lr9BNY8YaPraajod48sltdQPA0cMRJKsCCSx4Ue9fBfiDTTpGuX2nsd32aZowc5yAeP0xUyT3ZSZn0UUVIwooooAKKKKACiiigAooooAKKKKACug1Txp4m1XSF0rU9e1K601QgFrLOzRgL935fbArn6KAOz8P8AizSfD9t9p0zQZk1/7FLZ/bHv90AMisjSiHZnfsYj7+3vtrjKKKAP0k+FH/JLfB3/AGBrP/0QlfAvxX/5Kl4x/wCwzef+j3r7z+FkwT4YeD1P/QGs/wD0QlfBnxX/AOSpeMf+wzef+j3osK5ytMk+7T6ZJ92gZHRRRQA+P7x+lXNOSSXULWOCdLeVpVVJnk8tY2JGGLfwgdc9qpx/eP0qzZ20t5dwWttGZJ53WONB1ZicAfmaAPXY0k8NyaFpEd7oUujwa/b315qUOtWs73UisFD+WshZIlBc8jPOWx0DbwW3h3VfiBrF/qukXFvrEN5aWVrZahDdyXDTSgo7LEzBFUfPl8HIAAz05fx/4DfwasEV3JqrXLS+VJNNpbwWRIHzeTOzbpcHuEAI5GRjMknw9DeLfC2iWWt216uuW0dyt5FBIscYZ5FIVWAdsCMnlVyTjA60AcHRXeat4Ct7Kzl1OLVpW0UaUmoxXE9oIpXeSV4o4DGHYBmeNzkMcIpbtiuDoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAdGoeRVJwCQCfSu9n0ONdNhudI1SG7ihUBowNki+2O9cpodg928rxkbo1yoP8RrTW61O0bzokiAHDben4r61cRMR5bKB/Mtbi7gu+4IyrfTFS2txd3cjSiBjIvPmRDafxHQ0z7QkwaWWIMp5ZUXofp/hVuwmtwDKsEhUdWjkKsBTAz7tm3iSW38tjwGiGAfqO1b+g3K21q0siSPAf48ltn5Gkt4TqE6JEEeCRseYCNy+57GvWND+CN1eQJd6brdrNuXOyLAZvZlJximJs8xj1e3iv0FxGbq3fo2ApH+NdtpOqWtk0dxbQzsx6brYrt/4GD0robT4U3CaokUthaRyqfnPljn3xnn8K6Xx34Tkh8OCOx2rNGuDtVogf6VSJZN4S8Sa1qMRGiN5F0DkxszSI/+Fdrpml65q5J1QzwTY5BkPl59gK+bIptV0aaG2hlEUzkK3mSFV9zkEV9B/Dy6trO2jimumuLyQAnZdkrn2GaBB4j8HtZ2M8mqatugIOyKGz6H1JHNef2HiCTSYLiwtrmzunIIzcx7WT+v6V7rZ/2qdRP2+SFLJhlAj7j9Dmpb/wAHaFf3IuLqwieUdwNufrip5rbjtc+M7fQbPU9Zubm7vLaWR2JOd6LnP0ya7XQ/hheavewJEkEOlAgtLADuPqBur6Zt/D+i6exFvpltC56O0Yb8ea0rPT7e2O9UUyH+Pbg0cyHZnneh/DXS9GjjXTdO8wjG6W7k6++BXYzCLSrHzLl44YgOVj/dg/8AAjzXQVyHxDSG50zyZTGz8lUJ/mewpKV3YGrHnnin4lT2t4Yrezt1tU/1k8gdkXHt3/Sucu/Fmla6j3gj1G4hi+9JDEI0z/srkZ+tcJ4xVJNQazNzDM8Z/wBXEXeKP/ePeuT/ALShuLxdLF1cMg4LKoUH2A6Ae9XsK1z0K71eXUlYWklto9gDh57ife7D3x39hXlnxS8OxWBtdUsTNJaz/I0kvDO3rj0rrrzRtP0U29zqFo9ynWGBpSAze+eT+ArG8UaZLqVlPPfSSGZxuhgDYSP0468UpK6BbnlVFKQQxDDBHBpKxNAooooAKKKKACiiigAooooAKKKKACiireraddaTfPZ38ax3CKjlVkVxhlDrypI+6w78dDzQBUooooA/Qn4cT7Phz4SXcONGsu//AE7pXw/8Vv8AkqPjE/8AUZvP/R719jeArlR4B8LrxxpFkOv/AEwSvjf4oHd8TPFpHQ6vdn/yM9XJaImO5zFMk+7+NPpkn3agojooooAfH978K0tC1GTR9b0/U4FDS2VxHcop6FkYMB+lZsf3vwrW8M6Wdc8R6VpKyCJr+7itRIeib3C5/DNAHbeKfF+gXOjeIbPRDrEh1/UotQnW+jQLZ7S5KxlZD5jEyEbiE4UDHNZ3jfW9Eu7fw4/hu/1j7bpFpHZh7izS2+5JJIJVZJnIbLgYxxjOe1J4r1Hw1aXuraRpvhWGOK3d7e3vpLyc3W5Wx5kg3eUc4J2hFxnrxkp8Ol8MvBrC+Iv7J+3MsQ0/+1TeC33b/wB5uNr8w+XpnjNAG9onxMFubRNR1DXJZmtbj7VqhbzrtLuRdiSRlnBIjQBV+dT88hG3Ncb8QNbtvEXi/UNVso5Y4LgpjzgBI5VFUu4BI3MVLHk8seT1rtdR0HTvC+neINV1/wAN6ZdXcGq22nQ6fDdXAtI0aFpWlRxL5jb1VSpZiBuJx2HH/EzQ7Xw3471jStPLmygmBg8w5ZUZQ6qT3IDAZ9qAOZooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACj6UVZ0+ES3ALg+WnLEUAa9kUis4raUMuTubjB/Orc9iFKuZbjaR1zkj/GqF1fJLB5Ow5B+Ug8Ulr/aXkbQWaDrjO4fXFWIbcRtA+1J3Zf4WB6fX0q1azyW4U3Ep+XkY5P4VWFuWmB8yMAnkK1XJLPymUrELhepUtnH0oA6XRfFlnbSJutbSROAzcxv+J6V6lpnjnwzP5JgvW0+6XAK4GxvbIr511FIVbdHFsXumeauackaKr2wjmH8UMnOfpVKTE4n1NeeIL1rM3Gk21vchVzh0d/8AvllPBrn38TaxqtvMt5cjTo1GCh3N/OuA8PeJrWytYoria5sVz/qoS6D9a9N0DxB4bnsxiaKa4YZzPCsjf0NVcixy/hvxX4Y0e4c67odxqzE8S3A24+m41Y13x/ZXt7A/hKJ7FxnMUwUxj+laOsapJ5wjngtr3T5OBi3KFPw2msww6DpMbXcNtpIU/e82XlfbbigDe8OeLPEVnqcN1e2VtLY4/eThhgH254r1CT4peG1thMLxBLjgecev5V4Xb6bp3iCb7XEl4YRwTby+XAPruwDXYad4Tgu5YZESOGFCP3rL5qA/gMZotcDqbXxHfalci9t9cM8TH5EbARPwA5r0nQZy1uJrjUjMepUgY/CvOdc1DRfCWiNM1+13Iq8LDbA/p/jXjtjr+teMvELLY6ifs7Hi36NjPHyqKTSYH1F4l8SWdrplwsN2sdwVIBDDK+/NfL/jLxnqs81xYwajDFalv3lw8hmkI9scD8K6rxP8O9a1DTAdQmtrS0Xl9rCJnwO5JJrxDULA2F01tpUF7cxo2CkSl1LfXuKLW2HuLeXMcdnJ9iXzmbIMkzkFvwFN8IRTxu81vphurwn5XfOFPso/rWcbm6N1/pNtciXosXkkYP0rWh1rX7WNlgae3ZxgLGnzY92xgUijR1GLxJZs0ktjG17PwGPzSgew/hrk2gvxftHdwXM10TgokpJz71s2t5qSmVri7aSZxhgJOn1NTWupeVE1vZuiXEhIeZccZ6/NQBxPiHTpdPvQJIzGJBuCnse4rLr0bxTounL4cDQ3E0+ood5JBI9xzXnPaokrMadwoooqRhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH2h4KvNvgnw2u7G3S7Qdf8ApilfKHxGbf8AEHxO2euqXR/8itX0V4TvdvhPQl3Nxp1sP/IS184eOW3+NvELf3tRuD/5FatJ7IiO5h0yTpT6ZJ938azLI6KKKAHx/eP0qxbzS288c9vI0c0TB0dTgqwOQR75qvH978K1fDcaTeIdLjlRXje6iVlYZDAuMgjuKAN3XfGx1oXk134d0BdUvFIuNRjhlErk9XCGQxK56llQHOfU1l+Hdch0hLlLnQ9J1dJmRgt+kuYyucbWjkRgDnkZIOBkcV6b8YINMs7TxTaX8Hh2DUIddaPRotJjtlmjtVaUOs4g6ADywBJ+83A571xtxZWo+C1hfC2gF63iC5ha4EY8wxi2gIQt12gknHTJNACJ8RdSludWfWLDTNYt9SuIruW0vI5BEksYKxsgjdCuFJXGcFeCDXN+ItYvPEOuX2ranIJL28lM0rKNoyewHYDoBXeWXgnQ5U0nSZZNTOv6npD6rHdLIgtYiI5JFiaPYWYFYyC+8YJ+6QDWxa/CO01PSJLrTLu7+0X9vaT6NDJg+eSiNdh8Lz5e84xj7pzQB43RWr4rtbCw8T6raaRJNLp1vdSQ28kzAu6KxAYkADJAz0rKoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACrlus0SYUmMyjg5+8Kqxo0jhUGWPauigkSa2CSwxuq9j1X8apAVrXTxLEVuA0b/wt1BqSKKeyOQ4kQepx+lWYLl4UMUbHYf4GIOfzqtJdQmTa2VYdUIxTERXkcd0PNjxDMOoUdapiQMhV7uVXXoGGRWsDYXKhVCxTj+IEoT/SoLm0jQZnbd7lc/qKLAVrW3ku/uXyZHaQ4/nUjJFZkiZCso6PG3BqGNYnBSNCT25wakaJRA0czLu7ZGDQMsNrM80Ox53ZAOh5p9l586mRL4R7TwCf8abpdsTGTCP3nY4p9rYXjTsWZMZ4G08/lQI6bRdf1TH2W61G7NrnB8iUJxXY6P4c0rXbqO3825uTIc4lIR/++jXlU9tKJQJXeNR6Kf8ACrsEGpWoW6t9RDoo4DTkEfh1qkxNH2Jo3g+80jw5HZ6RoejzIVB/fuSSfUnHWsnXrbxbpGi3Et3aypbqDmO1uE2gY7DGa+a4PG/i4hFk8RXkVugwAHcgfjmpta8a61f2yxy+KbuZMYMYZlBp3FyjPEery6k03nG9VSSpRnIJ+tR+BoL6PUx/ZF+1mSeRvbJFc1PqS7T5d7PHIepaTIP6U6DW7mKPZ9oSROpIGD+dTfUdj7P8B+GLHUbFZtflmv3AHyXD5jB9hmuu1ifwt4a02We7hsba3jHISMD8MCvjzwF4v1OS8it4L63sYNwBkmcyt/wEMcV3HjSNrqxD3Gty3Uh+6bi42rn2VRVWvqTtoVPiZ8Q9K1WZ00S3j0q3BI88QjzX+lePyXE+pXDRwXd5JCfvNLMEB/wqxf6Tqt3cMIbWa8Un/WAMF/M9ahlsrmzAgSwdpjwQsJOPxPFSykbOleC5ry3e6kntbezQZLNNyf6mjT7PU2kkXRdMSO1ThrxxgEDvub+grMW5MBSGSZXnHJTOQv17VHqWs3Fyy27Xss0YGPLRiF/LpT0At3JeSR0uryWSIcPIpwp9gTXFahALe6dEBEecpnuK1r2XYyNJKoI6ITux/wAB6VT1aWS6CTyvI7gY+frjtUsaM2iiioGFFFFABRRRQAUUUUAFFFFABQaKt6tb2trfPDYXq31uFQrcLG0YYlQWG1uflJK++Mjg0AVKKKKAPoXw7ehfDmkLn7tlAP8AyGteH+LG3+KtZb+9ezH/AMfNej6Pe7dH09d4wttEOv8AsCvMtfbfrupN13XMh/8AHjWk9iYrUoUyT7v40+myfd/GsyiKiiigB8f3qt2D3EV9byWQY3SyK0QVdx3g/LgdznHFVI/vfhWx4W/5GbSP+vyH/wBDFAD9Wi1rVtd1q61C0u5dUSWW61L/AEcq0LGT940igDYA7YOQACQOK6OG48ceE/CyQXOiSwaBJP8Aao21TQYp4fNdVXcrzxNjKqo4PavQdTn0R/Fnxnj0/T9Sg1JbPUPPnnv0lif/AE6LdtjEKlctgjLtgcc9am8V614c0rx5qen6nPqEra7ZaTYX8UkSx2ttB5Vq7ShxIWkcInGVTaWbk9wDyU+O/EJ0t9PF7Ets0ckAK2kKyRxOSXiSQJvSMkn5FIXkjGKZpnjnxJpkmhyWGqywvoiypp5CIfIWUkyAZHOdx659B0Fe2yaLpZ1/SFvvDE6RnWljtXu/D9vp9u9v5UpMQ2ysblTtRhIQenLfMBXlPi+aLVvh/wCHtaew060vpNQvbRzY2kdurxolu6BlQAEgyMNx5I6k0AcJyTk8miiigAooooAKKKKACiiigAooooAKKKKACiiigAoop8ERmmSNerECgCzYxFgzhd3YU/8A0XOT50M49eVNepaL8OdF1q1iistdWz1MICySHdGx9j/Q1YuPgX4s2sYIrXUIx0aCQE/lWnKxcyPJvtL7hG7KoPRiP51ZbT3ZVkaWMjHBU5//AFV0ms/DnxLpiMtxo95GF7NGT+RFcnMlzasYLmNonHB3AqfypBcW5ygCsob0YDaar7bg5KlwPrUiW0rciYFfrQwkQ7Bk+nPWkMg8tnPyElvSrMUMpUtOr7R7dKga2uN2fLYH61cto2k+WV3ib0ZTzQgJVvJVjKxYaP1K5IqW31y9tomSOdXj64BwRVa7gEBBVlYnupIquwfYP9U2f9rmmBoxXst2++6e8J7GN8gVeF7HAuZpXnA6JLCDWHbytbEMLkAf3QGq419HOp2ZjP8AeAzQKw24v4bqcedbrBH0/c/LUzR/uvMspQFA/wCWswyfwrNmSJ5QDKHJ7AYNWJSI4AkNvKcjBMm3H6UDIyrTNmeJmx3UcVdilk8kxWcFvCMcsw3N+ZrOWbau2RA5P8KHFNjikuJRHHbrGD3IJ/WgDa0aS9guh5Txu7HlgcEflX0N8MtJ8MSQx3XiN5prjALB51RM+y5yfxrx3RNFsrG2Vn1aVpnHEMEO0D6lq0YNAmRhcxQXUmfu4kyB9QoqkQ9T6Q1bxroWkWj2/hTw4byRRjzTGqRL9WY5NfN3xH8Xa3qt40V1f28eeDDZ4Cr9WArP1/V72yzFcvPOR92FpSET/gIrhNQ1Ca5kJkSOP0VV/wAaTdhpE08MMafPMZmJyVj6Z/rTI71oh5cUAjzx8q/Magtg55kkaNe3bNOkWKMkick/r+VSUJKgLglSXP8ACvJ/E1aw9xF5JjEYA+6o3H8ao5O7Kl+e7Gr0N5cxQlI5FhXuV6/nTAypEZHKsCCOxptSTZLlixfdzuPeo6gAooooAKKKKACiiigAooooAKKKKACiiigDurC7K2FqoxxCg/8AHRXHao2/UrtvWZz/AOPGtSC4xbxDPRFH6Vj3TbrmU+rk/rVMViKmSfdp9Mk+7UjI6KKKAHx/e/CpKjj+9+FSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdJ4N0dr+5e4kSX7PF1eM4ZT6iubALMAoyTwBXq3hCbS9K0lbHWE1DSbyXH+k7d0T56blNVFXYma1los1yTcWF/bXkq/dZ/wBzOvs3Zv1rtND8SalpjJDrNre6dMv+rvInKqfTOPlNLosd1a2qOul2Wr2wXKT2x2OR9T/Wr8GuaZds1qlldWNyy7WgmRk3/llW/KtTM0bv4ya3oLRx6npttq1k3AkLBXI/kayvFHiPwZ490uRb7wdqtrckH/SLWIPsPYnb1/KmyeFoXik+yqojb71ncNhG+hxxWDaanD4K1TLRT2Ue7BJk+VfdXHBH1FKw7njGt6BLp13J9lFw1uD8jSRkHHuOoqto9o11dFS8eVHKsDX034n8Xvqnh8vb2+j61CyncJHVJV+hFeL2Gt2yX0xuNHgPJA/eBXT6N3pNFJnM3Gk3DXKRQyWoYnGxpQMfnXR2nw18Y39uJLC3EsZ6bZVYGrepaiZsP9ggmg/u3EXzL7h1FdDoXipNPtfK014rdmH3QTuU+x4oshXZzcXwk8a3LeXNohRv755X9KdefBfxhYwGe50n5B/zxLbv5V778OdR14xiW+nuruAjKq1wYj+o5/Ou/bVb8uFZLy2VhzukWYfmMGjlDmZ8KXmk3NjIY7rT9QVlPPzA/pVIwzjmIzJ/stEf6V9/xx6fARcahBbSg/MXaMMfxznFatrF4d1KIG3h02UeiqmR+FJqw1I/Oe3vbmOQ+WLbPq0YJ/WpbyaaVA0rQFvRY/8ACv0CvvAfhG6k8yXQ9Nkl7Ep3/CsHW/hV4Llty17YLEo5AhGwD9KQXPhFGuAmQ0MY98A/rQl0Ub5nAHdgc19Na38BbHU/Mk8LztCScANAWX/vpq868YfA3X/C1p9rv7m2uIzwAp7+9Fh8yMrwDY6Rqs6hTey3Q6yEZCn8eK7fxLoltbxBJPEl5CeojhwT9Oteb6Z4e1kwF4EWGPOCI2KE/ixrZtLUaJKslxcQS3XBERbznJ+gWrWxLMvV7C9jgcWGozPGRkl13O35CubOga66tKbScxjrI6YH616/p1re6oyz3kd1FGvKgylSR/uhePzrI8eXNzDbtb2ttHt/vzSSSkce+B/Ok4gmeUvZMhLSHew655A/pVNidxAKhR3C8CtFoL2QNJMwZB144H4VSln2yYZQ+OKgsA8UQ+RTJIfWgrI4JmIRfQDmriw3T2/mEQ20J/iIxml02zW8vEgtDJd3B6AL8o96AKUFo9zu8oYVRnLd6qEEHBGCOor6K+GHw1vLnU7d5oklHSY+WX8seg7D9K4f9oD4fy+B/FSNEkp0+9XfHI46sOo44/ChxsJO55bRRRUjCiiigAooooAKKKKACijnFXtbbTn1J20SO6isNkexLpg0gbYu/JHGN+4j2xQBRooooAnWYhQM9BULHLE+ppKKACmSfdFPpkn3fxoAjooooAfH978KkqOP734VJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBr+FEtDrdtJqcE01hGwMwiHOK9f1PWNGMAbRb5NQ08DBsrzHmxj2J61554RsjFZNeWupLBeA827dXX8aNZlW4RnAtGnHXauxx9RWi0RL1Z3Oj+L9O0WXztD1KbTWz80LL5kTH0Knp+FdVJ8Tlu7bddWFjdv1E1nKFb6lGr53HkvIRKhjf+8p4P4GpY/OQhIo0dT05xRzBynsNz8atRsbgxx29rPbjgJOhVhXR+F/HPh7xi4tNVhsrKeX5QWYqMntnpXgn9hajcoZFhkIHO3OfyqkS9hKUlSSN16hlxRzMOVH1DqXwQ1a4JuvC2q6e0bdInCspHpkV5r4g+GfinTZXk1C1t7d1PLRyb0Nef6d4y8QaUQ2marcQhegSQjH61rXnxP8Rajb+TqUtvdDGC0iEP+YIouuoWZp6T9mtZjFc3ptZzwQF+VvqKuW/iKy0TUhI+jWl+FP8ArInKg/VTXBC8+1v5hujFJ/d5IpJp5mGDcB/94A/0ouFj3uw+KGiRWuYtBFtJ1zG7ISce3H6UL8XXO/7PLZwLjjz2y38hmvntvtA+7NCfbdiq+91fduw3tzT5g5T22b4r6nd3Jha/tZUJxsjtAR9M96sf2trEaG60/S7iRz3hdIx9cCvG7TVYgVW4jm3DoUwP5Vs216zj/RrnUYWz2lOP1NCkJxPRY/FniaaQG+1C90jZ90Jal2/76rP1jxfrCgZ13WLmMNuBdmjUn6Vzh1zxBDEY7rUn8nGP3kgJxXPX+svvIVkcnjO3P86GwSPTvDnxt1DS3+zyzNsJ5O0MfzNeleH/AIkaLqMsd1q0Vvctnh7p84/4DivlS6VXj3ySjJHCpFiqsE1zACYS+0eoyKXMPlP0O0/WfCmraf5hvNIVDxhGRMf1rlr3Rfhwl+Z47eW+u2bP+il3APrkfKPzr488OeJtQ06YSRxW8jA/8tEz/PivX/DPxG1y/CLLbaVZ268PPKwzj2Xp+lNaiaset3kNikDy2enXbOvKRz3WxPbIFfPnxHhN1qrHUNVt4scpaW7lwn1PU16XD4+0+6vWsSGuBnD3Eu5k/wCAgDpXTR6F4QvyssVk1zcOOW+zhVB9lAqnqStD5euLpbK3+XMwPQtFkD6A1mado2oa7eD7Ha3EjMcb8BQP6CvqfUPhrpolN1Po+o3gHSMqlvEPTryan0yK2sLqKK38PRxFDhRFGZnH8lFTy3K5jy7wb8C9U1cJLqSyJDwCIwWP/fZ4/KvevAnwg8NaCAWtY5pQMlWO4fjWxqXic6Rpau1ksQA63kwAGfZf5V5h41+KtxaWbA6pcrLIP3Vtp1sIx+LNlsflRZ9BXPa9Z1/SPDNr5bNBCEGRGuFC189/tD+LdM8d+Cki0uOR5LObzPOb5V6YOB3rze91u61vc9680SA5IeQyOw9z1/UVUi1WSW3mtbOOGK227ZLm5I2qP9kdKLIep5X2oqxqESQXkqRSebGDw4GM1XrIsKKKKACiiigAoorQ0TR77W7v7NpkSTT8YQyohOTgAbiMnPYc0AZ9FWdQsp9Pumt7oRiVQCQkqyDBGRypI/Wq1ABRRRQAUUUUAFMk+7+NPpkn3fxoAjooooAfH978KkqOP734VJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVnTrKfULtLa1TfM5+UVWrsfAL2+nyS31/ZG7gxgBX2sp9RTSuxMzdZfVbAJaahbSRMg43pyPxrH+1TN947seozXp+ua3peq2jLBeSxHtDfR7gPo4rze7idJiyCM89Y2qmgQtg6TTBJWjXd/fOAfxrYk0V1UPCwCkZwTuX8xWFIrOuXjKn1xV3Trq7h+RZk8v0bBFCGPuDqNn80U0kajvFJkflVZ9SuLjC3dw0q/7Sgmu28P8Ahq18RTKk13HDJ3CuAfyPX866C9+GGnabCrSXUMz9eSY/50+Vk3R5S8FpKmYbgrJ/dePA/OqckbxP8w/HHFexaX4XsEJafSmuYfWC5UkD6VLq2h+EXt2WA6jp8+Puyp5iA+/ejlDmPFic44H1FOEjKc4z9a09Y0kWly6xXEUyZ4ZP8Ky2iZTjqPWp2KLMc5kGPJiP/AsGnzoxj4+X6VS8r1dPzp6OycBiR6Ci4FmyWBH3XDox9GJFbcUdrOh2eYuOmyXj9a5+LyHfdO7r/wAAyKuGKDaPJcsP9lNppoCSQxpPib5wD93uakkuLXpFAsK/3myTUDCAIQksiMRzlxWbMuGJ8wN+OaVwLU8aud3n7vTBpytMsfHmbfVjjNUo92cxg5FSvczhcPjHuKLgPt4GmlBwG+vT9a6zTNTntUEMNzFAuMHybdc/99GuKZ93UAVNaOA+Chk9hk0JgeoaZfabHeRz3t80gB5V3HPscZr07T/jjBpNstrpkVhawKMbkTcx/wA+9fN0sU82D9l8mMdSx25pkrQxDb+6T12ZY/maq5PKfQur/G3UNRTFuVYjkM3J/ADgVxh+LXiFLsSPMcA9uf0rydbpUI2RuR6s1W11gpCUjCqT1Krz+fWjmDlOw8R+PL/WLnzLqedgOivIePwFYx1wyuq3Wdn93BA/EDk/ia5Z5XeQkMwJ7k1JbyeTJvdix9B/jS5h2N/UZmuUCtLOkPURRLt3VDaxo2DJChVeiyOdq+59apT6nLMMExwR4xhByfqaijMk+CilY1/ic8UXAk1pBIRMjbwOCwXAH0rKrTuL39w0O5CD3XmsypYwooopAFFFFABW74E/5HXQv+v2L/0IVhVu+BP+R20L/r9i/wDQhQBgr90UtIPuj6Vb1K6jvbxp4rS3s0ZVUQ2+7YMKASNxJycbjz1JxgcUAVaKKKACiiigApkn3fxp9Mk+7QBHRRRQA+P734VJUcfU/SpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAFG4gAEk9hXTIbNdPQWN2wkxiSCQbSD7VmaFpsuoTt5UckgTkiMjcPcCtiazijnEd1Jlv7sybJAPx61SQjD+1vFIQJGUd1IyPyqCZtz712AnuvArevPDhuIzLptzDMR1hY7HH4Hr+Fc+0MsMpRwUccFW4odxlu21S4tsbdrL3VxkGug0S/wBCvJtuq25tWY/6yLkfiK5N1buo+op8VvLkMq7h3ANCYrHrMnhzQ54RJpV7YT8ZGJfKcVj6tqeuWKC2S8ka2AwFlZZB+dYWgz2DOFuGELj+9xj8a7iDTrC9gXytQspeOY5gM/nV7k7GFpVzq6RmeU3SxMeXiiEi/p0q/qeb21Ly3N3jGd/2P+q1o2UMGlSk20zWE3rFIJIz9VNVNa8Y6hbHZNa2NzngTQqY3+vBp7AebaskqXDKJjMgOASCD+tZpLd81vapJfagzSlZCpOeucVkywSDs5I9RWbRZXpwH90nNIQy/eBH1oDYPQUgHojbvnJC+uatBLfaNkg3/QioIvKY8sy456VoRXdvDHgxRSH3OKaAznSQnplfUDNJ+5UYZZc/gKszXLyk+VGqj2NVJHkz85FADWZf4AQPc0qFQfmUk/WmU5ZGUYB4+lICVpxjCRIB9M0RTPHyrbT/ALPWoRyfmOPelbA6En8KAJmkklOXb8Xekyqf6sqzeoGahQAkbs/hVhmVEwmxT9dxoAbveQ5l3MB2pJJF6Rpt/CmjceXcgUwnk7SaAJUWRRwNo9TVhDDjCxPNJ3JPAqntY8n9aCTjG7j0oAfKNr5IT/dByBQZJJflJ4HbsKjIA6HNPRB/E2PYUAPjWIffO4+gOB+dNnAD5UAKegFWAYII+gaT0qqxLksx59KGAyiiikAUUUUAFbvgT/kdtC/6/Yv/AEIVhVu+BP8AkddC/wCv2L/0IUAYK/dFLSL90UtABRRRQAUUUUAFMk+7+NPpkn3aAI6KKKAHx/e/CpKjj+9+FSUAFFFel/DTTftPhjUrjR9Ni1PX1voI5IzYR6hNBZENvlhtpPlkbdtB44GOVyWAB5pRXYfFnT10zxvdW4WBT5NvI6Q2S2QRnhRmVoVZhG4JIZQcBgcAdK4+gAooooAKKKKACiiigAooooAKKKKACiinxD94vy7hnketAHTaHBbJbK0u6OXqsqMVYfiK6JLzUHtjDMltrNmP4LgASAezCuOtbiGORVhdrdj1jmGUP0Par8puIE8+OIrjnKHcp/LpWiE0M1W1st+bUXWmy/8APGfJX8GrEuxcrj7UpYdm6j8DXQw6414nlNIyv02vh1P51QnSWF8E+UrH7pUgH+lJgYu4j7pIFOSUjqTj1BrptO8JvrBJsb+0Ep/5ZSNsyfaoNY8F65pPN3Yyqv8AeA3KfoRSswuZ1pbtdyAW7+a/9xuGrpNP02aEr9ssrmMj+IfL/PiuThtruOUGOJ1kHeu00XxHrVrCILoTPARt2yLvX9aaBnQR6iLWEJLBNNEe81osg/MVkavcabdI5S005m65VniYfgaJ9W2gSiGNd38O5ox9MisPUr+G+3KYzDJnq0gcfgSM1TYkjDvnlgkKxlok9BJuFUvNkJOZG/OpLmF43JYgrngg5qCs2UKxJ6kn8aTp2ooyT3pAPV1/iQGjbnlOlMo4pgKSeho4pVXPJIAoYDOAc/WgBtApSMdxSUgDNKCAemaSl7UwHMwIGP5UyiikAvXqaKMnGKSgAJzRTi5xjjH0ptABUqsiDONzVFRQA5mLHmm0UUAFFFFABRRRQAVu+A/+R20L/r9i/wDQhWFW74E/5HbQv+v2L/0IUAYK/dFOwfQgepFNX7oro9V8b+J9X0ZdJ1PXL+60xQgFtLJlAE+7x7YoAsxaFpM3w0u9dhur99XttQgtZYGiRIESRZ2G1txZz+6U5ITGSMN1rp4vAWitbxaUZNS/4SSXQP7cWbzU+zZ8ozCDy9m7Plj7+/73bFc3p3iPRrbwFf8Ah+fR9Rlu7yZLprtNRREWWNZVjxEYCdoEp3LvyccFc1qR/EWFNOST+xmPiBNHOhrf/av3Qg2eWG8nZnzBGdm7fjvjNAHntFFFABTJPu/jT6ZJ938aAI6KKKANfwvolxr2qC0tnhhVY2mnuJ22xwRKMtI59APTJJwACSBXaP4O0RNKW/dfF66UwwNbOjYsyc7c4352buM7s/7OeKx/Akcl7oPi7TbLJ1C4sY5Y41+9NHFMkkiD1O0b8ekZrpL/AMc6RZ+DtGtNNtprrWv7Al0i4maYrDbrJcSOy+UY8u+1gQwfaNw4ytAHB+JNFuNB1M2lzJDMjIs0FxA26OeJhlZEPoR64IOQQCCKbo2hajrQvDptv5q2kRmmYsFCr2AJIyxPCqOWPQGus1/R7y40jwnpMwKXdnYPc3bSA4sbeWdnTzT/AAjDb8f9NQBycVq+E77T38U+D7DRWIsrbXogjNBHHLcYKfvpGB8zJJbCkbVXABJ3U0hNnlg5pUVndURSzMcAAZJPpXWavbR+IobnULCKKPVrZmF7aRZBuFGT9pRMY4A+cDpjdgAnHNabIkOoWsshxGkqMx64AIJpDLuueG9c0ERHXdG1PTRKSIzeWskO/HXG4DNZVerfFTxdoXie216PRWhsca5LfhUSYrqiuSqzZfJjdRnKnapD8AEYPlNABRRRQAUUUUAFFFFABRRRQAVp6daxOge4MkZPKttyDVC2haedI06scc10ljZX9pmO3bf6wuoYGqSAinijEOGKTxgYzjlap2N3JbSFbO7aEH+BxuU1JqEnly/vbWS1m77Qdv5U20k02cbblWil/wCeicg/UGmItXBMjB54IoZf+ekQ+U/UVpWV95cQS+tI5YezxOV/xFVBJJbLtjjju7c/XIquDIuZLWKRV7rnOKYHQF/JBn0qNHXr5cihj+lTWvi69K+X9nng7EW8xx+KtxXPQTW1wP3ke1x3AKkfiKVrRJXD2+oRlgeFlbBH40XFY07i6t7mbbdPdKT3CrRLBd2q+bYyak8BH3hHnFFktyhX7RBHOg/jBD4/KvQ/CcrxxqI7a3ZT1USFT+n+FNK4m7HnVvdzTKxW/YN/EskfP5GsrUpVUHcY2b2TbXsfiDwlY6mTcYksrjGQzPlfzxXDarCmlI9vemObsJIyrUNDTPNZm3OeMVHWpqccTsWt5kZQeBtxWWeKzZQUUUUgFBwaCc0lFABSqSOlJRQA5pGbqf0ptFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFbvgT/kddC/6/Yv8A0IVhV3Pwe1GysPF8a3kO6e5QwW02M+VIx9PcfLntmk3ZEzk4xbSucKv3RS11HxH1LStV8TSXOhxhbcxIruF2rI4GCwXAwMYHvjPeuXoWqCL5op2sFFFFMoKKKKACmSfdp9Mk+7+NAEdFFFAFrTru4sb2G7sp5Le5hYSRSxMVZGByCCOQa6wePtT84XH2HQhqP/P8dLh83P8Af+7t3d923dnnOea4yP71dtrmkaa3gHwje6Pp9ymp313eWtyzTGZrh4xb7NihQFGZGwoBPPLHjABuan/wjV9pf2RvHMZmuJftV/dyaXcvNdzHP3mPOxc8DjJJYjOMWPC0nhHRLnRXk8ZyTxadqY1ExrY3AV8BAVCEYDfJ97PPA7VY+Gvw70zU9B1u41uWym1b7BfC2sJNSitpLGWGNiJZ0Z1cfOoABG0AFnOMV5DTv5E8vmd/Z2HhzT9XTUtO+IItbuKUzRSJpVwGQ5zWT4/i8O/2jDc+GNQW5S4TfcwJbSQpBL/F5e/qhPIHUdPQ1h6GiyazZK9hJqKmZAbOJmVrgZ+4CoJBPTjnmuo8daZZG5s4NE0mO31O3s3l1e106SW4gt2Dt/E7OwKpt3/MVB44OQBjscVRXrvjTwtoNj4O1D7BpiRarpttp00zCSbz4zMgMhm3MYXUsy7fKAPPIwCa8ipDCiiigAooooAKKKKACiiprO3a7u4oExukYLz2oA6Lw14f1Ge0fUobdZLdPvK46j+lbNjc6beSqJI5be4XgASbCPoelek2Fnq3g7wpFbSraSWki5DSJkDP+0K427sYbkmQ2X2ZX6vERNCfy5Fa2sRe5t2lyz2/kajpz39pjCzCIF1+uOv4VTu7TSRGztpEV3a/3kXZIn1FYcJ1bQZxcaTdOUBzhG3LXa6L48TVIfs2sWNpcS5wS48t/wDvr/GmI4m50q1nUyeHLqIsOsEjbJB+dcvftqMEh+1WhBzjevB/Mda9O1rw/oOpzl1a606c/d88fKT7OOD+dc/qelx6SGTVIpZoT92eEkH6+lJoaZxKx3FywZY3Z/8AZIDf/XqOayuJTh0mz/tx81p3wtdxexupWj7EryPrUFv9vlbNpqCS/wCyWww/A1JRXhtriDJXaWHYOY2/I1fsNae2mAlnuYCP7+HH51Ylj8SNCVeCa4j658rf/SsG9trwv/pNt5fsVKH8jRtsG56hpuutLZjZec4wHhnZD+RyK4XxTdzyTuZneTJxuYKT+YqnpNtaBv3moSWbHoXiLL+YrTvNI81Ga21PTrrHULLtJ/A07toSVjkMnnBNAxnnpUt1A8EpWQAc9jkVDUFEoWMj7xzUbAA8HNJRSAKDRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFbfgf8A5HLRP+vyP/0KsStvwP8A8jlon/X5H/6FQJmGOFH0q5qmn3Wl3r2l/F5Vwqo5TcGwGUMpyCRyrA/jVNeg+lKKBhRRRQAUUUUAFMk+7+NPpkn3fxoAjooooAfH978K3ZPFPiCTTbbT5Nd1V7C2KNBbNeSGKIr90qucKR2wOKwo/vVJQBbj1O+jurm5jvbpLm5WRJ5VlYPKrghwxzlgwJznrnmqlFFAE9jeXWn3kN3YXM1rdQtvjmhco6N6qw5B+lampeLfEeqMG1LxBq94wieEG4vZJP3b43pyx+VsDI6HAzWJRQBp3niDWr3S7fTL3V9RuNNt8CG0luXeKPAwNqE4GPYVmUUUAFFFFABRRRQAUUUUAFeqfAfwJfeKtaa9tPLEdowOJlOxz6Zry2NGlkWNASzEAAc191fAnwUvhzwVb3Gl3rC8uUDypIvyFvQg8iqj3EzK8QWVnYQC11yK60h243SJ51rJ9GHA/HFcDq/gnyZftejRvIrc7rKXGf8AgJ6/rX0BqJM0T2urk2EkmR+9QSW0v49B9DiuMfRde8I3JvtJtIrjTWO5orRgU+oQ9PwrS5meG3WizXeUhmjF0OsF3H5DMfr0JqjbeFtRuJxDJYO8ufuCQB/+At3r6o0bxB4X8XxeTdW9k90PvwTKFkU/TrTtT8C+H7kZgXyHA4AYqR/untRfuM+Y5PDviHSlK2s85iI+a01O2K/+PAY/GqjadqF3E0b2c9tn7xtp1kiP4GvpSOy1bT1MOnX0eohePst+QCR6LJ0/MVhal4i0O0vBb+KfDp0q5Jx52zZGT/10X5TTFc+dx4MvLeQTT2VzLbk/62GHDD/vnim3mj2+P9A1OBpAOYb2Law/MA19B6ho+lX8P2nQtRubB2HyzQgMjfXHBrhPEGk6pkpqVrYanbjOLiHCuB7qev4UWHc8nTU9T0uZRG/2SVeRJBLuU/ga6rTfG3id4VS6tdL1i2774lLfjinS+GboZaDToLmA/wAE6MhH0NTWGnpaSgvoKo/cBlkX9CGpWC5Q1WTTtZ3NPotvY3J6mKJ15/DiuL1fRorcMS0BA/vKQa9UuLWzZTJL4Y1NW6iSylYfoa5nWp7AW7Rx3mvWv+xeW5kX+VDQJnkd2io5ClePSoK1tciVZ2KyRSD+8qlP0rKAJ6dayZoJRQQR1FFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACtvwP/wAjnon/AF+R/wDoVYlbfgf/AJHLRP8Ar8j/APQqTEzDXoPpS0i/dFLTGFFFFABRRRQAUyT7v40+mSfd/GgCOiiigB8f3vwqSo4/vfhUlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHXfC/Q21zxZaxbVMcbBm3DK496+8NAuoba2t7NJzbSqoCrL80bf7p6j6V8mfAyzu9OaTUILRL3s0aEGRef7vB/KvpHw5450rUybWeH/SF4aCVdsi/gcGtUtDNvU9GaZ1TFxbsw7mMbwfw61QWC3+c2IX1YQNtI+qdKZp+r2Um1Le68vHHlTDA/A1py2tvdgNNEjnGAw6j6Ec1Gw9zy3xv4AsddYz4Ed2pyLiP93Ih+o/rXNW+geLtIQRJfHU7dPuiQ4kx+PX8DXtV1oUU5BW4uUYHg784/PmoP+EeQqQ07k+uOv1q1JC5WeK3XifUdHcJq63lp6O0ZdR+fOPxNbGn+LrzVLcxWz6NqsR6r5mx/xU112v8AhnUxG/2K6dkxzEQJUP8AwFufyNebXPg21adnvbaG2l6l0iO3P06iqTTJH3+rQaEks83h6601sbjPaHMefcDII/CufX4qHzTHc6PZ6vbE8vAQJAPdTW/d+G9RitSdF1JJRt4iackN+DZxXmuuHWbO+23/AIUhuD/z0RcE/wDAhQNHaL4m8Mzjz7GPVtFuD18tsoPYqaivdbvbqJmWXT9ShYDErRhHx75zXHy3OpzwZg8Oapa7TyUUTIfqDzUGnIZbvF9ZJGWPLjdbv/hQFjRm1e/tZC6WsoBPIgdl/kSKtReKPD1wPK1waxb8YJlJZPzq4+gWr2rSBLokDPzRh/8Ax5Dk1y2pLqtsSunpIydCsqlh+TDNAFTxZZeCLq1kl0+7mebt+8/pXkd/DHDORCSU967+90S+lmaW/jity3JYggVmXthpqRGOTyZJOzxzEc/Sokrlo4z5MdTmm1eurHyyTGHK+/P8qpNgHGMGosUJg+hopy7uxNKwbvQAyig0UgCiiigAooooAKKKKACiiigAooo60AFFGPzowe9ABRQAacEY9qAG0U7ac4HJ9BV+10i5mXey+XH/AHm4p2AzqmNtL5Rk2EL71px2trA2HmQkdW61cN1ZtCY4keV/7x/pTsBzVbfgf/kctE/6/I//AEKsidGjlYMpXnoa1/A//I5aJ/1+R/8AoVSwMMfdFW9TggtbxorS8jvYQqMJ40ZAxKgkYYA8Elfw44qoOg+lLQAUUUUAFFFFABTJPu/jT6ZJ938aAI6KKKAHx/e/CpKjj+9+FSUAFFFFABRRRQAUUUUAFFFFABRRRQAVZ06D7TfQxFlXc2MscD86rV0nhHSJdQmLxw+cB1UEZH4Gmldge3aWbaz0m2tbq1iSUD93Ju8l/wDgMo4P41uWd6Z5Y7fUVa7QHMZuo/3qf7si8n8685sNPdYzDDJcQqeqJ8w/GNv6VYtbPW7Fg9hcGWAdfJOcfWNun4VsZH0H4f1KeGJAh+32y/wn5pE9ueTXd6NqmnXMY+zyCCTun3cH/dPSvAvC2u3kkarqVt5u3gzQD51+q9a7q0vonMbpeJIPXqy/VW5H50NXDY9bO8rwwI7Mn+FVp/twU+V5M2OgyY2/qK5zT7qRbfzCFkUj78LlT/n61q2F/K7BYbgTZ/5Zzrtf8CODWbjYfNcbJqF6jbZ7ORR6OAQfoy1SvXS+VoZ7RwexcBv14NdSkgYDepVvRqfgYxgY9KOa3QfLc8ovvC9ukhkksZZEPeLcjY/Ws5fDfh+8dUTWtb0257Ry5I/UYP517JI2xcFG29MqM4rLuLB5m3Q3Kn1WRM//AF6pSuKx58fAOtW0bNpvihnRvu/aLQE4+orlvEHhzxUmUutb050bp51oWXH1wa9zto541VfNIA6jAYf0NXACy4kCsD7UuawWufKNx8NtSumaePVLaNu/2OQoD+BrB1T4fa3b5I1K8lA6HG7+Rr7JNnbFtxgi3eu0ZrP1bS0uLZzbjbLjjaB/hQpJjs0fFa+HdYhLG4SS6jB5WSNv5ZrU0y18PbhHqfhyMy/xExyLXtHiXT/EcczCG8KRg4z9nycfWsOXwzqWpqBLrUYf+4yGP9cVdibnITeF/B99F+40WWBmHLR3LRgf99Vyuu/CqMoZdMt71weyzRyf1r2fS/AV/bMGu2u7u36/unyP0rrrDwl4dcbW0+9il6HeGAzQ7Amz4u1LwpJp8jLc216hH95V/wAawbu1jiPyCTg/xECvvu4+F+i3agvbQ4I43ruNYGp/A7R7lXMKWERI/wCfTd/Wodi02fDAKZ5T9aVtgHCH8a+o9d+BAEhFvHI2e8UGwfh1rnj8BplOZZ50OeVZ0U/qKXKHMj55PPYCgAnoK+h/+Gf3uDi3Zy3q0wIH5Crtp+zJcSkG61VIU9UiY/zo5A5kfN6QO/TH41L9ifGSyivoy6/ZzgtIy1vrd3LKP4Vtsg1yOpfBnxDFNstTLIvq8YU/lmjkDmR43JH5Z5YH6VHXrlx8GtbgTdcW07n1JVB/PNJa/BvVp23PayrF3PmKAPxNHKx8yPJKckbv91SfoK9R1T4apYFVMsJfuol8w/oKz18Hy8iJywB+6lHIw5kcBJE0f3hj60kQBPPSutvvDMkDkCIu47J8xrM/sm7D4W2K+mSM0uULmcCoGIlG496t2+nCX5p5VU+nWrD2EsKYm8mI98nmqN03ljbHLkeo4pjJ54LSDADGRvQU6101rlhukWFD2ALMfwFZ1vIY33JHvb1arrXd9IhjEqxJ0IXigC5ObPS1Agj3zf35Tls/7oqk5vr5t0zOqernH5Cm28GG3GUBv7//ANc1dje3U4UvcS9KBEUVpbxgNIA/+0/b6CozfJA5S0i+c8byMn8KsXKPIMsAhx90daqJZyuxaMIoH8bHgUAR6jaTRqJp2BZu2cmtL4fWlzdeMdINtbzTCK6jaTy0LbBuHJx0FVZ4N8HzTbwP4jwPwqtpGtaposssmjanfafJKvlyPaTtEXXOcEqRke1TJAVbm2ns5TDdwywTAAlJUKsM9ODUVW9U1O/1a8a71W9ur67YBWnuZWkcgDABZiTwKqUhhRRRQAUUUUAFMk+7+NPpknSgCOiiigB8f3qkqOP734VJQAUUUUAFFFFABRRRQAUUUUAFFFFACopd1VQSxOAAM5r0HQtDuEsluLT96V5328m11PuO9ch4fKx3ryebFFOkbGAyNtXeRgHPYgEke4FdFpJa0ljH2m50+c/dYjhvcdm+ozVREzqrbxHq9qNk8EWpovVZEKTL/X8RWzYeMRO4BtHXttkOSD7MOR+NZr3OpPaBrhLTU4l/jX5JF/Ec1Xj1WJ33tbSq443MBuH1YcN+IrQg9AtNTu7kJJBDIzqeBINkg/3XHX8a3bTVL8sI7qFXY9C6hJB+PRq81s/Ei2oHzXFuenmw8qf95P8ACtyz8Q61dwkWl5bX1v2DKCf8RVCPSNLvNXtJ/Ms7e3uh/Eschhlx7qeDXSW+uWk0i/aRdaXdd1uItqk/UcV5JZXmr3LhEktI5/8AnlM7Qt+B6Gt+LWPFulL/AKbp89xaY+6+24THsRzQI9t0jVy6hZJIpU7OrZFaUlxG65hl2OehB+WvJ9C8QWk0XmLbmxYdcKQua3hfvMg8mWB/eNwD/SpcUO7Osk1PUbVsS2gmj/vp/wDWq3BqokRWe2lXPfGQPyrzySLVJm/0W8KP0xu61GbPX4JA0l7KnuuRz/KjlQXZ6kt7GwyoYj2GaguLmA8mWWIjqVH8685F74qtMNCbTUoh/DMNr/XI61bg8RXM7LFdmTTJj/e+Zc/Wp5B8x21tqMRYI9yJM92Tb/8AWq3LaQzfMEXP95Tj+VcRDLqe/cl5o1+nUBmMbZ+o4rch1p4kH2mxuIsjkxOJBn2ocewJ9zais9ibS29fRxkVSvdBsLpP3tugPqrFaov4itAcG9uIDjkSW+cfiBWbqni5YEPk3tu49WiI/CklINC6NFksSTpt00P/AG1BH5Gr2nS3qnF7fWzc9AwB/SvLtZ8YWk5+a2jlf1hmRT/Osyw8dyWNyI7e2ZVJ6ysrj+dXa4j3tFA+YSkg+4xUpP41wmmeL/tVspLQFiOgytadv4jXeFZNwPdZQf0qHBlKR07AkfK20+uM1kajpV5eLtGqPEPaBD/OpxqUUiZzMp9lz/Ko49QtxL895KPaRAB/KlZod0yDTNAks23S6lcTn3UKPyFbLq+zCMufVhmof7Rs8f8AH3B/32KztR16OBG+z273Rx/AwAP50asNEWZYpJDsubmIr/cWPk/rSpZWqLtW0Lf8BAzXkfjbx/dWMbmDSoopBkAmVmP/AI7Xhmv/ABR8STSMpvpLOPP8IYk/maq1idz6r8SXml6fCwlt7aFh/E8i5FeNeJdc0C7kYzaz5WCQBHulx+A4rwq58ZajdTFptSllYn7zgH9KZ/bGoSsPLvFcnuYwtUmkHKelXF5od0QIL7Wrwjp+4CJ+gqneXulxIVkub7j/AJZh1XFYGlaNrGpEPdXETQ4ziafYn5CtO60u2tIGVJ9NeQDlbaBnI/GmIy77WNGgBLWc8uOzXB5/Ksm41ea8jP8AZ+m21pD3fqfzNVdQ0a9nuGCRgAngsQCfoBzWxo/w61m7UPNFLHGRlTIwQH8/8KnUrRHI3dpdTEspVu5YsAPzNU00i5lPy5lxziNSR+de36F8Jb55FZbeKZscMVef/AV6Fp3wmvBAq3/mlR1UlYUx9BzRy9w5j5NbT7pDtWNh7U8aS6YM8hBPZR/WvrW6+Hmj6dFuulSBe4ij+ZvbJqpa+DVuJMeHPCsZB/5fNRb9QD/hRyhznyvJYbE3MjbM9SCc0zdJGmI1aNfXGK+qr74R3zoZr+W1ibqW2AAfTNeb+JPBGgacWa+1Ga7kB+5DGW/LtRyj5jxbzwWABaZ/bkVFPPIT+9wSOik5x+HSun1WGOR2i0228iIHALHcx/LgVkvp+nWgL3t00r/884efzNSO5nRfvz+9clR+QqK4jwS8at5YO3cRxn0qa5uwcC2gWCPt3P51fgtZYNOvU1R1t0mjEkaSn94ZAflITrg5Iz6H2qWMw6va2dMOpOdCW8XT9kewXZUy7ti787eMb92PbHeqP1opAFFFFABRRRQAUyT7v40+mSfd/GgCOiiigB8f3vwqSo4/vfhUlABRRRQAU+GJ5pUiiRnkchVRRksT0AHc0yut+FMUknjvT5IXCTW0c92jFd3zRQvIOPXK0m7K4pOyuzndV0y/0i7Nrq1jdWN0AGMNzE0bgHodrAGqldf42vjqPh/wbM0sssiadJDI8pJYuLmUnknkYYVyFCba1FFtrUKKKKZQUUUUAFKWYqqlmKr0BPT6UlFAGjp2tahp5Btrhsf3W5Fblv4sEsoe8iMcv/PSI4rkqKabFY9g0PUf7SULbXFleEc+XOAr/mME1qReRbzeYILjT7jvJAfNjz7r1rwtSVYMpIYdCDgir8OsajCcpdyn/eOatTFyn0npOtwzQCLVYfNtj/y82hEi/wDAkPIrqtI0a7liNz4Q8TRBRyYZkJT6Edq+a/DHjYWVyp1NbgD/AJ62xG78QetfQXgzxBpF5puk3FvqVo5v711hWZDDJK6KqsoH8RG8fXcKJTstNzKpeK0OkaLXkbGr6ZaySf8APzZSbT+INZuoW3mkmURnPdj5L/mODVO41KKxVRBd3Ea4/wCWc4kU/rWY3iizu2NvJqLwyHgeZGGU/XIrQY+6s5bY+YL6+hVeg3eYB+Irc8N64Iv3beIpiM/d3Hj8CK5eSxvCfOtvsV5FjO6AlGP4ZqOPTra8I8+wzMP+eVw0Umfx60DPXFuZbgFrPVdOmfrtmTy2H4ioLmXUHXZfWttInTKASgj+deS39hLZxD7JqWsWZGcLctvT6ZwapW+u6raSYeaG9XONy3Cxv/SgVj1ZdLt3Je3a1ikHWMu6D8jWrZW0w4ksoGBH3obkiuJ0TxVcOBvtryLHHzlJ1P5VoXfipFb/AEjSrabj7yBojQB6DBpE5IeNW/3XctWhBpdtIpjvY1jPfapH8647wb4htLmVRHpl8vPQS7h/OvUbSVZIgVilQejiok2hpXOI1b4YeGtXJ8+PcT9Mj8ua5uX4I6LZsZrOVlwcgNIR/WvXZNuMhXB/2V5rG1RdWxnTnx6CZFx+NJNjaseXXIXQx5MUImxxyy1U/e6mxy0FmO7K67gPzrb8Ux+JWjYaiNHWPH3gisa8wv206yuvNuLy5EoOcWsKjn2rREnoFt4cjRt8nifVjnkpFKQK1IYNNg2q+qFiO9y7Mf1NeUT+Nr6JRFoUmos3TNxGCP0FQDxL4scibUdLtp7cDOGj2mkFj2c3WlxqSuvWUfqAi5/U1xniXXdFZZE/4SWSXPG2AHH6CvM9d8cTuoSz0zSbN+5lQMf5VxepeJfEE7EtqNvs7JDtT+QouNI3fF2paaWYx6heM2OPMVuR+NecXmoQGQlCJCP7ycVNfX99KSZFDN/eb5v51jS3Vwx+ZgfYKKhs0SsWRes5wogRT6JWlYPFAwaSQMfRcZrn2eVjl8gfTFSW+A3DEt7CpTGdp/bN2ylIGSNf7zEE1Une4uTtk1OVQe3mED9KNHs0uP8AX35hH91YyzH8BW5beGpLpwttb3E6f35U2Kfer3J0RF4b0aBrlS3iAwn/AKZcn/vo17d4Y1Twx4WjSS81m2urojgSTedIP6Cua8E+ArKUZv0sMejFjj8BXptj4e8M6Wg+ywWfmgdYbUZz9WqkiW7liP4pz3xEOjxxlOilIXct+QArftYvFWrwCUXK6bEw/wBZKoDY9hyf5Vi2wSWXEBePH3cBmOPYAAV01no7zJuNvPM/rcSbR+VKyFcis/C+kWUwudT1qS9uRyWkl4z9BW1P4j0vToeJ0RexfCD/ABP5VzPiCCx0qAvq2sadpsQ5OZVj49Msc15H4k+Kvg3SZJI9O1Ke7mGR5mn24d/wlk4H1ANLTqw9D1LxP4kgnheVoJmix/rZT5EQ/wCBPyfwFeQ+JZzqULyRi2gtF6yqp2gezN1rzbXPi1PPMX0nSolmHS71SQ3s491DYRfwWuD1vxBq2uzmXV9QuLtj2dvlH0UcD8qXOlsUos6TxFqekwO0dvcSXsncqcIK5G5uzM5KoqjPHc1Vr6H+G+o397B8MJr7UrgzxjxAkNxPK7tDGtmoQg8sFXBwB0xwKhyuUlY+eWJY5Y5NIxLEsxJJ6knOa+hvC3ie2u5Zg3iW81HWNO8N6i154gtI5DNhnjMaxmXy5HMYDEFiv38A4Ga57QdTm1S18Uaro2ua54j8SafpsTWM+rQD7RbIZwJnhXzpeVUj5gQRuYgDrSGeNUV6T47k1HVfh3oWt3nifVdbt5Lya1VNUtFWWJ1RGYrL5js6ZfAyR0PArzagAooooAKKKKACmSfdp9Nk+7QBFRRRQA+P734VJUcf3vwqSgAooooAK6TwNPYW11q82o3jWjrpN2tqy5/eTtHtVMgcZ3H0+tc3RQ9RNXVjsfE1nDH8N/BF4gbzpmv43yeNqSoVwP8AgbVx1dRqkt5c/Dnw8ZNzWdrfXkEbYACMwhcrn1PJrmERncIiszt0VRkmkgT0EorqbfwRq2A2rGz0OMgHdqs4t25zj93zIRx1C+nam2uneF7UwyarrlxeKRmS30y2IYHJGPMlwOmD0PpRzIXMuhzH1q1e6de2KxtfWdzbLJ9wzRMgb6ZHPWtxPE1vphb/AIRrSrewk6LeXB+03IHqGb5EPuqg+9Mg8a+IFO281S51K2YAPa6i5uYnUEHBVycdOowR2Io1C77HOUV08mq+F7i8FxN4auLddxJtbLUSsTDHAzIrsvPPU1LG3gTcnmReKNpVi+2S3+VuNoHy8jrk8fSi4X8jk6K6ZtU8LpDALfw1dvMhHmNc6mWWQD/ZRFxk+/8AjU9v4yigthAnhXwuyAEbpLN2fBz/ABGTOeetJt9EJyfRHLW8EtzOkFtG807nCxxqWZj6ADk0txbzW07wXMUkMyHDRyKVZT7g810b+ONbjt/s2lzw6RbDACabCtu2AQRmQfvG5GeWPU0+18balcQ/YvEks+uaUxLPb3UzFwx/5aJJyVcdicjsQRxT1Hd9jlMdq9O0GVdMm+Ej3V3GLQ6g2oOoH+pBu1Qk9+kINYAtPAqbJn1bxBMhbLWiWUSSBTnjzS5Ukcc7efQVDqms2+qeKdHOnwNDp1h5FparIqiVo0fIaQrwXJY5Iqb8xN+bpsUNbv7y08R6qLe5mixdzcK3H327dK0dJ8bXdnIpvLO2vkH97cjf99LVDx1afYfG3iC1D+YIdQnTfjG7Eh5xWbpmnXuq3aWum2s11cMcCOFCx/ToPerjLS6KVmkz2TQvin4cUAXVlqdhLj7yss6A/o1bEvjXwxeYki1S2mXj5JUeJx+f9DXkb+DJ7FpF8QappejPFII5IbiYyTgZwWEcQY8e+M9s08DwVpykl9Y1y4UgqoVbO3brkE/NIRnBBG0kccHmmqvzJvF7HtWl6/pF8xt7C8uZJT0hhmMhP/AcHiuf1Se0F1IYnMjqxVkmjAIPcHGCD9a8nvvFep3FvJa2rQabYuctbafGIEI9CR8zf8CJrV074gXywwQa3bxarHGf+Ph2Md3sxjYJhyQOoDhsVSqPsHKz1Pw/e2EzgXmkXI/6aWcxBH4Zr0PRPsalBbX2rQjrsu4C6j8SK8HtPifYWaItvolwduMtPcxyl+ckk+WMZHHHTr1rWb412jIUPhhlQnpHqBXH/jtUpoVmfS1h9hUBpIbaUA/ejQxtV9PEOkwHyvtV7at/vtivl2z+MOlQzK40i+iPO4y3AugM46A7Rx/Wus0f4z+Gw/8ApWoXcAJzh9JUhfoVkJ/Spc29kS+dbI98Fyb1M2HihYgehk5B+mcVUn07XGBYeLtM2+nkg/rvrzm3+M/giQrE+txSAjq9jKgH5girM3xE+Gd5Htutb0/5uubZif8A0GhNtgubZoseLNR1vTYjjVtLvRjo8IGf/Hq8i1O8v9Uu/wDSo7VST963gGf510viif4a6lGTYeKbGN8H7quv8xXlV/Ppljdf6FrvmoDwUGf61dykj0HSrawsxvudSv4W6kLFtxUGv69ZwQMLPxBPI3ZJFBzXLWHiq0jG2XWTtx/y0tVYfqaoaxrun3BbbNYyn++U2H8hRcdijf8AiDWp2IjaIgn7whHI/Gsie8nYH7SZnk9AwUfpUN5cW5J23MH/AGzDE/rWXLLHuO1nb8MVDZaRfDE5LxhB/tHP86ZLdBBtEiL/ALq5rOMxIxgD8KYxyc80rjJZZA5+87/XgVa04RmQb1Y/RsVn1LHcSRHKkfjSuB6j4XvmtQosohG/95VyfzxXVm48QTMGVgiN0ebk/lnFeJxeIdTgXFtc+R7xKFP59aq3ep394WN1e3U245IeViCfpmr57E8p9FaZ4ittKcNrWr2aqeNskgA46jaDV2++OHhbT4ilr9ovXH/PtB5a/mcZr5cxS0udhyo9x1T9oPUizDR9NWEHoZ5T/Jcfzrjdc+L/AI41dDHJrk9pCTkx2Q8kfmOf1rgKKlybHZEt3cz3s7T3k8txM3V5XLsfxNRUUUhhRRRQA6N3ikWSJ2SRSGVlOCCOhB9a1bzxPr97qUeo3muapcX8cbRJcy3cjyqjAhlDk5AIZgRnkE+tZFFAF7R9Y1PRLw3Wi6jeaddFSnnWk7QvtPUblIOOBxVu88U+IL3VLbUrzXdVuNRthiC6lvJHliHPCuTlep6HvWNRQBo63rur69LHLreq3+oyxghHvLh5ioPYFicVBqdzFeXrz29nBZRlUUQQFigIUAn5iTkkFjz1JxgYFLpUlhFfI2rW11dWYB3xWtwsEhOOMOyOBzj+E/h1r0zx14Q8H+F9H8I3N5H4gtb7V4zeXdgbuGeSC1IOzB8qPDscdRgYYYOKAPKKK9M8f+BdN0P4faJ4iht9Y0e/1C6kgOlarIskjRqCfOVhHGdv3Rgr/EOfW/4P8D6PrvwTvtXma0stb/t5LCLULqWYRpGyRnYVQMOWY87SRnqAKAPJKK9Luvg5runw61NrOo6PpcOkXsVjcSXMspG6QKyMuyNsoQ689RnkDBpLz4OeINPbxOdVvNKsYvDzQfa5ZpJSrrL9x49sZLL+APbGeKAPNaZJ92vTdb+DfiHSB4gWa80mafRbZL24ghmcs9u3SVCUCkcHgkNx05GfM5Pu/jQBFRRRQA+P734VJUSHB5p28e9AD6KZvHvRvHvQA+imbx6GjzB70Aei+FdKk8ReAfsT3EVvp+naubq7mA3PBC8B3Sbc8j9zgdPmYDPNY9x4tNizR+ELT+w4WUK88che6lwMZMp5TPUqmBn1rmIbyaGKaKGaWOKZQsqI5AkAOQGHcZ55qHePep5UTyomnlknlaWd3klb7zuxZj9SaZTN496N49DVFD6KZvHvRvHvQA+imbx70bx70APopm8e9G8e9AD6KZvHvRvHvQA+nRSNFIssbFZEIZSOxHINRbx70u8e9AHqPjbSLPQ/E2p654oi/tE3168lpYxylUu1IDPK8q4IXLgALyWB6Ac8hqni/WtQtHsjdfZdNZmIsbNBBCATnaVUDcBgY3Z/nWJeX9xeeT9rnmn8mJYYvMYtsReijPQD0qvvHvUqPclRXUf+Aopm8e9G8e9UUPopm8e9G8e9AD6KZvHvRvHvQA+imbx70bx70APopm8e9G8e9ADse1GBTd496N496AHYpaZvHvRvHvQA+imbx70bx70APopm8e9G8e9AD6KZvHvRvHvQA+imbx70bx70APopm8e9G8ehoAfRTN496N496AH0U3ePek3j3oAfRTN496N496AH0UzePejePegB9FM3j3o3j3oA0/D15aafrlhealY/2hZ28yyy2nmeWJgDnYWwcA9+DxXS+LvHCeMPiLP4k8Q6X9pspW2/2clyY9kQXaqLIBwRwc7cE9Rg4rh9496N496AO88QeOba68AWng/Q9JmstKhvTfvJeXYupnlKlcBhHGqrg9Av49c3fB3xD0/RvAUvhbV9An1K1k1VNUMkN+LckqqARkGJ8qdnPQ89utebbx70bx70Ae+XPxY0XxF4M8XS+LYpJdS1TV7e7j0q1keLdDGqKAJjG6gAIM5AJ5xjPHP+IvjPeeILDxxBqGlR+Z4l+zKjRzkLaJAflUKVO/Pc5Xkk+1eR7x70bx70Aeya18av7Tv/ABTc/wBgeV/bmjJpG37Zu8naCPMz5Y3dfu8fWvG5Pu0bx70jsCOKAGUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with fibroelastic deficiency with flail P2 scallop. Note focal involvement of the middle posterior scallop.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1166px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83603/3D_SHAX_nonclass_MVP_video.mp4?title=PLAX+view+of+nonclassic+MVP\" style=\"width:512px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Three-dimensional short-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with fibroelastic deficiency with flail P2 scallop. Note focal involvement of the middle posterior scallop.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24775=[""].join("\n");
var outline_f24_12_24775=null;
var title_f24_12_24776="Darier disease";
var content_f24_12_24776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Darier disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24776/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24776/contributors\">",
"     Pui-Yan Kwok, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24776/contributors\">",
"     Susan J Bayliss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24776/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/12/24776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7872118\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darier disease, also known as Darier-White disease or keratosis follicularis (MIM #1242000), is a rare autosomal dominant genodermatosis. It is characterized by a persistent eruption of greasy hyperkeratotic papules in seborrheic areas, nail abnormalities, and mucosal changes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/1\">",
"     1",
"    </a>",
"    ]. The disease usually starts around puberty and runs a chronic course with exacerbations induced by sun exposure, heat, friction, or infections.",
"   </p>",
"   <p>",
"    This topic will discuss the pathogenesis, clinical features, diagnosis, and management of Darier disease. Other acantholytic skin disorders, including Hailey-Hailey disease and Grover disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/40/11912?source=see_link\">",
"     \"Hailey-Hailey disease (benign familial pemphigus)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31381?source=see_link\">",
"     \"Grover's disease (transient and persistent acantholytic dermatosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7872125\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darier disease occurs worldwide with a prevalence of 1 to 4 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The disease affects both sexes and all ethnic groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7872132\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darier disease is caused by mutations in the",
"    <em>",
"     ATP2A2",
"    </em>",
"    gene on 12q23-24.1 that encodes the",
"    <span class=\"nowrap\">",
"     sarcoplasmic/endoplasmic",
"    </span>",
"    reticulum Ca",
"    <sup>",
"     2+",
"    </sup>",
"    -ATP isoform 2 protein (SERCA2), which is a calcium pump [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/4\">",
"     4",
"    </a>",
"    ]. SERCA2 actively transports calcium ions from the cytosol into the lumen of the endoplasmic reticulum to maintain a low cytoplasmic Ca",
"    <sup>",
"     2+",
"    </sup>",
"    level.",
"   </p>",
"   <p>",
"    The molecular mechanisms by which specific",
"    <em>",
"     ATP2A2",
"    </em>",
"    mutations alter the function of the SERCA2 protein and cause loss of desmosomal adhesion (acantholysis) and abnormal keratinization (dyskeratosis) are not known. In in vitro models, specific mutations of",
"    <em>",
"     ATP2A2",
"    </em>",
"    induce defects in protein expression, ATP hydrolysis, calcium transport, and calcium binding and kinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <em>",
"     ATP2A2",
"    </em>",
"    mutations also have been associated with impaired synthesis, folding, or trafficking of desmosomal proteins and abnormal cytokeratin expression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Darier disease is inherited in an autosomal dominant fashion, with complete penetrance and variable expressivity. Haploinsufficiency (one copy of the wild-type gene is not able to prevent disease) is thought to be the mechanism for the autosomal dominant inheritance pattern.",
"   </p>",
"   <p>",
"    More than 150 familial and sporadic mutations in",
"    <em>",
"     ATP2A2",
"    </em>",
"    have been identified in patients with Darier disease, including missense mutations, frameshift mutations, and in-frame deletions or insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/9\">",
"     9",
"    </a>",
"    ]. However, attempts to establish genotype-phenotype correlations have been unsuccessful. The observation that family members with identical",
"    <em>",
"     ATP2A2",
"    </em>",
"    mutations may have significant differences in the clinical manifestations of the disease suggests that other genes or environmental factors affect disease expression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49418038\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acantholysis (loss of cell-to-cell adhesion) and dyskeratosis (abnormal premature keratinization) are the main histologic features of Darier disease. Acantholysis results in the formation of characteristic suprabasal clefts (lacunae). The underlying dermal papillae covered by a single layer of epithelium (stratum basale) project into the clefts forming villus-like structures (",
"    <a class=\"graphic graphic_picture graphicRef86189 \" href=\"UTD.htm?30/4/30791\">",
"     picture 1",
"    </a>",
"    ). A large keratin plug, often showing focal parakeratosis, overlies each lesion. Hyperkeratosis is also common.",
"   </p>",
"   <p>",
"    Two types of dyskeratotic cells are present: &ldquo;corps ronds&rdquo; and &ldquo;grains.&rdquo; Corps ronds are predominantly located in the stratum spinosum and stratum granulosum and are characterized by an irregular eccentric and sometimes pyknotic nucleus, a clear perinuclear halo, and a brightly eosinophilic cytoplasm. Grains are mostly located in the stratum corneum and consist of oval cells with elongated cigar-shaped nuclei and abundant keratohyalin granules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7872139\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49417901\">",
"    <span class=\"h2\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial lesions of Darier disease typically appear during the teenage years as skin-colored or yellow-brown keratotic papules with a greasy, warty texture. The lesions typically involve the seborrheic areas (ie, forehead, scalp, hairline, nasolabial folds, ears, chest, and back) and may coalesce to form large, crusted plaques (",
"    <a class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188 \" href=\"UTD.htm?43/4/44106\">",
"     picture 2A-E",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most patients also have mild involvement of the intertriginous areas (groin, axillae, and, in women, submammary fold). In a small subset of patients, flexural disease predominates, with large, warty, vegetative plaques in the axillae, groin, or perineum. Flexural lesions may be disabling because of maceration and malodor.",
"   </p>",
"   <p>",
"    The hands are involved in most patients. Palmar lesions include punctate keratoses, pits, and, less frequently, hemorrhagic macules. In severe cases, palmoplantar hyperkeratosis may occur (",
"    <a class=\"graphic graphic_picture graphicRef86185 \" href=\"UTD.htm?9/36/9796\">",
"     picture 3",
"    </a>",
"    ). Many patients have warty, flat-topped papules on the dorsa of the hands and feet. These are clinically indistinguishable from acrokeratosis verruciformis, another rare autosomal dominant genodermatosis. The observation that some patients with acrokeratosis verruciformis, which involves only the dorsa of the hands and feet, harbor mutations in",
"    <em>",
"     ATP2A2",
"    </em>",
"    suggests that this condition may actually be a localized form of Darier disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49417908\">",
"    <span class=\"h2\">",
"     Nail changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail changes of the fingers are present in most patients with Darier disease and provide an important diagnostic clue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/13\">",
"     13",
"    </a>",
"    ]. White and red longitudinal bands, longitudinal nail ridges, longitudinal splitting, and subungual hyperkeratosis are common. A sandwich of red and white longitudinal bands, often with a V-shaped nick at the free margin of the nail, is a pathognomonic finding (",
"    <a class=\"graphic graphic_picture graphicRef81865 \" href=\"UTD.htm?25/36/26178\">",
"     picture 4",
"    </a>",
"    ). Less commonly, these nail changes also occur on the toes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=see_link&amp;anchor=H343070#H343070\">",
"     \"Overview of nail disorders\", section on 'Darier disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49417918\">",
"    <span class=\"h2\">",
"     Mucosal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal lesions consisting of white papules with a central depression may be seen infrequently in some patients with Darier disease (",
"    <a class=\"graphic graphic_picture graphicRef86184 \" href=\"UTD.htm?4/13/4307\">",
"     picture 5",
"    </a>",
"    ). These cobblestone lesions are most commonly found in the mouth, but may also occur on the anogenital mucosa. At times, oral lesions may cause blockage of the salivary ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58289047\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms reported by most patients with Darier disease include itch, malodor, and pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49417925\">",
"    <span class=\"h2\">",
"     Neuropsychiatric abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neuropsychiatric abnormalities such as epilepsy, mental impairment, and mood disorders have been reported in association with Darier disease, there is no evidence that mutations in",
"    <em>",
"     ATP2A2",
"    </em>",
"    are associated with these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Genetic linkage analysis in families with co-occurrence of Darier disease and major affective disorders suggests that a susceptibility locus for bipolar disorder co-segregates with genetic markers found in the Darier disease region, but is distinct from the gene for Darier disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58289039\">",
"    <span class=\"h1\">",
"     CLINICAL VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical variants of Darier disease include hypertrophic, vesicobullous, erosive, and acral hemorrhagic types, and the type that predominantly involves the intertriginous areas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Linear or segmental forms of Darier disease may result from genetic mosaicism of",
"    <em>",
"     ATP2A2",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/23\">",
"     23",
"    </a>",
"    ]. Type 1 mosaicism, reflecting a postzygotic somatic mutation in",
"    <em>",
"     ATP2A2",
"    </em>",
"    early during embryogenesis, presents with one or more unilateral bands of keratotic papules following the Blaschko lines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/24\">",
"     24",
"    </a>",
"    ]. Type 2 mosaicism reflects a postzygotic mutation causing loss of heterozygosity at the",
"    <em>",
"     ATP2A2",
"    </em>",
"    locus and manifests with more severely affected linear bands of lesions superimposed on generalized disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49418100\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the severity of Darier disease is variable, the condition generally runs a chronic course with frequent exacerbations. Exacerbating factors include heat, sweat, sun exposure, friction, or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/25\">",
"     25",
"    </a>",
"    ]. The appearance and malodor of the skin lesions are a source of considerable distress for patients and may lead to social isolation.",
"   </p>",
"   <p>",
"    Bacterial and fungal infections are frequent complications. Widespread herpes simplex virus infection (eczema herpeticum) and pox virus infection may rarely occur in patients with Darier disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Eczema herpeticum is suspected if there is a sudden eruption of vesicular and crusted lesions with skin pain and fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H31627071#H31627071\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Eczema herpeticum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7872153\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Darier disease is suggested by the clinical finding of a persistent eruption of skin-colored or yellow-brown keratotic papules involving seborrheic areas such as forehead, hairline, nasolabial folds, ears, chest, and back (",
"    <a class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188 \" href=\"UTD.htm?43/4/44106\">",
"     picture 2A-E",
"    </a>",
"    ). Nail changes, including white and red longitudinal bands, a V-shaped nick at the free nail margin, and subungual hyperkeratosis, are an important diagnostic clue (",
"    <a class=\"graphic graphic_picture graphicRef81865 \" href=\"UTD.htm?25/36/26178\">",
"     picture 4",
"    </a>",
"    ). A sandwich of red and white longitudinal bands, often with a V-shaped nick at the free margin of the nail, is a pathognomonic finding. (See",
"    <a class=\"local\" href=\"#H7872139\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A skin biopsy for",
"    <strong>",
"    </strong>",
"    histologic examination is needed to confirm the diagnosis. The histologic diagnosis is based upon the finding of focal suprabasal acantholysis and dyskeratosis with characteristic eosinophilic &ldquo;corps ronds&rdquo; and &ldquo;grains&rdquo; in the epidermis and stratum corneum. (See",
"    <a class=\"local\" href=\"#H49418038\">",
"     'Histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When bacterial or fungal superinfection is suspected, bacterial and fungal cultures of the involved sites are useful to determine appropriate antibiotic or antifungal treatment. In patients with vesicular lesions suggesting herpes virus superinfection (eczema herpeticum) a Tzanck smear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    viral culture can confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Viral culture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Tzanck smear'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7872160\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of Darier disease includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Seborrheic dermatitis",
"      </strong>",
"      &ndash; The skin lesions of seborrheic dermatitis are erythematous plaques with yellowish, greasy scales involving the scalp, eyebrows, nasolabial folds, or, occasionally, flexural areas such as axillae and groin (",
"      <a class=\"graphic graphic_picture graphicRef59104 graphicRef68137 graphicRef53407 \" href=\"UTD.htm?27/12/27850\">",
"       picture 6A-C",
"      </a>",
"      ). Seborrheic dermatitis does not involve hands, feet, or nails. Histology shows focal parakeratosis, psoriasiform acanthosis, and mild to moderate spongiosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=see_link\">",
"       \"Seborrheic dermatitis in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acrokeratosis verruciformis of Hopf",
"      </strong>",
"      &ndash; Acrokeratosis verruciformis (AKV) of Hopf (MIM #101900) is a rare autosomal dominant disease that usually presents at birth or in early childhood. Asymptomatic, skin-colored, flat-topped warty papule on the dorsa of the hands and feet, palmar pits, and punctate keratoses are typical lesions of AKV (",
"      <a class=\"graphic graphic_picture graphicRef86092 graphicRef86093 \" href=\"UTD.htm?29/12/29897\">",
"       picture 7A-B",
"      </a>",
"      ). Histology shows hyperkeratosis, hypergranulosis, and acanthosis with papillomatosis. Acantholytic and dyskeratotic keratinocytes are absent.",
"     </li>",
"     <li>",
"      <strong>",
"       Hailey-Hailey disease (familiar benign pemphigus)",
"      </strong>",
"      &ndash; Hailey-Hailey disease (HHD) primarily affects the intertriginous areas and may be difficult to differentiate from Darier disease with flexural involvement (",
"      <a class=\"graphic graphic_picture graphicRef76004 \" href=\"UTD.htm?17/11/17589\">",
"       picture 8",
"      </a>",
"      ). Nail dystrophy is typically absent in HHD. Histology shows areas of partial suprabasal acantholysis with the characteristic appearance of a &ldquo;dilapidated brick wall&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef75555 \" href=\"UTD.htm?8/21/8535\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/40/11912?source=see_link\">",
"       \"Hailey-Hailey disease (benign familial pemphigus)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Grover disease (transient and persistent acantholytic dermatosis)",
"      </strong>",
"      &ndash; Grover disease is an uncommon pruritic papular or papulovesicular rash that most commonly affects the trunk (",
"      <a class=\"graphic graphic_picture graphicRef76504 \" href=\"UTD.htm?37/5/37983\">",
"       picture 10",
"      </a>",
"      ). The face, palms, soles, or nails are not involved. Histology shows subtle and focal acantholysis, with intraepidermal clefts and dyskeratotic cells (",
"      <a class=\"graphic graphic_picture graphicRef56584 \" href=\"UTD.htm?10/62/11239\">",
"       picture 11",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31381?source=see_link\">",
"       \"Grover's disease (transient and persistent acantholytic dermatosis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7872169\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no cure for Darier disease. The goals of treatment are the improvement of the skin appearance, relief of symptoms (eg, irritation, pruritus, or malodor), and prevention or treatment of infectious complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52210573\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with Darier disease should be educated about simple measures to reduce the impact of exacerbating factors and control skin irritation. These measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keeping the skin cool and minimizing perspiration. Flares may be prevented by wearing lightweight cotton clothes, avoiding hot environments, and using sunscreens, especially during the summer.",
"     </li>",
"     <li>",
"      Regular use of moisturizers containing keratolytics such as urea or lactic acid. Moisturizers reduce irritation, decrease scaling and hyperkeratosis, and improve the skin appearance.",
"     </li>",
"     <li>",
"      Use of antiseptic washes containing Triclosan or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine gluconate",
"      </a>",
"      or bleach baths",
"      <span class=\"nowrap\">",
"       (1/4",
"      </span>",
"      cup [60 mL] of household bleach in a full tub of water). Antiseptics reduce the burden of skin bacteria and odor. Patients may also be instructed to soaks in astringents, such as Burrow or Domeboro solution, if crusting is prominent or bacterial overgrowth is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52210643\">",
"    <span class=\"h2\">",
"     Topical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapies for Darier disease are aimed at controlling skin inflammation, reducing hyperkeratosis, and flattening the papular lesions. Topical treatments include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Topical corticosteroids",
"      </strong>",
"      &ndash; Low to medium potency topical corticosteroids (class four to six (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) may reduce skin inflammation. Although their efficacy has not been evaluated in clinical trials, they are frequently used in patients with Darier disease on the basis of their antiinflammatory properties and clinical experience.",
"     </li>",
"     <li>",
"      <strong>",
"       Topical retinoids",
"      </strong>",
"      &ndash; Topical retinoids, including tretinoin 0.1%,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1%, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"       tazarotene",
"      </a>",
"      0.05%, have been used in patients with mild or localized disease to reduce hyperkeratosis and flatten papular lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/29-33\">",
"       29-33",
"      </a>",
"      ]. Their efficacy has not been evaluated in clinical trials. Evidence is limited to reports of single cases or small series of cases.",
"     </li>",
"     <li>",
"      <strong>",
"       Other topical agents",
"      </strong>",
"      &ndash; There are isolated reports of response to treatment with topical 5-fluorouracil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      , and tacalcitol [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/34-37\">",
"       34-37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52210686\">",
"    <span class=\"h2\">",
"     Systemic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral retinoids, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , and etretinate may decrease hyperkeratosis, smoothen papules, and reduce odor in patients with severe or generalized Darier disease. Etretinate is no longer available in most countries and has been replaced by acitretin. Acitretin and isotretinoin are usually given at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. (See",
"    <a class=\"local\" href=\"#H17980233\">",
"     'Patients with severe or generalized disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The efficacy of oral retinoids for the treatment of Darier disease has not been evaluated in randomized trials and evidence is limited to small observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/32,38-40\">",
"     32,38-40",
"    </a>",
"    ]. In a study including 26 patients with Darier disease treated with 30 mg per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    or etretinate for four months, remission or marked improvement was achieved in 18 of 24 patients who took the drug for the duration of the study period, without difference between the two drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral retinoids do not induce prolonged remission in Darier disease and long-term treatment is needed to prevent relapse. Adverse effects of systemic retinoids include mucosal dryness, photosensitivity, hyperlipidemia, transaminase elevation, and skeletal hyperostosis. Oral retinoids are teratogenic, and appropriate counseling and contraception must be given to women of childbearing age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52210715\">",
"    <span class=\"h2\">",
"     Surgical or destructive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches for localized hypertrophic, erosive, or recalcitrant lesions that are resistant to conventional treatment include dermabrasion, electrosurgery, laser ablation, surgical excision, and photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/41-51\">",
"     41-51",
"    </a>",
"    ]. None of these treatments has been evaluated in clinical trials. Recurrence of lesions following excision is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58288203\">",
"    <span class=\"h2\">",
"     Treatment of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial or fungal superinfections are generally treated with topical antibiotics or antifungals (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    2% cream,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    0.1% cream, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% cream). Antibacterial washes such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    &nbsp;4% wash may be used as an adjunct to topical antibiotics. Patients with extensive cutaneous infection that does not respond to topical treatment may require systemic treatment with oral antibiotics or antifungals guided by culture results.",
"   </p>",
"   <p>",
"    Patients with eczema herpeticum are treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\", section on 'Atopic eczema, burns, and other skin disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17980217\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education about avoidance of triggers (eg, heat, sun exposure, sweating, or friction), control of skin irritation, and prevention of superinfection is an important component of treatment. The choice of topical or systemic therapies is based upon the disease severity and patient&rsquo;s preference. Since Darier disease is an autosomal dominant disorder with high penetrance, genetic counseling may be offered if appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17980225\">",
"    <span class=\"h2\">",
"     Patients with mild or localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mild or localized disease, avoidance of triggers, regular use of emollients, and intermittent use of medium potency topical corticosteroids (groups four and five (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) are generally sufficient to control symptoms. (See",
"    <a class=\"local\" href=\"#H52210573\">",
"     'General measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with mild or localized disease that is not controlled by emollients and topical corticosteroids, we suggest topical retinoids. Tretinoin 0.05% or 0.1% cream,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    0.1% cream, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    0.05% or 0.1% cream are applied to the involved skin once daily for three months.",
"   </p>",
"   <p>",
"    Because of the irritancy potential of topical retinoids, treatment is started with the lowest retinoid concentration applied on alternate days. After the first two weeks of treatment, frequency of application and retinoid concentration are gradually increased as tolerated. Emollients are used liberally in conjunction with topical retinoids. Intermittent use of medium potency topical corticosteroids (groups four and five (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) may reduce retinoid-induced irritation.",
"   </p>",
"   <p>",
"    Treatment with topical retinoids should not be started during pregnancy, and should be discontinued in patients who become pregnant, although there is no direct evidence that topical retinoids cause congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24776/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17980233\">",
"    <span class=\"h2\">",
"     Patients with severe or generalized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest oral retinoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    for patients with severe or extensive Darier disease. Treatment is generally started with a low dose (10 to 25 mg per day) to avoid initial exacerbation of the disease; the dose is then gradually increased as tolerated, up to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Treatment should be continued for a minimum of three to four months to achieve reduction of hyperkeratosis, flattening of papular lesions, and reduction of malodor. Long-term treatment is needed to prevent relapse.",
"   </p>",
"   <p>",
"    Common side effects of systemic retinoids include mucosal and skin dryness, cheilitis, photosensitivity, hair loss, hyperlipidemia, and elevation of liver transaminase levels. Measurement of baseline serum lipid and liver enzyme levels is indicated before initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy. Monitoring of serum lipid and liver enzyme levels for the first two months and then every three months is adequate for patients on long-term retinoid therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    &nbsp;and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    are teratogenic. Appropriate counseling and contraception must be given to women of childbearing age before starting oral retinoids. Women should avoid pregnancy for",
"    <strong>",
"     three years",
"    </strong>",
"    &nbsp;after discontinuing acitretin and for",
"    <strong>",
"     one month",
"    </strong>",
"    after discontinuation of isotretinoin. Isotretinoin is thus preferred to acitretin for women of childbearing age who have severe Darier disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link&amp;anchor=H7#H7\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Isotretinoin safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with localized hypertrophic lesions that do not respond to oral retinoids, surgical excision, laser ablation, or photodynamic therapy are therapeutic options. However, these approaches are associated with pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scarring and their long-term benefits are uncertain. (See",
"    <a class=\"local\" href=\"#H52210715\">",
"     'Surgical or destructive therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7872176\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Darier disease have a normal life expectancy, although their quality of life may be significantly impaired. The disease follows a chronic course and relapse is common when treatment is stopped. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58288266\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Darier disease, also known as Darier-White disease or keratosis follicularis (MIM #1242000) is a rare autosomal dominant genodermatosis characterized by a persistent eruption of greasy hyperkeratotic papules in seborrheic regions, nail abnormalities, and mucosal changes. Sporadic cases are also common. (See",
"      <a class=\"local\" href=\"#H7872118\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Darier disease is caused by mutations in the",
"      <em>",
"       ATP2A2",
"      </em>",
"      gene on 12q23-24.1 that encodes a",
"      <span class=\"nowrap\">",
"       sarcoplasmic/endoplasmic",
"      </span>",
"      reticulum a calcium pump (SERCA2). Acantholysis and dyskeratosis are the histologic hallmark of Darier disease (",
"      <a class=\"graphic graphic_picture graphicRef86189 \" href=\"UTD.htm?30/4/30791\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7872132\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H49418038\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial lesions of Darier disease appear during the teenage years as skin-colored or yellow-brown keratotic papules that involve the face, chest, and back, and, less frequently, the flexural areas (",
"      <a class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188 \" href=\"UTD.htm?43/4/44106\">",
"       picture 2A-E",
"      </a>",
"      ). Nail changes, including red and white longitudinal bands with a V-shaped nick at the free margin of the nail, are frequent and characteristic (",
"      <a class=\"graphic graphic_picture graphicRef81865 \" href=\"UTD.htm?25/36/26178\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7872139\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58289039\">",
"       'Clinical variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Darier disease is suggested by the clinical finding of a persistent eruption of keratotic papules involving the seborrheic areas. A skin biopsy for",
"      <strong>",
"      </strong>",
"      histologic examination is needed to confirm the diagnosis and exclude other conditions with similar clinical findings. (See",
"      <a class=\"local\" href=\"#H7872153\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7872160\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild or localized disease, avoidance of triggers, regular use of emollients, and intermittent use of medium potency topical corticosteroids (groups four and five (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) are generally sufficient to control symptoms. For patients with limited disease that is not controlled by emollients, we suggest topical retinoids such as tretinoin 0.05% cream,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% cream, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"       tazarotene",
"      </a>",
"      0.05% cream (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical retinoids are applied once a day for three months. (See",
"      <a class=\"local\" href=\"#H52210573\">",
"       'General measures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17980225\">",
"       'Patients with mild or localized disease'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We suggest oral retinoids such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       acitretin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      for patients with severe or extensive Darier disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Acitretin or isotretinoin is given at a dose of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for three to four months. For women of childbearing age, isotretinoin is preferred to acitretin. (See",
"      <a class=\"local\" href=\"#H17980233\">",
"       'Patients with severe or generalized disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/1\">",
"      Darier FJ. De la psorospermose folliculaire v&eacute;g&eacute;tante. Annales de dermatologie et de syphilographie 1889; 10:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/2\">",
"      Cooper SM, Burge SM. Darier's disease: epidemiology, pathophysiology, and management. Am J Clin Dermatol 2003; 4:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/3\">",
"      Godic A, Miljkovic J, Kansky A, Vidmar G. Epidemiology of Darier's Disease in Slovenia. Acta Dermatovenerol Alp Panonica Adriat 2005; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/4\">",
"      Sakuntabhai A, Ruiz-Perez V, Carter S, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 1999; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/5\">",
"      Miyauchi Y, Daiho T, Yamasaki K, et al. Comprehensive analysis of expression and function of 51 sarco(endo)plasmic reticulum Ca2+-ATPase mutants associated with Darier disease. J Biol Chem 2006; 281:22882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/6\">",
"      Dhitavat J, Fairclough RJ, Hovnanian A, Burge SM. Calcium pumps and keratinocytes: lessons from Darier's disease and Hailey-Hailey disease. Br J Dermatol 2004; 150:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/7\">",
"      Dhitavat J, Cobbold C, Leslie N, et al. Impaired trafficking of the desmoplakins in cultured Darier's disease keratinocytes. J Invest Dermatol 2003; 121:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/8\">",
"      Leinonen PT, H&auml;gg PM, Peltonen S, et al. Reevaluation of the normal epidermal calcium gradient, and analysis of calcium levels and ATP receptors in Hailey-Hailey and Darier epidermis. J Invest Dermatol 2009; 129:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/9\">",
"      Klausegger A, Nischler E, Wagner RN, et al. Seven novel mutations in the ATP2A2 gene of Austrian patients with Darier's disease. Arch Dermatol Res 2011; 303:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/10\">",
"      Onozuka T, Sawamura D, Yokota K, Shimizu H. Mutational analysis of the ATP2A2 gene in two Darier disease families with intrafamilial variability. Br J Dermatol 2004; 150:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/11\">",
"      Bchetnia M, Charfeddine C, Kassar S, et al. Clinical and mutational heterogeneity of Darier disease in Tunisian families. Arch Dermatol 2009; 145:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/12\">",
"      Dhitavat J, Macfarlane S, Dode L, et al. Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2: evidence that it is allelic to Darier's disease. J Invest Dermatol 2003; 120:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/13\">",
"      Munro CS. The phenotype of Darier's disease: penetrance and expressivity in adults and children. Br J Dermatol 1992; 127:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/14\">",
"      Bernab&eacute; DG, Kawata LT, Beneti IM, et al. Multiple white papules in the palate: oral manifestation of Darier's disease. Clin Exp Dermatol 2009; 34:e270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/15\">",
"      Jacobsen NJ, Lyons I, Hoogendoorn B, et al. ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes. Hum Mol Genet 1999; 8:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/16\">",
"      Gordon-Smith K, Jones LA, Burge SM, et al. The neuropsychiatric phenotype in Darier disease. Br J Dermatol 2010; 163:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/17\">",
"      Ruiz-Perez VL, Carter SA, Healy E, et al. ATP2A2 mutations in Darier's disease: variant cutaneous phenotypes are associated with missense mutations, but neuropsychiatric features are independent of mutation class. Hum Mol Genet 1999; 8:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/18\">",
"      Jones I, Jacobsen N, Green EK, et al. Evidence for familial cosegregation of major affective disorder and genetic markers flanking the gene for Darier's disease. Mol Psychiatry 2002; 7:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/19\">",
"      Green E, Elvidge G, Jacobsen N, et al. Localization of bipolar susceptibility locus by molecular genetic analysis of the chromosome 12q23-q24 region in two pedigrees with bipolar disorder and Darier's disease. Am J Psychiatry 2005; 162:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/20\">",
"      Telfer NR, Burge SM, Ryan TJ. Vesiculo-bullous Darier's disease. Br J Dermatol 1990; 122:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/21\">",
"      Rongioletti F, Cestari R, Rebora A. Verrucous and malodorous vegetations on the legs. Darier's disease, cornifying type. Arch Dermatol 1992; 128:399, 402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/22\">",
"      Foresman PL, Goldsmith LA, Ginn L, Beck AL. Hemorrhagic Darier's disease. Arch Dermatol 1993; 129:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/23\">",
"      Meziane M, Chraibi R, Kihel N, et al. Linear Darier disease. Dermatol Online J 2008; 14:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/24\">",
"      Sanderson EA, Killoran CE, Pedvis-Leftick A, Wilkel CS. Localized Darier's disease in a Blaschkoid distribution: two cases of phenotypic mosaicism and a review of mosaic Darier's disease. J Dermatol 2007; 34:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/25\">",
"      Otley CC, Momtaz K. Induction of Darier-White disease with UVB radiation in a clinically photo-insensitive patient. J Am Acad Dermatol 1996; 34:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/26\">",
"      Okada E, Nagai Y, Motegi S, et al. Fatal case of Darier's disease with recurrent severe infections. Acta Derm Venereol 2009; 89:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/27\">",
"      Woo SM, Won CH, Cho S. Darier's disease: variable clinical presentation and a fatal outcome. Clin Exp Dermatol 2009; 34:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/28\">",
"      Haase O, Moser A, Rose C, et al. Generalized cowpox infection in a patient with Darier disease. Br J Dermatol 2011; 164:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/29\">",
"      Casals M, Campoy A, Aspiolea F, et al. Successful treatment of linear Darier's disease with topical adapalene. J Eur Acad Dermatol Venereol 2009; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/30\">",
"      Burkhart CG, Burkhart CN. Tazarotene gel for Darier's disease. J Am Acad Dermatol 1998; 38:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/31\">",
"      Oster-Schmidt C. The treatment of Darier's disease with topical tazarotene. Br J Dermatol 1999; 141:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/32\">",
"      Dicken CH, Bauer EA, Hazen PG, et al. Isotretinoin treatment of Darier's disease. J Am Acad Dermatol 1982; 6:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/33\">",
"      Dogan S, Karaduman A, Erkin G, Gokoz O. Effective treatment of linear Darier's disease with topical retinoids: case report and review of the literature. Acta Dermatovenerol Croat 2011; 19:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/34\">",
"      Schmidt H, Ochsendorf FR, Wolter M, et al. Topical 5-fluorouracil in Darier disease. Br J Dermatol 2008; 158:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/35\">",
"      Yoon TY, Kim JW, Kim MK. Successful treatment of Darier disease with topical 5-fluorouracil. Br J Dermatol 2006; 154:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/36\">",
"      Le Bidre E, Delage M, Celerier P, et al. [Efficacy and risks of topical 5-fluorouracil in Darier's disease]. Ann Dermatol Venereol 2010; 137:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/37\">",
"      Rubegni P, Poggiali S, Sbano P, et al. A case of Darier's disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol 2006; 20:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/38\">",
"      Farb RM, Lazarus GS, Chiaramonti A, et al. The effect of 13-cis retinoic acid on epidermal lysosomal hydrolase activity in Darier's disease and pityriasis rubra pilaris. J Invest Dermatol 1980; 75:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/39\">",
"      Suzuki K, Aoki M, Kawana S. Localized Darier's disease of the scalp: successful treatment with oral etretinate. Dermatology 2004; 208:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/40\">",
"      Christophersen J, Geiger JM, Danneskiold-Samsoe P, et al. A double-blind comparison of acitretin and etretinate in the treatment of Darier's disease. Acta Derm Venereol 1992; 72:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/41\">",
"      Wheeland RG, Gilmore WA. The surgical treatment of hypertrophic Darier's disease. J Dermatol Surg Oncol 1985; 11:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/42\">",
"      Toombs EL, Peck GL. Electrosurgical treatment of etretinate-resistant Darier's disease. J Dermatol Surg Oncol 1989; 15:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/43\">",
"      Ahcan U, Dolenc-Voljc M, Zivec K, et al. The surgical treatment of hypertrophic intertriginous Darier's disease. J Plast Reconstr Aesthet Surg 2009; 62:e442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/44\">",
"      Brown VL, Kelly SE, Burge SM, Walker NP. Extensive recalcitrant Darier disease successfully treated with laser ablation. Br J Dermatol 2010; 162:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/45\">",
"      McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease. J Am Acad Dermatol 1990; 23:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/46\">",
"      Minsue Chen T, Wanitphakdeedecha R, Nguyen TH. Carbon dioxide laser ablation and adjunctive destruction for Darier-White disease (keratosis follicularis). Dermatol Surg 2008; 34:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/47\">",
"      Beier C, Kaufmann R. Efficacy of erbium:YAG laser ablation in Darier disease and Hailey-Hailey disease. Arch Dermatol 1999; 135:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/48\">",
"      Roos S, Karsai S, Ockenfel HM, Raulin C. Successful treatment of Darier disease with the flashlamp-pumped pulsed-dye laser. Arch Dermatol 2008; 144:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/49\">",
"      Katz TM, Firoz BF, Goldberg LH, Friedman PM. Treatment of Darier's disease using a 1,550-nm erbium-doped fiber laser. Dermatol Surg 2010; 36:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/50\">",
"      Exadaktylou D, Kurwa HA, Calonje E, Barlow RJ. Treatment of Darier's disease with photodynamic therapy. Br J Dermatol 2003; 149:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/51\">",
"      Avery HL, Hughes BR, Coley C, Cooper HL. Clinical improvement in Darier's disease with photodynamic therapy. Australas J Dermatol 2010; 51:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/52\">",
"      Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005; 136:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24776/abstract/53\">",
"      Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet 1997; 350:1143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15462 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24776=[""].join("\n");
var outline_f24_12_24776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H58288266\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872118\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872125\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872132\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49418038\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872139\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49417901\">",
"      Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49417908\">",
"      Nail changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49417918\">",
"      Mucosal lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58289047\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49417925\">",
"      Neuropsychiatric abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58289039\">",
"      CLINICAL VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49418100\">",
"      CLINICAL COURSE AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872153\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872160\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872169\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52210573\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52210643\">",
"      Topical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52210686\">",
"      Systemic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52210715\">",
"      Surgical or destructive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58288203\">",
"      Treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17980217\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17980225\">",
"      Patients with mild or localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17980233\">",
"      Patients with severe or generalized disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7872176\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58288266\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15462|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/4/30791\" title=\"picture 1\">",
"      Darier histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/3/29748\" title=\"picture 2A\">",
"      Darier disease - dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24164\" title=\"picture 2B\">",
"      Darier disease - light skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/9/32915\" title=\"picture 2C\">",
"      Darier plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/40/6792\" title=\"picture 2D\">",
"      Darier forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/17/21781\" title=\"picture 2E\">",
"      Darier keratotic papule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9796\" title=\"picture 3\">",
"      Darier plantar hyperkeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/36/26178\" title=\"picture 4\">",
"      Darier disease - nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/13/4307\" title=\"picture 5\">",
"      Darier mucosal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/42/28320\" title=\"picture 6A\">",
"      Seborrheic dermatitis face 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/8/19591\" title=\"picture 6B\">",
"      Seborrheic dermatitis groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/14/25827\" title=\"picture 6C\">",
"      Seborrheic dermatitis axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/49/35605\" title=\"picture 7A\">",
"      Acrokeratosis verruciformis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/10/31908\" title=\"picture 7B\">",
"      Acrokeratosis verruciformis punctate keratoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/11/17589\" title=\"picture 8\">",
"      Hailey-Hailey 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/21/8535\" title=\"picture 9\">",
"      Haley-Haley histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/5/37983\" title=\"picture 10\">",
"      Grovers disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/62/11239\" title=\"picture 11\">",
"      Grovers histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31381?source=related_link\">",
"      Grover's disease (transient and persistent acantholytic dermatosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/40/11912?source=related_link\">",
"      Hailey-Hailey disease (benign familial pemphigus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=related_link\">",
"      Overview of nail disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_12_24777="Diagnostic approach to the patient with polycythemia";
var content_f24_12_24777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to the patient with polycythemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24777/contributors\">",
"     Ayalew Tefferi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24777/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24777/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/12/24777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of polycythemia is most commonly suspected in a patient with an abnormally high result on one or more of the following blood tests [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/1\">",
"     1",
"    </a>",
"    ]: (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Laboratory testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematocrit &mdash; The hematocrit (HCT) is expressed as the percent of a blood sample occupied by intact RBCs. Polycythemia in the adult patient is suspected when the HCT is &gt;48 or &gt;52 percent in women and men, respectively.",
"     </li>",
"     <li>",
"      Hemoglobin concentration &mdash; The hemoglobin concentration (HGB) is its content in grams per 100 mL of whole blood. Polycythemia in the adult is suspected when the HGB is &gt;16.5 or &gt;18.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in women and men, respectively.",
"     </li>",
"     <li>",
"      Red blood cell count &mdash; The red blood cell (RBC) count is expressed as the number of RBC per microL or L of whole blood. It is least often used to suggest polycythemia since patients with thalassemia minor may have an elevated RBC count, but a normal or reduced HCT or HGB due presence of small (microcytic), poorly hemoglobinized (hypochromic) red cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to the patient with an elevation in one or more of the above RBC parameters will be reviewed here. The approach to confirming a diagnosis of polycythemia vera is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three measurements listed above (RBC count, HGB, and HCT) are concentrations and therefore dependent upon the plasma volume as well as the RBC mass (RCM).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Relative polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An isolated decrease in plasma volume can elevate the hemoglobin, hematocrit, and RBC count. The state of chronically reduced plasma volume with elevated hemoglobin or hematocrit has been called Gaisbock's disease, spurious polycythemia, stress erythrocytosis, apparent polycythemia, and pseudopolycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], although many may be examples of smokers' polycythemia (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Reduced plasma volume'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absolute polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In absolute polycythemia (erythrocytosis) there is an increased RCM. Patients are further categorized into primary and secondary forms (",
"    <a class=\"graphic graphic_table graphicRef76036 \" href=\"UTD.htm?30/46/31468\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Primary polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary polycythemia is caused by an acquired or inherited mutation leading to an abnormality within RBC progenitors; it includes polycythemia vera and rare familial variants (eg, activating mutations of the erythropoietin receptor, Chuvash polycythemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Idiopathic erythrocytosis has been used to categorize patients with primary polycythemia who do not fulfill conventional criteria for the diagnosis of polycythemia vera [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/7\">",
"     7",
"    </a>",
"    ], including negativity for the exon 14 V617F mutation of JAK2 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/8\">",
"     8",
"    </a>",
"    ]. The status of this term may change in the near future, since some patients considered to have idiopathic erythrocytosis have been found to have JAK2 mutations within exon 12 rather than exon 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'JAK2 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Secondary polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary polycythemia is caused by a circulating factor stimulating erythropoiesis, usually erythropoietin (Epo). It is most often due to an Epo response to hypoxia, but can also result from an Epo-secreting tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H24\">",
"     'Tumor polycythemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Combined polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may have an increased RCM as well as a reduced plasma volume, a combination most commonly seen in smokers (ie, \"smokers' polycythemia\") [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Inapparent polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the RCM and plasma volume are equally increased, HGB and HCT remain normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/11\">",
"     11",
"    </a>",
"    ]. Polycythemia can only be detected via blood volume studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF ERYTHROPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to all other blood cells, red blood cells (RBCs) are derived from the pluripotent hematopoietic stem cell after a hierarchical process of lineage-commitment and differentiation. Under normal conditions, the earliest, erythroid- committed progenitor cells depend on the trophic hormone erythropoietin (Epo) to further differentiate and produce RBC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ninety percent of circulating Epo in humans is synthesized by the kidneys in response to a hypoxic signal. The hypoxic signal to the Epo-producing renal cells may be the result of reductions in hemoglobin concentration (anemia) (",
"    <a class=\"graphic graphic_figure graphicRef53916 \" href=\"UTD.htm?34/53/35677\">",
"     figure 1",
"    </a>",
"    ), reduced hemoglobin oxygen saturation (hypoxemia), decreased oxygen release from hemoglobin (eg, high oxygen-affinity hemoglobinopathies), or reduced oxygen delivery to the kidney (eg, vascular occlusion). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H19#H19\">",
"     \"Regulation of erythropoiesis\", section on 'Hypoxia-inducible factor and the response to hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A negative feedback inhibition mechanism downregulates Epo production with increasing oxygen delivery. Thus, Epo-independent erythrocytosis (as in polycythemia vera) suppresses renal Epo production resulting in low serum Epo concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Epo- driven erythropoiesis (eg, hypoxia or an Epo-secreting tumor) characterizes secondary erythrocytosis and is associated with normal or high serum Epo concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a high value for hemoglobin or hematocrit has been reported, it should be confirmed by repeat testing. The importance of repeat testing was shown in a study of 10,000 residents of Vicenza, Italy, in whom 88 (0.9 percent) had an initially elevated hematocrit (ie, &gt;48 or &gt;51 percent in women and men, respectively, values slightly greater than the 99th percentile for hematocrit in this population) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/16\">",
"     16",
"    </a>",
"    ]. The hematocrit was elevated in only 35 of the 88 patients (40 percent) on repeat testing at a median interval of eight months (range: 6 to 14 months).",
"   </p>",
"   <p>",
"    The major causes of polycythemia are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef76036 \" href=\"UTD.htm?30/46/31468\">",
"     table 1",
"    </a>",
"    ). Several basic steps towards this evaluation are described below [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate history may be critical. The most common cause of polycythemia is hypoxia secondary to pulmonary disease; as a result, eliciting symptoms pertaining to altered lung function is of paramount importance. These include shortness of breath, dyspnea on exertion, chronic cough, history of cyanosis, hypersomnolence with unintentional sleep, as well as details of previously diagnosed heart and lung conditions.",
"   </p>",
"   <p>",
"    Other historical information may point directly to the etiology, such as living for extended periods of time at high altitude, patients previously placed on home oxygen therapy or respiratory assist devices, known intracardiac or intrapulmonary shunts, or renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=see_link\">",
"     \"Erythrocytosis following renal transplantation\"",
"    </a>",
"    .) The occurrence of hemorrhagic or thrombotic events, or the presence of post-bath pruritus should raise the suspicion of polycythemia vera.",
"   </p>",
"   <p>",
"    Since some polycythemic conditions can be inherited (eg, high oxygen affinity hemoglobinopathies), a family history of increased RBC count, HGB, or HCT should be sought. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary hemorrhagic telangiectasia, which can cause gastrointestinal bleeding and anemia, can also cause polycythemia secondary to the presence of pulmonary arteriovenous malformations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features\", section on 'Physiological tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medications and lifestyle activities can result in an increase in RCM. These include androgens (eg, testosterone) or anabolic steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/18\">",
"     18",
"    </a>",
"    ], self-injection of erythropoietin, or transfusion of stored autologous or allogeneic RBCs in order to improve athletic performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of androgens and other hormones to enhance athletic performance\", section on 'Erythrocytosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H21#H21\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Erythrocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A careful smoking history should be obtained, including the number of cigarettes (or cigars) smoked daily and whether or not the patient inhales the smoke. As noted above, polycythemia in association with plasma volume depletion can occur in smokers and in patients with marked volume depletion of any cause [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/6,19,20\">",
"     6,19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic exposure to carbon monoxide (CO) should also be sought, especially in patients with recently detected polycythemia and symptoms such as headache, dizziness, nausea, malaise, and altered cognition. CO sources are often occupational, such as workers in underground parking lots or tunnels, taxi cab drivers working in congested environments, and workers in industries exposed to engine exhausts or products of combustion. It is reasonable to have the patient recount a typical workday in order to assess potentially toxic environments. This questioning can also include home situations, such as use of home heating devices and faulty venting of furnaces or fireplaces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many medical centers, pulse oximetry for estimation of arterial oxygen saturation is considered a fifth vital sign; a low value suggests the presence of cardiopulmonary disease. Since some patients will not show reduced values for oxygen saturation while at rest or during the daytime, pulse oximetry should be obtained after minimal exertion and, if suggested by the clinical history, sleep studies may be necessary to determine the presence of nocturnal desaturation.",
"   </p>",
"   <p>",
"    Most pulse oximeters are",
"    <strong>",
"     not sensitive",
"    </strong>",
"    to the presence of carbon monoxide. As a result, direct blood testing via co-oximetry should be performed in all patients in whom CO poisoning is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General examination of the patient includes observation for cyanosis in the lips, earlobes and fingers, and for clubbing in the nailbeds. The patient's breathing patterns should be noted, along with any obvious dyspnea or shortness of breath during the examination. Abnormalities such as plethoric facies, dilated lingual or retinal veins, or areas of painful erythema may be seen in patients with polycythemia vera, while purple striae, ecchymoses, hirsutism, a buffalo hump, central obesity and moon facies suggest the diagnosis of Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .) Excessive sweating along with labile hypertension may be due to the presence of a pheochromocytoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should also be examined for cardiac murmurs or bruits (as in pulmonary arteriovenous shunts and right to left cardiac shunts). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .) The presence of hepatomegaly and splenomegaly in a patient with polycythemia may reflect the presence of polycythemia vera or an Epo-secreting hepatoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of routine laboratory tests can give valuable information concerning the cause of polycythemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is imperative to apply the sex and age-adjusted \"normal\" reference intervals before considering polycythemia on the basis of HGB, HCT, or RBC count. The normal range in adults refers to the lower and upper limits observed in 95 percent of the normal population (",
"      <a class=\"graphic graphic_table graphicRef64238 \" href=\"UTD.htm?41/52/42827\">",
"       table 2",
"      </a>",
"      ). This does not necessarily imply that outlying values are always abnormal, since, by definition, 2.5 percent of the normal population will have values that exceed these 95 percent confidence limits. Normal values for children are strongly dependent on age and sex, and are given separately (",
"      <a class=\"graphic graphic_table graphicRef57465 \" href=\"UTD.htm?5/34/5679\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A high RBC count along with a normal to reduced HGB and HCT and a reduced mean corpuscular volume (MCV) is a common finding in thalassemia minor. These patients have an increased number of very small RBC, and are not considered to have polycythemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Beta thalassemia minor'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An elevated total white blood cell",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      platelet count",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a reduced MCV, should raise the suspicion of polycythemia vera. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Microscopic hematuria may be the only clue to the presence of an Epo-secreting renal cell carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\", section on 'Symptoms and signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Functioning endocrine tumors associated with polycythemia can produce hyperglycemia and electrolyte disturbances such as hypokalemia.",
"     </li>",
"     <li>",
"      Abnormal liver function tests may suggest hepatoma, especially if the patient has a previous diagnosis of cirrhosis, viral hepatitis, or hemochromatosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Paraneoplastic syndromes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest x-ray may provide additional information (eg, arteriovenous malformations, chronic obstructive lung disease, pulmonary hypertension).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DOCUMENTATION OF POLYCYTHEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Blood volume measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic method for documenting polycythemia is a blood volume study, using isotopic dilution methodology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/24-27\">",
"     24-27",
"    </a>",
"    ], although non-radioactive labels (eg, carbon monoxide,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    ) have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Where testing is available, the RBC mass (RCM) is directly determined following infusion of the patient's own RBCs labeled with a radioactive isotope (eg, Tc99m, Cr51), while the plasma volume is simultaneously and directly determined following infusion of isotopically-labeled human albumin.",
"   </p>",
"   <p>",
"    While normal values differ according to age and sex, as well as from laboratory to laboratory, normal results are generally within the following ranges [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      RBC mass: 24 to 30",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      Plasma volume: 39 to 49",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These methodologies have been standardized through the International Council for Standardization in Hematology (ICSH), with recommendations that volumes be normalized to body surface area (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) rather than body weight or lean body weight, since the latter two methods are inaccurate in overweight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood volume estimation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible to measure either the RCM or the plasma volume and to estimate the other from the hematocrit of a blood sample taken from a peripheral vein. However, total body hematocrit (defined as RCM &divide; [RCM + plasma volume]) is usually 8 to 11 percent lower than the hematocrit obtained from large peripheral vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/31\">",
"     31",
"    </a>",
"    ]. Because of this error, use of the indirect method is not recommended for diagnostic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although directly measured values for RCM and plasma volume are accurate and constitute the \"gold standard\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/33\">",
"     33",
"    </a>",
"    ], an evidence-based critical review has raised several clinically relevant issues [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood volume measurements using isotope dilution are costly, time consuming, and no longer available in many locations.",
"     </li>",
"     <li>",
"      There is an excellent correlation between RCM and HCT; the additional information obtained from blood volume studies may not be critical.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, it has been the Mayo Clinic experience that all female patients with a hemoglobin concentration above 16.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and all male patients with a hemoglobin concentration above 18.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (or a hematocrit greater than 50 and 56 percent, respectively) have an increased RCM. Somewhat different values were obtained in a report from Belgium in which HCT above 55 and 60 percent in women and men, respectively, were associated with an increase in RCM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, the expense of a directly-measured RCM may not be justified for this group of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Reduced plasma volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;It might be argued that RCM and plasma volume measurements at lower HGB values (&lt;16.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women and &lt;18.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in men) are needed in order to distinguish absolute polycythemia from relative or inapparent polycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/11\">",
"     11",
"    </a>",
"    ]. However, some studies have questioned the existence of relative polycythemia as a separate nosologic entity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/4,26\">",
"     4,26",
"    </a>",
"    ]. The original studies regarding relative polycythemia had the following problems [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They included patients with high normal hematocrit values.",
"     </li>",
"     <li>",
"      The observations were based on plasma volume estimates indirectly derived from RCM measurements.",
"     </li>",
"     <li>",
"      The observed values were not corrected for lean body mass or for the difference between venous and whole body hematocrit values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In studies performed at the Mayo Clinic, only 7 of 40 patients with relative polycythemia were found to have reduced plasma volumes when both RCM and plasma volumes were measured independently and the measurements were calculated on the basis of ideal body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/35\">",
"     35",
"    </a>",
"    ]. In a later evaluation of 119 consecutive RCM and plasma volume measurements at the Mayo Clinic, not a single case of relative polycythemia was encountered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/26\">",
"     26",
"    </a>",
"    ]. However, this position is not universally held [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One setting in which reduced plasma volume may be important is in polycythemic smokers. Studies in such patients have found a combination of an increased RCM and a reduced plasma volume in the majority [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/6,19\">",
"     6,19",
"    </a>",
"    ]. These abnormalities return to normal with cessation of smoking.",
"   </p>",
"   <p>",
"    Extracellular fluid volume depletion of any cause can produce relative polycythemia that is readily reversed with fluid repletion, or by removal of the offending agent (eg, smoking of tobacco, use of caffeine-containing beverages, diuretics) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial evaluation, the clinician should be able to rule in or out a number of conditions associated with polycythemia. If repeat blood counts have been performed and are normal, and if no suspicious findings have been uncovered, no further investigation is necessary.",
"   </p>",
"   <p>",
"    If the initial evaluation indicates polycythemia, the following guidelines will help in determining the next diagnostic steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If exposure to tobacco smoke, engine exhaust, or other sources of carbon monoxide is a possibility, a blood carboxyhemoglobin (COHGB) determination should be performed. If exposures are related to smoking or the subject's occupation, the sampling should be performed at the end of the day, when levels will be at their highest. If exposure to CO is in the home, sampling should be performed as soon as possible after arising in the morning.",
"      <br/>",
"      <br/>",
"      COHGB values in excess of 5 percent strongly suggest polycythemia secondary to CO poisoning. This diagnosis is confirmed only if CO exposures can be stopped, with subsequent return of blood values to normal over the ensuing two to three months [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/6,19\">",
"       6,19",
"      </a>",
"      ]. A clue to the presence of smoking-related polycythemia is prompt reversal of a low plasma volume following cessation of smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/6\">",
"       6",
"      </a>",
"      ]. This is manifested clinically by a reduction in HCT of four or more percentage points within a few days of stopping smoking. Phlebotomy is not indicated in these patients unless the patient is symptomatic AND the total blood volume of the patient is increased.",
"     </li>",
"     <li>",
"      If hypoxia is a clinical possibility, screening with pulse oximetry should be performed. If this is not available, arterial oxygen saturation should be measured with the patient at rest, after minimal exercise, or during sleep, depending upon the clinical situation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"       \"Pulse oximetry\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the cause of polycythemia is not clear, and especially when arterial oxygen tension (pO2) is normal,",
"    <strong>",
"     direct measurement",
"    </strong>",
"    of arterial hemoglobin oxygen saturation should be performed. A low saturation in the presence of normal arterial oxygen tension suggests the presence of high concentrations of carboxyhemoglobin or methemoglobin, which can be confirmed via co-oximetry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a high oxygen affinity hemoglobin may be suggested by a positive family history of polycythemia, and is confirmed by showing a \"left-shifted\" hemoglobin oxygen dissociation curve, characterized by a reduced P50 (ie, the oxygen partial pressure at which hemoglobin is 50 percent saturated with oxygen) (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 2",
"    </a>",
"    ). Indirect calculation of the arterial oxygen saturation from the arterial oxygen tension alone will miss these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined blood volume study may be ordered to determine whether polycythemia is due to an elevation in RCM, a reduction in plasma volume, or both (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Blood volume measurement'",
"      </a>",
"      above). A venous hematocrit significantly in excess of 56 to 60 percent in men and 50 to 55 percent in women is almost always associated with an absolute increase in RCM [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In all other cases, it is reasonable to start the investigation by measuring the serum Epo concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serum erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low serum Epo level in the patient with erythrocytosis is relatively specific for the diagnosis of polycythemia vera (PV), although it can also be seen in the rare cases of congenital erythrocytosis characterized by an activating mutation in the erythropoietin receptor (called primary familial and congenital polycythemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. If polycythemia vera is strongly suspected and the initial value for Epo is normal, repeat testing may reveal a reduced value (",
"    <a class=\"graphic graphic_algorithm graphicRef52465 \" href=\"UTD.htm?8/56/9103\">",
"     algorithm 1",
"    </a>",
"    ). Confirmation of the diagnosis of PV can then be made via methods outlined elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythrocytosis associated with increased serum Epo is unlikely to represent PV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/14,15,41\">",
"     14,15,41",
"    </a>",
"    ] and a working diagnosis of secondary erythrocytosis should be made (",
"    <a class=\"graphic graphic_algorithm graphicRef65297 \" href=\"UTD.htm?8/63/9200\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/12,14\">",
"     12,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EVALUATION OF SECONDARY ERYTHROCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary erythrocytosis can be either congenital [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/42\">",
"     42",
"    </a>",
"    ] or acquired (",
"    <a class=\"graphic graphic_table graphicRef76036 \" href=\"UTD.htm?30/46/31468\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/43\">",
"     43",
"    </a>",
"    ]. In both situations, the increase in serum Epo level may represent an \"appropriate\" response to generalized hypoxia, as in chronic obstructive lung disease or a high oxygen affinity hemoglobinopathy. In some of these patients, serum Epo is normal because the appropriate Epo response is feedback-sensitive to the subsequent elevation in oxygen-carrying capacity.",
"   </p>",
"   <p>",
"    On the other hand, erythrocytosis associated with tumors or renal vascular disease is usually associated with significantly elevated serum Epo, since areas of hypoxic kidney and Epo-secreting tumors are not generally feedback sensitive to the increased oxygen carrying capacity generated by an elevated RCM (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Tumor polycythemia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Congenital polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital polycythemia is suspected when disease onset is at an early age or there is a positive family history of polycythemia. Mutant high-affinity hemoglobins have abnormal migration on starch gel electrophoresis in about 50 percent of cases. However, laboratory investigation usually begins with the determination of the oxygen pressure at 50 percent hemoglobin saturation (P50) (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 2",
"    </a>",
"    ). A low P50 suggests either a high oxygen affinity hemoglobinopathy (autosomal dominant) or familial 2,3-diphosphoglycerate (DPG) deficiency (autosomal recessive). Serum Epo is usually normal in both of these disorders because of the negative feedback inhibition of Epo by the erythrocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A normal P50 in a patient with a familial erythrocytosis is consistent with either autosomal dominant (benign) familial erythrocytosis (BFE) or autosomal recessive familial erythrocytosis (RFE) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BFE is usually associated with low or normal Epo and erythroid progenitor Epo-hypersensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/44\">",
"       44",
"      </a>",
"      ]. Activating EPO receptor mutations have been recognized in many of these patients, a disorder also called primary familial and congenital polycythemia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. However, some patients with autosomal dominant disease have autonomous overproduction of Epo and elevated serum Epo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RFE is the most frequent form of familial erythrocytosis and is prevalent in Russia (Chuvash polycythemia). Epo levels in RFE are variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Acquired secondary polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired secondary erythrocytosis is an Epo-driven process initiated by either an oxygen-sensitive Epo response to hypoxia or an unregulated pathologic production of Epo by tumors (",
"    <a class=\"graphic graphic_table graphicRef76036 \" href=\"UTD.htm?30/46/31468\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An oxygen-sensitive Epo response is further classified as being \"appropriate\" or \"inappropriate\" depending upon whether the hypoxic stimulus is generalized or regional. The degree of EPO elevation may differ among the various conditions associated with secondary erythrocytosis. In general, serum EPO concentrations are highest in congenital heart disease with right-to-left shunting or following renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link&amp;anchor=H4#H4\">",
"     \"Medical management of cyanotic congenital heart disease in adults\", section on 'Erythrocytosis and anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=see_link\">",
"     \"Erythrocytosis following renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients with posttransplant erythrocytosis do not have elevated serum EPO. Non-Epo factors in this setting may either enhance the sensitivity to Epo or directly promote erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/46\">",
"     46",
"    </a>",
"    ]. Implicated proteins include insulin-like growth factor-1 and insulin-like growth factor binding proteins, growth factors known to enhance erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/47\">",
"     47",
"    </a>",
"    ]. Regardless of the mechanism, posttransplant erythrocytosis generally responds to the administration of an angiotensin converting enzyme inhibitor or receptor antagonist.",
"   </p>",
"   <p>",
"    If arterial oxygen tension, hemoglobin oxygen saturation, and carboxyhemoglobin levels are normal, further investigation depends upon the particular clinical situation and the degree of Epo elevation. An otherwise unexplained erythrocytosis associated with increased serum Epo may require performance of an abdominal ultrasound or renal vascular studies to rule out renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], or other imaging procedures (eg, abdominal CT scan) to rule out the presence of an Epo-secreting tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Tumor polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five tumors most commonly associated with the overproduction of Epo (ie, paraneoplastic erythrocytosis) are hepatocellular carcinoma, renal cell carcinoma, hemangioblastoma (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=see_link\">",
"     \"Hemangioblastoma\"",
"    </a>",
"    ), pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/51\">",
"     51",
"    </a>",
"    ], and uterine myomata:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Raised serum Epo is present in up to 23 percent of patients with hepatocellular carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/22\">",
"       22",
"      </a>",
"      ]. However, the incidence of elevated serum Epo is higher than the incidence of erythrocytosis, presumably due to the inhibition of erythropoiesis by the malignancy as well as bleeding associated with esophageal varices",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a coagulopathy due to reduced hepatic production of clotting factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Erythrocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythrocytosis occurs in 1 to 5 percent of patients with renal cell carcinoma and appears to be due to the constitutive production of erythropoietin&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\", section on 'Erythrocytosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Since the mutated von Hippel-Lindau gene, which is present is many of these tumors, impairs the regulation of hypoxia-induced proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/52,53\">",
"       52,53",
"      </a>",
"      ], erythrocytosis may be directly related to impaired sensing of the ambient oxygen tension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"       \"Regulation of erythropoiesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H9#H9\">",
"       \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'Chuvash Polycythemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link&amp;anchor=H3#H3\">",
"       \"Molecular biology and pathogenesis of von Hippel-Lindau disease\", section on 'Hypoxia-inducible factor-1 and 2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uterine myomata (fibroids) have been associated with secondary erythrocytosis, normal to increased serum Epo levels, immunologic evidence for Epo production by the leiomyoma cells, and reversal of erythrocytosis following myomectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. A clue to the presence of the myomatous erythrocytosis syndrome is the absence of anemia in a patient with significant menorrhagia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"       \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of secondary erythrocytosis is two-fold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control of the underlying cause, if possible (eg, removal of an Epo-secreting tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24777/abstract/55,57\">",
"       55,57",
"      </a>",
"      ], cessation of exposure to carbon monoxide)",
"     </li>",
"     <li>",
"      Limited phlebotomy, as tolerated, if symptoms are present. Such patients may achieve relief following a modest reduction in their hematocrit, but may become more symptomatic if the hematocrit is reduced to the normal range. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link&amp;anchor=H18#H18\">",
"       \"Medical management of Eisenmenger syndrome\", section on 'Noncardiac surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia is considered to be present when the hematocrit is &gt;48 or &gt;52 percent in women and men, respectively, or when the hemoglobin concentration is &gt;16.5 or &gt;18.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women and men, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a high value has been reported, it should be confirmed by repeat testing to rule out laboratory error.",
"     </li>",
"     <li>",
"      An accurate history and physical examination is critical in order to determine the etiology of polycythemia (",
"      <a class=\"graphic graphic_table graphicRef76036 \" href=\"UTD.htm?30/46/31468\">",
"       table 1",
"      </a>",
"      ). The most common cause of polycythemia is hypoxia secondary to pulmonary disease; as a result, eliciting symptoms pertaining to altered lung function is of paramount importance.",
"     </li>",
"     <li>",
"      A low value for pulse oximetry suggests the presence of cardiopulmonary disease (eg, chronic obstructive pulmonary disease, pulmonary A-V malformations, right to left cardiac shunt). Pulse oximetry should be obtained after minimal exertion and, if suggested by the clinical history, sleep studies may be necessary to detect nocturnal oxygen unsaturation.",
"     </li>",
"     <li>",
"      A low serum Epo level in the polycythemic patient suggests the diagnosis of polycythemia vera (",
"      <a class=\"graphic graphic_algorithm graphicRef52465 \" href=\"UTD.htm?8/56/9103\">",
"       algorithm 1",
"      </a>",
"      ). Polycythemia associated with increased serum Epo is unlikely to represent polycythemia vera and a working diagnosis of secondary erythrocytosis should be made (",
"      <a class=\"graphic graphic_algorithm graphicRef65297 \" href=\"UTD.htm?8/63/9200\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Evaluation of secondary erythrocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If polycythemia vera is a diagnostic consideration, other testing, such as for the JAK2 mutation, is indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link&amp;anchor=H32#H32\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/1\">",
"      Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005; 129:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/2\">",
"      LAWRENCE JH, BERLIN NI. Relative polycythemia; the polycythemia of stress. Yale J Biol Med 1952; 24:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/3\">",
"      Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and reprise. J Lab Clin Med 1997; 130:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/4\">",
"      Brown SM, Gilbert HS, Krauss S, Wasserman LR. Spurious (relative) polycythemia: a nonexistent disease. Am J Med 1971; 50:200.",
"     </a>",
"    </li>",
"    <li>",
"     Weinreb NJ. Relative polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.226.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/6\">",
"      Smith JR, Landaw SA. Smokers' polycythemia. N Engl J Med 1978; 298:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/7\">",
"      Messinezy M, Sawyer B, Westwood NB, Pearson TC. Idiopathic erythrocytosis--additional new study techniques suggest a heterogenous group. Eur J Haematol 1994; 53:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/8\">",
"      Rossi D, Cortini F, Deambrogi C, et al. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. Leuk Res 2007; 31:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/9\">",
"      Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/10\">",
"      Tefferi A. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications. N Engl J Med 2007; 356:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/11\">",
"      Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med 1997; 102:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/12\">",
"      Birgeg&aring;rd G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol 1992; 81:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/13\">",
"      Weinberg RS. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 1997; 34:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/14\">",
"      Najean Y, Schlageter MH, Toubert ME, Podgorniak MP. Radioimmunoassay of immunoreactive erythropoietin as a clinical tool for the classification of polycythaemias. Nouv Rev Fr Hematol 1990; 32:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/15\">",
"      Remacha AF, Montserrat I, Santamaria A, et al. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica 1997; 82:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/16\">",
"      Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003; 139:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/17\">",
"      McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/18\">",
"      Krauss DJ, Taub HA, Lantinga LJ, et al. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991; 146:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/19\">",
"      Aitchison R, Russell N. Smoking--a major cause of polycythaemia. J R Soc Med 1988; 81:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/20\">",
"      Pollak R, Maddux MS, Cohan J, et al. Erythrocythemia following renal transplantation: influence of diuretic therapy. Clin Nephrol 1988; 29:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/21\">",
"      Sakisaka S, Watanabe M, Tateishi H, et al. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology 1993; 18:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/22\">",
"      Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/23\">",
"      Da Silva JL, Lacombe C, Bruneval P, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990; 75:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/24\">",
"      Pearson TC, Messinezy M. Investigation of patients with polycythaemia. Postgrad Med J 1996; 72:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/25\">",
"      Bernard PJ. Measurement of red-cell and plasma volumes. Nouv Rev Fr Hematol 1994; 36:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/26\">",
"      Fairbanks VF, Klee GG, Wiseman GA, et al. Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis 1996; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/27\">",
"      Holme S, Elfath MD, Heaton A, et al. Prediction of red cell and blood volumes distribution by various nomograms: do current nomograms overestimate? Transfusion 2008; 48:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/28\">",
"      Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol 2005; 95:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/29\">",
"      Mock DM, Matthews NI, Strauss RG, et al. Red blood cell volume can be independently determined in vitro using sheep and human red blood cells labeled at different densities of biotin. Transfusion 2009; 49:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/30\">",
"      Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/31\">",
"      BUTTON LN, GIBSON JG 2nd, WALTER CW. SIMULTANEOUS DETERMINATION OF THE VOLUME OF RED CELLS AND PLASMA FOR SURVIVAL STUDIES OF STORED BLOOD. Transfusion 1965; 5:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/32\">",
"      Nielsen S, R&oslash;dbro P. Validity of rapid estimation of erythrocyte volume in the diagnosis of polycytemia vera. Eur J Nucl Med 1989; 15:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/33\">",
"      Spivak JL. The optimal management of polycythaemia vera. Br J Haematol 2002; 116:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/34\">",
"      Ferrant A. What clinical and laboratory data are indicative of polycythemia and when are blood volume studies needed? Nouv Rev Fr Hematol 1994; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     Fairbanks VF, Tauxe WN. Plasma and erythrocyte volumes in obesity, polycythemia, and related conditions. In: , Pools and Spaces in Medical Physiology, USAEC Division of Technical Information, Oak Ridge, TN 1967. p.283.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/36\">",
"      Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100:4272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/37\">",
"      Landaw SA. Polycythemia vera and other polycythemic states. Clin Lab Med 1990; 10:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/38\">",
"      Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/39\">",
"      Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/40\">",
"      Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/41\">",
"      Messinezy M, Westwood NB, El-Hemaidi I, et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002; 117:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/42\">",
"      Prchal JT, Sokol L. \"Benign erythrocytosis\" and other familial and congenital polycythemias. Eur J Haematol 1996; 57:263.",
"     </a>",
"    </li>",
"    <li>",
"     Copelan EA, Balcerzac SP. Secondary polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/44\">",
"      Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991; 78:3066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/45\">",
"      Distelhorst CW, Wagner DS, Goldwasser E, Adamson JW. Autosomal Dominant familial erythrocytosis due to autonomous erythropoietin production. Blood 1981; 58:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/46\">",
"      Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/47\">",
"      Brox AG, Mangel J, Hanley JA, et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 1998; 66:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/48\">",
"      Chagnac A, Zevin D, Weinstein T, et al. Erythrocytosis associated with renal artery thrombosis in a patient with polycystic kidney disease on hemodialysis. Acta Haematol 1990; 84:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/49\">",
"      Bacon BR, Rothman SA, Ricanati ES, Rashad FA. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med 1980; 140:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/50\">",
"      Schramek A, Better OS, Adler O, et al. Hypertensive crisis, erythrocytosis, and uraemia due to renal-artery stenosis of kidney transplants. Lancet 1975; 1:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/51\">",
"      Dr&eacute;nou B, Le Tulzo Y, Caulet-Maugendre S, et al. Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouv Rev Fr Hematol 1995; 37:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/52\">",
"      Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996; 93:10595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/53\">",
"      Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/54\">",
"      Yoshida M, Koshiyama M, Fujii H, Konishi M. Erythrocytosis and a fibroid. Lancet 1999; 354:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/55\">",
"      Suzuki M, Takamizawa S, Nomaguchi K, et al. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol 2001; 113:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/56\">",
"      LevGur M, Levie MD. The myomatous erythrocytosis syndrome: a review. Obstet Gynecol 1995; 86:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24777/abstract/57\">",
"      Lanne JS, Dumortier J, Hervieu V, et al. Polycythemia and elevated serum erythropoietin associated with a liver haemangioma. Gastroenterol Clin Biol 2010; 34:629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7075 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FDEBE4EB0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24777=[""].join("\n");
var outline_f24_12_24777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Relative polycythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absolute polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Primary polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Secondary polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Combined polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Inapparent polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHYSIOLOGY OF ERYTHROPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DOCUMENTATION OF POLYCYTHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Blood volume measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood volume estimation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Reduced plasma volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FURTHER EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serum erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EVALUATION OF SECONDARY ERYTHROCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Congenital polycythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Acquired secondary polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Tumor polycythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7075\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7075|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/56/9103\" title=\"algorithm 1\">",
"      Diagnosis erythrocytosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/63/9200\" title=\"algorithm 2\">",
"      Diagnosis erythrocytosis II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7075|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/53/35677\" title=\"figure 1\">",
"      Serum EPO and anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 2\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7075|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/46/31468\" title=\"table 1\">",
"      Causes of erythrocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/52/42827\" title=\"table 2\">",
"      Normal red cell values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/34/5679\" title=\"table 3\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Surface Area (Mosteller, square root method)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=related_link\">",
"      Erythrocytosis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=related_link\">",
"      Hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=related_link\">",
"      Medical management of cyanotic congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=related_link\">",
"      Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=related_link\">",
"      Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=related_link\">",
"      Use of androgens and other hormones to enhance athletic performance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_12_24778="Euthanasia and physician assisted suicide";
var content_f24_12_24778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Euthanasia and physician assisted suicide",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24778/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24778/contributors\">",
"     Ezekiel J Emanuel, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24778/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24778/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24778/contributors\">",
"     Claudia Bausewein, PhD, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/12/24778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/12/24778/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/12/24778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Euthanasia and physician-assisted suicide (PAS) burst into the United States public arena in 1988 with publication of \"It's over, Debbie\" in JAMA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/1\">",
"     1",
"    </a>",
"    ]. This article stirred a debate with many people criticizing assisted suicide, especially by a physician who did not know the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sentiment of the medical community became more favorable toward euthanasia and PAS with publication of Timothy Quill's article on his patient Diane [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/4\">",
"     4",
"    </a>",
"    ]. Since that time, there have been numerous papers debating the ethics and legality of these interventions, as well as empirical studies examining their practice [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past decade, studies have shown significant gains in understanding about attitudes of physicians and the public towards euthanasia and PAS in the United States, as well as the practices themselves. Clinical materials have also provided guidance on how to manage requests. This review will discuss the following aspects of euthanasia and PAS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Definitions",
"     </li>",
"     <li>",
"      Practical guidance in managing requests for euthanasia and PAS",
"     </li>",
"     <li>",
"      Ethical arguments for and against",
"     </li>",
"     <li>",
"      Current legal circumstances",
"     </li>",
"     <li>",
"      Public attitudes",
"     </li>",
"     <li>",
"      Physician attitudes",
"     </li>",
"     <li>",
"      Physician practices and experiences",
"     </li>",
"     <li>",
"      Physician responses to patient requests for euthanasia",
"     </li>",
"     <li>",
"      Patient attitudes and experiences",
"     </li>",
"     <li>",
"      Complications of performing euthanasia and PAS",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the problems plaguing the field of euthanasia and PAS is vague and emotionally laden definitions (",
"    <a class=\"graphic graphic_table graphicRef50242 \" href=\"UTD.htm?21/51/22332\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/5\">",
"     5",
"    </a>",
"    ]. The term euthanasia without a qualifying phrase means voluntary active euthanasia; that is, the physician intentionally ends the patient's life at the patient's request and with the patient's full informed consent. This is the intervention that has been the subject of intense public debate and controversy. At present, voluntary active euthanasia is legal only in the Netherlands and Belgium. Only a few people argue for nonvoluntary active euthanasia, which is generally viewed as wrong. Euthanasia is not legal in any state in the United States.",
"   </p>",
"   <p>",
"    The terms \"passive\" euthanasia and \"indirect\" euthanasia are occasionally heard; these are inaccurate terms because they are not really types of euthanasia. Passive euthanasia refers to the practice of terminating life-sustaining treatments, such as respirators and artificial nutrition. For centuries these practices have been deemed ethical and legal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/6\">",
"     6",
"    </a>",
"    ]. Similarly, administering drugs such as benzodiazepines or opioids for comfort but that pose a risk of death (so-called &ldquo;indirect&rdquo; euthanasia) is better characterized as palliative sedation and is an ethical practice. Since the discovery of ether anesthesia and hypodermic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    in the 19th century, medical societies and others have endorsed their use for terminally ill patients even if the patients die from respiratory depression, as long as the intention was pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Since these are not cases of euthanasia, the term should not be associated with them; it confuses the issue and can make people unwilling to use appropriate palliative intervention. Palliative sedation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"./palliative-sedation?source=see_link\">",
"     \"Palliative sedation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PAS refers to the physician's act of providing medication, a prescription, information, or other interventions to a patient with the understanding that the patient intends to use them to commit suicide. PAS is legal in the Netherlands, Belgium, and Switzerland. In the United States, Oregon legalized PAS in 1997, and the practice was legalized in Washington State in March of 2009. The state Supreme Court of Montana ruled in 2009 that state law permits physician-assisted suicide for terminally ill patients. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Legal status'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRACTICAL GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multistep approach to handling requests for euthanasia or PAS should allow satisfactory resolution of most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/10\">",
"     10",
"    </a>",
"    ]. The following is a brief summary of the steps that should be followed when such a request is made. Additional suggestions about how to explore some of these issues are provided below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'How should physicians handle such requests?'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, listen to the person's request and affirm that you understand that a great deal of suffering underlies the request. Being heard and affirmed can remedy some of the major sources of psychosocial suffering that tend to accompany such requests.",
"      <br/>",
"      <br/>",
"      Avoid taking a moral stance. While it is helpful to understand the issues and acceptable to have your own opinions about the morality of euthanasia and PAS, it is usually not helpful to make it part of the patient-clinician relationship. A principled stance against the act can make the person who has just requested euthanasia or PAS feel judged, which may add to his or her suffering. A principled stance for the act risks inadvertently compounding the person's sense of worthlessness and conviction that they would be better off dead.",
"     </li>",
"     <li>",
"      Second, conduct a comprehensive assessment like the kind done by palliative care specialists to understand the nature and sources of all the patient's physical, psychological, spiritual and social suffering.",
"     </li>",
"     <li>",
"      Third, address each of those sources of suffering with the full armamentarium of palliative care strategies. Most pain and other physical causes of suffering can be reduced to acceptable levels. Much of the depression, anxiety and other psychological suffering can be minimized. Spiritual suffering can be addressed, as can social issues. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link\">",
"       \"Assessment and management of depression in palliative care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"       \"Religion, spirituality, and end of life care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With skilled use of palliative care, most experts find that a great majority of cases are resolved and the request goes away. Consulting a specialist in palliative care may well be necessary for difficult cases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fourth, for cases that do not resolve even with these measures, make sure that other measures that are less morally controversial have also been discussed. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Withholding nutrition and hydration at a point that they have become medically contraindicated (eg, due to the discomfort hydration can cause from edema and effusions) is widely accepted as morally correct.",
"     </li>",
"     <li>",
"      Withdrawal of unwanted life-sustaining interventions, with medical management for comfort, is also accepted as morally correct. An individual who has clear understanding and full capacity who declines continued support on a ventilator has the right to have it removed, even if death is expected from the underlying disease as a result.",
"     </li>",
"     <li>",
"      Palliative sedation, in which a person is sedated for lack of available alternatives to control pain and suffering, knowing that such a state cannot be improved on until death, is also accepted as morally correct. (See",
"      <a class=\"medical medical_review\" href=\"./palliative-sedation?source=see_link\">",
"       \"Palliative sedation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifth, consult with colleagues. Decisions about life and death matters should never be made in isolation. Palliative care specialists are often helpful, as are pastors, social workers, and other medical specialists. If necessary or if it seems like it might be helpful, consult with an ethics committee.",
"     </li>",
"     <li>",
"      Since these interventions may not improve the situation to the point where the individual will no longer desire euthanasia or PAS, an eventual decision about PAS may have to be made. As many as 40 percent of patients requesting euthanasia or PAS have already been receiving hospice care, suggesting that requests can persist despite efforts at good end of life care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most of the US, both euthanasia and PAS are illegal. For persistent requests the patient must be told, as gently as possible without taking a moral stand (see above) that the practices are illegal (unless they live in Oregon, Washington state, or Montana), and alternatives are the best that can be offered in the state.",
"   </p>",
"   <p>",
"    As of 2010, PAS is legal only in Oregon, Montana, and Washington state. The practice is highly regulated and is described below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Legal status'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In locations where the practice is legal and in circumstances of persistent requests despite all efforts, and after suitable consultation and inclusion of all relevant parties (including the patient's close family, relevant close friends, providers and the health care team members), if there is consensus that assisted death is the best available direction, the physician must make a personal decision about whether he or she will participate or refer the patient to another physician.",
"   </p>",
"   <p>",
"    Requests for euthanasia or PAS that come from anyone other than the patient represent difficult issues. Family members or caregivers who raise the question are evidencing significant distress, and an evaluation by a social worker to assess and address their burdens is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETHICAL ARGUMENTS FOR AND AGAINST",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least five distinct and reinforcing arguments have been used for permitting or legalizing euthanasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PAS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, it is argued that individual autonomy justifies euthanasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAS. Autonomy means that individuals have the right to pursue their own personal view of what kind of life is best, including when and how to die. Thus, to respect autonomy requires permitting individuals to decide when it is better to end their lives by euthanasia or PAS than to continue living.",
"     </li>",
"     <li>",
"      Second, beneficence, that is, furthering the well being of individuals, also supports permitting euthanasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAS. In some cases, living creates more pain and suffering than death. In these cases, ending a painful life will actually relieve more suffering and thereby produce more good. In fact, just the reassurance of having the option of euthanasia or PAS, even if people do not use it, can provide \"psychological insurance\" and be beneficial.",
"     </li>",
"     <li>",
"      Third, euthanasia and PAS may be considered no different from terminating life-sustaining treatments, which is recognized as ethically justified. In both cases, the patient consents to die, in both cases the physician intends to end the patient's life and takes some action to cause this to happen; the final result is the patient's death. If there is no difference in patient consent, physician intention, or the final result, there can be no difference in the ethical justification.",
"     </li>",
"     <li>",
"      Fourth, the supposed \"slippery slope\" that would result from permitting euthanasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAS is not necessarily likely. The assumption that permitting euthanasia or PAS will undermine the physician-patient relationship or lead to forced euthanasia is completely speculative and not borne out by the available data, and therefore should not govern public policy.",
"     </li>",
"     <li>",
"      Fifth, results of surveys of physicians find that even in countries where PAS is illegal, they receive and carry out requests to hasten death in some situations [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"       11",
"      </a>",
"      ]. Legalization would bring honesty, clarity, and transparency to an existing practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Four arguments have been raised against permitting or legalizing euthanasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PAS, several of which parallel the arguments in favor of these practices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, autonomy does not justify euthanasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAS. The classical ethicists on autonomy, Kant and Mill, argued that the concept that autonomy did not permit the voluntary ending of the conditions necessary for autonomy. Although used initially as an argument against voluntary enslavement and suicide, this concept also applies to euthanasia and PAS. Stated another way, the exercise of autonomy cannot include the ending of one's life because that would mean ending the possibility of exercising autonomy.",
"     </li>",
"     <li>",
"      Second, the principle of beneficence does not necessarily mean that euthanasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAS are acceptable as a means of improving well being. We know that quality care for the dying is not provided to many patients, leading to needless pain and suffering [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/12\">",
"       12",
"      </a>",
"      ]. Adequate care would relieve most pain and suffering. While even with optimal end of life care, a few patients may still suffer uncontrolled pain and suffering, it is unjustified to use the condition of these few patients as a justification to permit euthanasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAS for any dying patients.",
"     </li>",
"     <li>",
"      Third, the distinction between intentionally ending a life and terminating life-sustaining treatments is reasonable and accurate. The actual acts are different: injecting a life ending medication or providing a prescription for one is not the same as removing or refraining from introducing an invasive uncomfortable medical intervention. Patients who have life sustaining interventions discontinued do not always die; some, such as Karen Ann Quinlan, live for years.",
"      <br/>",
"      <br/>",
"      The intention underlying these two acts is also very different. By terminating or withholding life-sustaining treatments, the physician's intention is not to expressly end the patient's life but to remove or avoid invasive treatments that adversely impact quality of life and offer no meaningful chance of benefit. In many ethical and legal situations, the evaluation critically depends upon the intention of the actor.",
"     </li>",
"     <li>",
"      Fourth, there are potential adverse consequences of permitting euthanasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PAS. Involuntary euthanasia occurs in the Netherlands and Belgium [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. In the most recent comprehensive report of end of life practices in the Netherlands, the frequency of ending of life without explicit request by the patient declined from 0.8 percent of all deaths in 1990 attributed to euthanasia, PAS or other end of life practices, to 0.4 percent in 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/14\">",
"       14",
"      </a>",
"      ]. In Belgium, euthanasia was legalized in 2002 and the frequency of ending life without explicit request by the patient declined from 3.2 percent in 1998 to 1.5 percent in 2001, but then increased to 1.8 percent in 2007 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these concerns, there could easily be coercion of expensive or burdensome patients to accept euthanasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PAS. Finally, legalizing euthanasia or PAS may lead to further intrusion of lawyers, courts, and legislatures into the physician-patient relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LEGAL STATUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30038480\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;On June 26, 1997, the United States Supreme Court ruled 9 to 0 that there is no constitutional right to euthanasia or PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. While the written opinions are diverse and many have tried to discern possibilities for endorsement of a right to euthanasia or PAS, this ruling seems definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Nevertheless, the Supreme Court did rule that there is no constitutional prohibition against states legalizing these interventions; this permitted states to enact statutes legalizing them.",
"   </p>",
"   <p>",
"    A few weeks after the United States Supreme Court ruling, the Supreme Court of Florida, a state with a strong constitutional guarantee of privacy, also ruled that there is no state constitutional right to PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/20\">",
"     20",
"    </a>",
"    ]. This is consistent with the general trend in state legislatures against legalizing euthanasia and PAS; seven state legislatures have voted explicitly to prohibit these practices since the early 1990s, and overall, 38 states have laws that make assisting such a suicide a crime [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In November 1994, 51 percent of Oregonians voted for The Oregon Death with Dignity Act which legalized physician-assisted suicide but not euthanasia. Because of legal challenges, the law was not immediately implemented. In November 1997, Oregon voters rejected a measure to repeal the Death with Dignity Act and the act became effective in 1997. However, in 2001, the federal government began trying to block physicians from prescribing medications for PAS claiming the prescriptions did not serve a \"legitimate medical purpose\" and therefore violated the Controlled Substances Act. The Ninth Circuit Court of Appeal rejected the federal government's argument permitting physicians to continue offering PAS under Oregon's Death with Dignity Act. The Oregon law was upheld by the United States Supreme Court in January 2006.",
"   </p>",
"   <p>",
"    In November 2008, Initiative 1000 was passed by voters in Washington State, and the law was passed on March 5th, making it the second state to legalize PAS. In 2009, the state Supreme Court of Montana ruled that state law permits physician-assisted suicide for terminally ill patients. Euthanasia is not legal in any of the 50 states [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Oregon Act requires the following of an individual seeking PAS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resident of Oregon",
"     </li>",
"     <li>",
"      Adult, 18 years of age or older",
"     </li>",
"     <li>",
"      Terminal illness must be present that will lead to death within six months or less",
"     </li>",
"     <li>",
"      Mentally competent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients must request a prescription from their doctor for PAS and repeat the request 15 or more days later, and submit a written request signed by two witnesses. The physician and a consulting physician must confirm the terminal diagnosis and prognosis. If there are suspicions of depression or other psychological problems, a referral to a psychiatrist is necessary. The physician must request that the patient notify the next of kin about his or her petition for PAS, although the patient can refuse this request.",
"   </p>",
"   <p>",
"    The Washington law enacts similar requirements; the individual must be a resident of Washington State with two oral and one written request witnessed by two people including one independent person; that is someone who is not a relative, heir, or doctor involved in the case.",
"   </p>",
"   <p>",
"    It appears that interest in legalization has gone through a cycle and is currently on the decline, due in part to more attention focused upon improving end-of-life care and the recognition that euthanasia and PAS influence the dying process of only a handful of decedents.",
"   </p>",
"   <p>",
"    Other than Oregon and Washington State, only one committee of one state legislative body has ever voted to endorse legalizing PAS or euthanasia. In Maine, a bill to legalize euthanasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PAS was considered by a full chamber of a state legislature and defeated 99 to 42 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/23\">",
"     23",
"    </a>",
"    ]. Two years later, the citizens of Maine voted against legalizing PAS. In 1998, 70 percent of Michigan voters opposed legalizing PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/24\">",
"     24",
"    </a>",
"    ]. In Vermont, a proposal to legalize PAS was subjected to three days of hearings by the state legislature in 2005 and is still under discussion by legislators.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a brief time in the late 1990s, euthanasia was legalized in the Northern Territory in Australia through the Rights of the Terminally Ill Act 1995. Subsequently, the Australian Commonwealth government overturned this law, and only seven people received euthanasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Switzerland, assisted suicide has been legal since 1918 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the Swiss law was enacted mainly to permit \"suicides motivated by honour and romance\" not medical conditions. Importantly, Swiss law does not require that assistance come from physicians, but uniquely permits regular citizens to assist suicide. Euthanasia remains illegal in Switzerland.",
"   </p>",
"   <p>",
"    After studies showed a relatively high frequency of euthanasia and assisted suicide, the Belgian parliament enacted a bill to legalize euthanasia on May 16, 2002 which went into effect on September 23, 2002. Interestingly, the term physician-assisted suicide (PAS) is not used in the bill, but the Federal Commission of Control and Evaluation, which is responsible for reviewing the reported euthanasia cases, treats PAS cases the same as euthanasia cases, making PAS legal from a practical standpoint. Euthanasia is legal if it is performed by a physician and if the due care requirements of the law (ie, patient has to make a voluntary and well-considered request, based on unbearable suffering, and no prospect of improvement) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/27\">",
"     27",
"    </a>",
"    ]. There is a separate set of requirements for euthanasia based upon an advance directive in persons in a persistent vegetative state or an irreversible coma. The law also makes a distinction between patients who are expected to die in the near future and those who are not expected to die, with two additional requirements for those whose deaths are not expected (physician consultation with two other independent physicians rather than one, and at least one month delay between the patient&rsquo;s request for euthanasia and its performance). &nbsp;",
"   </p>",
"   <p>",
"    For decades, the Netherlands has permitted euthanasia and PAS although they were not legal. Through an agreement between the Dutch medical association and the Dutch government, physicians who committed euthanasia or PAS but followed certain safeguards were not prosecuted. After extensive empirical study, the Netherlands legalized euthanasia and PAS in 2002 through enactment of the Termination of Life on Request and Assisted Suicide Review Procedures Act. Certain safeguards are required by law, including the physician being convinced that the request for euthanasia or PAS is voluntary and well considered, and convinced that the patient has unbearable and hopeless suffering. The physician must fully inform the patient of his or her diagnosis and prognosis, and be convinced that there are no alternative interventions after consulting with one independent physician who has seen the patient and provided a written assessment.",
"   </p>",
"   <p>",
"    In 2009, Luxembourg legalized euthanasia and physician-assisted suicide in certain cases. The law states that doctors who carry out euthanasia or assisted suicides will not face legal penalties as long as they first consult a colleague to ensure that the patient has a terminal illness, is in a &ldquo;grave and incurable condition&rdquo;, and has repeatedly asked for the right to die [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ATTITUDES OF THE AMERICAN PUBLIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been multiple surveys of the American public on euthanasia and PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]; only a few have been in-depth analyses. Nevertheless, a few conclusions can be drawn from these data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11516540\">",
"    <span class=\"h2\">",
"     Deep divisions of opinions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are deep divisions of opinion about the morality of euthanasia and physician assisted suicide. The American public has been polled on this issue since 1947 with a somewhat ambiguous question, but with a more precise one for the last 10 years. When asked about the moral acceptability of physician-assisted suicide, 49 percent find it acceptable and 44 percent unacceptable. These percentages have remained the same for nearly a decade [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this Gallup survey, people leaning toward the Democratic political spectrum were more likely to support physician assisted suicide while those leaning toward the Republican side were more likely to find it morally unacceptable.",
"   </p>",
"   <p>",
"    Other studies find important divisions along religious lines. Catholics and others who describe themselves as religious are significantly more likely to oppose euthanasia or PAS, as are African-Americans and older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. Some, but not all, surveys suggest that women are significantly more opposed to euthanasia or PAS than are men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Framing effects in response to questionnaires",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant framing effects in the public's response to questions, based not only on how the questions are phrased, but also on how the answer categories are provided. Public support varies from under 50 percent to almost 70 percent depending upon how questions are worded and the types of choices offered (",
"    <a class=\"graphic graphic_table graphicRef78787 \" href=\"UTD.htm?25/60/26573\">",
"     table 2",
"    </a>",
"    ). However, very few surveys find public support in excess of 70 percent, regardless of how the questions are crafted. Consistently the strongest support is for patients with terminal illness who are experiencing severe pain.",
"   </p>",
"   <p>",
"    This leads to what might be called the \"Rule of Thirds\" (",
"    <a class=\"graphic graphic_table graphicRef67869 \" href=\"UTD.htm?18/33/18971\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Roughly one-third of Americans support euthanasia or PAS regardless of the situation; their attitudes are not affected by the interventions or the circumstances. As an example, 29 percent of Americans support euthanasia or PAS for terminally ill patients who are not in pain but desire these interventions because they view life as meaningless [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"       33",
"      </a>",
"      ]. Similarly, 36 percent support euthanasia or PAS for terminally ill patients who do not want to burden their family.",
"     </li>",
"     <li>",
"      Approximately one-third of Americans oppose euthanasia or PAS regardless of the circumstances, even for terminally ill, competent patients with unremitting pain despite optimal management [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31\">",
"       31",
"      </a>",
"      ]. These numbers are approximately the same even among caregivers of terminally ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The remaining one-third of Americans support euthanasia or PAS in some circumstances, usually involving extreme pain, but oppose it in other circumstances, such as for reasons of indignity, or meaninglessness, or because the patient feels he or she is a burden.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that support for euthanasia or PAS is not as strong as might appear from reports that two-thirds of Americans support these interventions. Furthermore, legalizing euthanasia or PAS is a leading issue for only a few organized groups, such as members of the Hemlock society. Thus, support for euthanasia and PAS is not a \"litmus test\" issue (ie, a controversial matter for which a position either for or against determines many votes). Politicians know that support for these practices is neither firm nor deep, and therefore are unwilling and unlikely to take chances in voting to legalize them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Distinction between euthanasia and PAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second general conclusion drawn from public surveys is that the American public does not distinguish between euthanasia and PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/34\">",
"     34",
"    </a>",
"    ]. Medical ethicists, philosophers, lawyers, and others have spent considerable time debating whether euthanasia is fundamentally different from PAS and elucidating potential distinctions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/5\">",
"     5",
"    </a>",
"    ]. As noted above, the Oregon law permits PAS but not euthanasia.",
"   </p>",
"   <p>",
"    Despite these issues, the American public does not seem to make much distinction. Americans support euthanasia at the same rate that they support PAS. As an example, 66 percent of the public supports both euthanasia and PAS for a terminally ill patient with unremitting pain; 29 percent support euthanasia because a terminally ill patient feels life is meaningless, while 33 percent support PAS in the same circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ATTITUDES OF PHYSICIANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;American physicians have been extensively surveyed about euthanasia and PAS over the last decade [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11,35-53\">",
"     11,35-53",
"    </a>",
"    ]. Many surveys, especially the early ones, are methodologically problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/5\">",
"     5",
"    </a>",
"    ]. The surveyed cohorts are narrow or biased, the response rates low, the questions are either poorly worded (eg, confusing euthanasia versus termination of medical treatment), emotionally laden, biased, or the questions do not probe very deeply. More recent surveys have addressed these problems, and the data are more reliable.",
"   </p>",
"   <p>",
"    Most surveys find that the majority of American physicians oppose euthanasia and PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11,35-54\">",
"     11,35-54",
"    </a>",
"    ]. As an example, in one study of Michigan physicians, 57 percent supported PAS only when they were forced to choose between legalization or an explicit ban; without being forced into this choice, only 39 percent supported permitting PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/46\">",
"     46",
"    </a>",
"    ]. In a survey of oncologists, 46 percent supported PAS for a terminally-ill cancer patient with unremitting pain, while 23 percent supported euthanasia in the same situation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that unlike the American public, American physicians distinguish between euthanasia and PAS, and are much more likely to support PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31,41,46,52,53\">",
"     31,41,46,52,53",
"    </a>",
"    ]. The only surveys to report consensus by close to a majority of American physicians ask about PAS; no study has found a majority of physicians supporting euthanasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2009 survey of UK physicians found that the majority of UK doctors are opposed to legalization of PAS and euthanasia, in contrast to the UK general public [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Predictors of physician support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are important predictors of physician support for euthanasia or PAS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with the American public, American physicians who are Catholic or hold other strong religious beliefs are significantly less likely to support either practice [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11,31,41,44,46,53\">",
"       11,31,41,44,46,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain specialties are more supportive than others: surgical oncologists support euthanasia or PAS more than medical oncologists [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/53\">",
"       53",
"      </a>",
"      ]; psychiatrists, obstetricians, and gynecologists are more supportive than internists, especially oncologists [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11,44,46,47\">",
"       11,44,46,47",
"      </a>",
"      ]; family or general practitioners are more supportive than internists. Palliative medicine specialists in the UK were found to be particularly opposed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A significant decline in support for euthanasia or PAS occurred among American oncologists in the 1990s (",
"    <a class=\"graphic graphic_figure graphicRef53299 \" href=\"UTD.htm?11/41/11934\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31,53\">",
"     31,53",
"    </a>",
"    ]. Between 1994 and 1998, support declined by 50 percent for PAS and by 75 percent for euthanasia for the terminally-ill cancer patient with unremitting pain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31,53\">",
"     31,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two reasons may explain this decline in physician support of euthanasia and PAS. First, in part as a result of the debate on euthanasia and PAS, there has been greater attention paid to improving end-of-life care. Physicians have begun to understand and more effectively implement interventions that can be used to relieve symptoms and improve quality of life. The success of these efforts in improving end of life care has diminished the appeal of euthanasia and PAS as an option for dying patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second, while individuals (patients, caregivers, physicians) may be willing to endorse euthanasia or PAS when discussing it in the abstract, they tend to be less supportive when it might require personal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"     33",
"    </a>",
"    ]. In 1994, euthanasia and PAS seemed abstract possibilities; however, by 1998, Oregon had legalized PAS, and more physicians had been confronted with requests for euthanasia and PAS. Thus, as the question became more personal, and there was a real possibility that they might be asked to perform these interventions, support decreased (",
"    <a class=\"graphic graphic_figure graphicRef53299 \" href=\"UTD.htm?11/41/11934\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31,53\">",
"     31,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Objections from the medical community may be based on the belief by some physicians that it is inappropriate or wrong for a physician to play an active role in ending a patient&rsquo;s life. Proposals have been put forth for an independent dispensing mechanism that would remove the physician from direct involvement in the process of assisted dying [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/56\">",
"     56",
"    </a>",
"    ], but the feasibility of such an approach has not been shown. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ATTITUDES AND PRACTICES OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the attitudes of American patients regarding euthanasia and PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/29,52,53,57-59\">",
"     29,52,53,57-59",
"    </a>",
"    ]. These studies show that the attitudes of patients with terminal illnesses such as cancer and chronic obstructive pulmonary disease are almost identical with the public view [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, having a serious, even life-threatening illness itself does not seem to affect attitudes toward the permissibility or opposition to euthanasia or PAS. Similarly, being a caregiver for a terminally ill patient or a recently bereaved caregiver does not seem to affect attitudes toward these practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have examined the experiences of American patients regarding euthanasia and PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31,33,58-63\">",
"     31,33,58-63",
"    </a>",
"    ]. They have focused on patients with cancer,",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    and amyotrophic lateral sclerosis (ALS), and on the experience in Oregon. At least four major conclusions can be drawn from these data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is mainly oncology patients who utilize euthanasia and PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11,13,25,27,60,63\">",
"       11,13,25,27,60,63",
"      </a>",
"      ]. This is illustrated by the following data:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Twelfth Annual Report on Oregon's Death with Dignity Act cataloging PAS events through 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/60\">",
"       60",
"      </a>",
"      ]. Since 1998, when the law was enacted, of the 460 patients who died after taking a legal dose of medication (PAS), 81 percent had cancer, 8 percent had ALS, 4 percent had COPD, 2 percent had",
"      <span class=\"nowrap\">",
"       HIV/AIDS,",
"      </span>",
"      and 6 percent had other illnesses. The results of the first year of reporting under Washington State&rsquo;s Death With Dignity Act (modeled on Oregon&rsquo;s law) finds similar results: 79 percent of patients had cancer, and 8 percent had a neurodegenerative disease including ALS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These data are comparable to those from the Netherlands and Belgium, where more than 80 percent of euthanasia and PAS cases involved patients with cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/13,27,65\">",
"       13,27,65",
"      </a>",
"      ], and from Australia, where all seven patients who received euthanasia had cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most reports, uncontrolled pain is not a major determinant of interest in or use of euthanasia or PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11,13,25,31,48,59,60,62,66-68\">",
"       11,13,25,31,48,59,60,62,66-68",
"      </a>",
"      ]. In the most recent report, only 22 percent of the patients who received PAS experienced or were fearful of inadequate pain control [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/60\">",
"       60",
"      </a>",
"      ]. Similarly, among the seven patients to receive euthanasia in Australia, three had no pain and pain was controlled in the other four.",
"      <br/>",
"      <br/>",
"      In another report, pain, pain intensity, and pain-related functional impairment were not associated with interest in PAS among patients with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/58\">",
"       58",
"      </a>",
"      ]. However, others have found that in terminally ill patients, pain was among the factors associated with personally considering euthanasia or PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"       33",
"      </a>",
"      ], and a survey of physicians found that most requests for PAS came from patients who were near death and had a significant burden of pain and physical discomfort [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depression, hopelessness, and general psychological distress are consistently associated with interest in PAS and euthanasia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31,33,58,61,67\">",
"       31,33,58,61,67",
"      </a>",
"      ]. The importance of depression in particular was shown in a study in which Dutch researchers who, doubting the importance of depression among patients requesting euthanasia or PAS, followed 138 terminally-ill cancer patients to their death [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/70\">",
"       70",
"      </a>",
"      ]. To the surprise of the researchers, depressed patients were four times more likely to request euthanasia or PAS. Nearly one-half of the patients requesting euthanasia in this series had a depressed mood, although other reports note a much lower percentage of patients seeking euthanasia who meet criteria for major depression (17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/71\">",
"       71",
"      </a>",
"      ]. In Oregon, between 1998 and 2009, 87 percent of patients undergoing PAS reported &ldquo;less able to engage in activities making life enjoyable&rdquo; as an end-of-life concern, the second-most reported factor behind loss of autonomy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/65\">",
"       65",
"      </a>",
"      ]. Results were similar in Washington state in 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/64\">",
"       64",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      While depressed patients are more likely to express an interest in euthanasia and PAS, they are also more likely to change their minds about euthanasia or PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"       33",
"      </a>",
"      ]. Among patients with ALS, researchers in Oregon found that measure of hopelessness rather than depression were better predictors of interest in PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The data are conflicting regarding the role that real or perceived caregiving needs plays in the decision to request euthanasia or PAS among terminally ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33,59,61\">",
"       33,59,61",
"      </a>",
"      ]. In the Oregon series, losing control of bodily functions was important for about 58 percent of patients, while concern about being a burden on one's family and friends was important for 37 percent of patients who underwent PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The actual frequency of use of PAS and euthanasia in the United States is not clear. In Oregon, the proportion of all deaths by PAS reported to the Oregon Health Division is 0.2 percent of all deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/60\">",
"     60",
"    </a>",
"    ]. Between 1998 and 2008, 460 patients committed PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/60\">",
"     60",
"    </a>",
"    ]. This rate is extremely low compared to rates found in the Netherlands (1.7 percent of all deaths in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/14\">",
"     14",
"    </a>",
"    ]) and Belgium, raising the question of whether all cases of physician-assisted death are reported in Oregon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/60\">",
"     60",
"    </a>",
"    ]. Another study that followed terminally ill American patients reported a rate for PAS or euthanasia of 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PRACTICES OF AMERICAN PHYSICIANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many American physicians have reported receiving requests for euthanasia or PAS; there is significant variation in the reported frequencies of these requests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that 19 percent of Rhode Island physicians received requests for PAS, while 13 percent received requests for euthanasia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of Michigan oncologists, 38 and 43 percent received requests for PAS and euthanasia, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twenty-one percent of Oregon physicians surveyed received requests for PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twenty-six percent of Washington state physicians had been asked to hasten death in another study; 18 percent of oncologists had received requests for PAS and 9 percent for euthanasia within the previous year [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of American oncologists, 51 and 38 percent had received requests for PAS and euthanasia, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A national survey in 1998 found that since entering practice, 18.3 percent of physicians reported having received a request from a patient for assistance with suicide, and 11.1 percent had received a request for a lethal injection [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences may reflect methodological issues: the differences between mailed and telephone surveys; the different dates (with physicians more willing to acknowledge performing these interventions in later years, as the debate becomes more public and accepted); different regions of the country (those in the West perform these interventions more frequently than the New England or North Central regions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"     11",
"    </a>",
"    ]); and different investigators (with physicians more willing to acknowledge performing these interventions when the survey comes from investigators from the same state or a colleague in the same specialty [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/31,45-48,53\">",
"     31,45-48,53",
"    </a>",
"    ]). However, differences in specialty may play the most important role. Oncologists are more likely to care for dying patients than internists, surgeons, or any general list of physicians. As a result, surveys of oncologists are more likely to report higher proportions of requests.",
"   </p>",
"   <p>",
"    In general, physicians who have received requests have received few of them [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/48,49,53\">",
"     48,49,53",
"    </a>",
"    ]. In one study, physicians who had requests for PAS received a median of three requests in their careers (range 1 to 100) and a median of four requests for euthanasia (range 1 to 50) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physician response to requests for euthanasia or PAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several surveys have evaluated physician responses to requests for euthanasia or PAS. One group reported that initially 76 percent of physicians increased treatment of physical symptoms, 65 percent treated depression and anxiety, and 24 percent referred the patient for a psychiatric evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/48\">",
"     48",
"    </a>",
"    ]. Similarly, another study found that 71 percent of physicians responded to requests for euthanasia or PAS by increasing analgesic treatment, while 30 percent used fewer life-prolonging therapies, and 25 percent prescribed antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"     11",
"    </a>",
"    ]. A study of 2600 Oregon physicians reported that since passing the Death with Dignity Act, 30 percent increased the number of referrals to hospice, and 76 percent who cared for terminally-ill patients made efforts to improve their knowledge of analgesic use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite being illegal, many studies indicate that a small but definite proportion of American physicians have performed euthanasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. However, the data provide conflicting evidence on the precise frequency of such interventions, varying more than sixfold among even the best studies.",
"   </p>",
"   <p>",
"    Much of this variation may be attributable to the reasons cited above, especially the differences among specialties. However, there is another methodological concern. Only one study reported that more American physicians perform euthanasia than PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"     11",
"    </a>",
"    ], suggesting that physicians were not reporting all cases of euthanasia. On the other hand, despite careful wording, physicians frequently confound euthanasia and the termination of life-sustaining treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/66\">",
"     66",
"    </a>",
"    ]; this may be more common and harder to control in mailed rather than telephone surveys, because there is no opportunity to clarify responses. Thus, many cases classified as \"euthanasia\" may represent overreporting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When American physicians have performed euthanasia or PAS, they have done so very rarely. One study found that the median number of PAS and euthanasia instances since physicians entered practice was two (range 1 to 25 and 1 to 150, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"     11",
"    </a>",
"    ]. In a separately reported multivariate analysis, physicians were more likely to have honored requests for PAS from patients who were in severe pain or discomfort, had a life expectancy of less than one month, and were not believed to be depressed at the time of the request [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survey of oncologists reported that of those who had performed PAS, 37 percent had done so only once in their careers, while 18 percent had done so five or more times [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/53\">",
"     53",
"    </a>",
"    ]. Similarly, among American oncologists who had performed euthanasia, over one-half had done so only once, and just 12 percent had done so five or more times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     How should physicians handle such requests?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians should pursue several avenues when they receive a request for euthanasia or PAS (",
"    <a class=\"graphic graphic_table graphicRef62176 \" href=\"UTD.htm?27/34/28204\">",
"     table 4",
"    </a>",
"    ). The majority of requesting patients have cancer, and recommendations from the National Comprehensive Cancer Network (NCCN) suggest that the most appropriate response to a request for a hastened death by a cancer patient is to intensify palliative care and explore the issues underlying the request (",
"    <a class=\"graphic graphic_table graphicRef56848 \" href=\"UTD.htm?3/57/3996\">",
"     table 5",
"    </a>",
"    ). Some general points follow.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physician should not take the interest in or explicit request for euthanasia or PAS as final. He or she should inquire about what motivates the request and explore how serious the patient is by asking if any concrete steps have been taken beyond the request. Some patients may be confused about",
"      <span class=\"nowrap\">",
"       legal/ethical",
"      </span>",
"      distinctions. Treatment withdrawal, withholding of food and fluids, and aggressive management of symptoms such as pain (even if there is a possibility that death may be hastened by the use of sufficient medication doses to provide symptom relief) do not constitute physician-assisted suicide and are legal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H12#H12\">",
"       \"Ethical issues near the end of life\", section on 'Withholding and withdrawing care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physicians should determine what social relationships and supports the patient has and encourage interactions with family and others. Reassurance should be provided that the physician will be available and will not abandon the patient.",
"     </li>",
"     <li>",
"      While physical symptoms such as pain, fatigue, and dyspnea have not been consistently associated with interest in and requests for euthanasia or PAS, they should be evaluated and treated as part of high-quality end-of-life care. Hospice and palliative care services may be very helpful in addressing these symptoms for patients who are staying at home. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"       \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depression and anxiety should be specifically addressed. Consultation with a psychiatrist or a psychologist may be indicated to rule out potentially reversible causes of severe symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     A five-step approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed in more detail above, a multistep approach to handling requests for euthanasia or PAS should allow satisfactory resolution of most cases. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Practical guidelines'",
"    </a>",
"    above.) Briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Listen to the request and affirm the substantial suffering that underlies it. Avoid taking a moral stance on the issue.",
"     </li>",
"     <li>",
"      Conduct a comprehensive assessment to understand the nature and sources of the patient&rsquo;s physical, psychological, spiritual and social suffering.",
"     </li>",
"     <li>",
"      Address each of these sources of suffering to the extent possible. Consultation with a colleague in palliative care medicine may be needed.",
"     </li>",
"     <li>",
"      Discuss other measures that are less morally controversial, including withholding nutrition and hydration, terminal sedation, withdrawal or refusal of invasive life-sustaining interventions with medical management for comfort.",
"     </li>",
"     <li>",
"      If the patient persists in requesting PAS or euthanasia once potential sources of suffering have been addressed and minimized, and other alternative measures discussed, consult with colleagues, including palliative care specialists, clergy, social workers, other medical specialists, and if necessary, an ethics committee.",
"     </li>",
"     <li>",
"      Despite all of these measures, some patients will still desire euthanasia or PAS. In most of the US, this practice is not legal, and the patient must be told, as gently as possible, without taking a moral stance, that the practice is illegal and that alternatives are the best that can be offered in the state.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those in Oregon and Washington, PAS is legal and highly regulated. In locations where the practice is legal and in circumstances of persistent requests despite all efforts, and after suitable consultation and inclusion of all relevant parties, if there is consensus that assisted death is the best available direction, the physician must make a personal decision about whether he or she will participate. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Legal status'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PRACTICES IN THE NETHERLANDS AND BELGIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best studied practices of euthanasia and PAS come from the Netherlands and Belgium where government-funded studies have taken place. Dutch data was collected in several nationwide surveys in 1990, 1995, 2001, 2005, and 2009 with the results from the combined analysis of the 1990, 1995, 2001 and 2009 data illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef71554 \" href=\"UTD.htm?38/13/39132\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/14,73,74\">",
"     14,73,74",
"    </a>",
"    ]. The most important findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2001, 7 percent of dying patients explicitly requested euthanasia or PAS at a specific time. Physicians provided euthanasia to 2.6 percent of dying patients, PAS to 0.2 percent of dying patients, and intentionally ended a patient's life without his or her explicit request (involuntary euthanasia) in an additional 0.7 percent of deaths. Thus, 3.5 percent of all deaths in the Netherlands in 2001 occurred by euthanasia or PAS, a value that had increased since 1990.",
"      <br/>",
"      <br/>",
"      In the 2010 analysis, 2.8 percent of all deaths in the Netherlands were the result of euthanasia, and 0.1 percent of deaths were from PAS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/74\">",
"       74",
"      </a>",
"      ]. Thus, the total number of deaths occurring by euthanasia and PAS was 2.9 percent. There was a decline in the number of deaths that were the result of the use of lethal drugs not at the explicit request of the patient (0.2 versus 0.7 percent in 2001).",
"     </li>",
"     <li>",
"      Another important finding was that 57 percent of physicians had performed euthanasia or PAS at least once in their medical careers; 30 percent had done so in the two years prior to the 2001 survey [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As previously noted, euthanasia and PAS were predominantly interventions for cancer patients. Overall, 80 percent of all deaths by euthanasia or PAS have occurred in cancer patients. However, only 8.4 percent of all cancer deaths occurred by euthanasia, PAS, or the explicit ending of a patient's life without consent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Euthanasia and PAS occurred in younger patients. As an example, in 2010, 39 percent of all deaths by euthanasia or PAS occurred in patients under the age of 65, an age group that constituted only 19 percent of all deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/74\">",
"       74",
"      </a>",
"      ]. In contrast, only 23 percent of the deaths by euthanasia and PAS were in individuals over the age of 80, despite the fact that they accounted for 51 percent of all deaths overall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In Belgium, the situation is much the same as in the Netherlands, except there are substantially more cases of involuntary euthanasia (ie, administering a lethal dose of drugs without the patient's consent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/15,75\">",
"     15,75",
"    </a>",
"    ]. In the most recent update, 1.9 percent of patients died by euthanasia, 0.07 percent by PAS, and 1.8 percent by the physician administering medications without the patient's explicit consent (involuntary euthanasia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/15\">",
"     15",
"    </a>",
"    ]. The majority of cases of euthanasia occurred in cancer patients who were under the age of 65.",
"   </p>",
"   <p>",
"    The following table provides a comparison of euthanasia and PAS practices in six European countries (",
"    <a class=\"graphic graphic_table graphicRef58741 \" href=\"UTD.htm?25/20/25932\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/76\">",
"     76",
"    </a>",
"    ]. In those countries in which euthanasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PAS are legal (Belgium, the Netherlands, and Switzerland), doctor-assisted death is reported much more frequently. Furthermore, rates of doctor-assisted death appear unrelated to religion or cultural issues; Sweden and Italy have similar rates (0.23 and 0.1 percent, respectively), but markedly different cultures and religious traditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     IMPACT OF PERFORMING EUTHANASIA OR PAS ON PHYSICIANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that examine the impact on physicians find that the majority are comfortable with having performed euthanasia or PAS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11,66\">",
"     11,66",
"    </a>",
"    ]. In one, only 19 and 12 percent of American physicians were uncomfortable after performing PAS or euthanasia, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"     11",
"    </a>",
"    ]. The lower proportion of those feeling uncomfortable after performing euthanasia may reflect the fact that many of these cases were actually termination of life-sustaining treatments rather than true euthanasia. For physicians who regret performing euthanasia or PAS, the regret does not appear to be related to fear of prosecution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the Netherlands show that about one-half of all doctors felt \"comfort\" after performing euthanasia or PAS but that 42 percent report discomfort, specifically emotional uneasiness and burdensomeness [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/77\">",
"     77",
"    </a>",
"    ]. These feelings were more common after euthanasia than after PAS. In addition, 5 percent had doubts (but not regrets) about having performed euthanasia, specifically about whether other treatments should have been tried and the role of relatives in the decision. Physicians reported that recent cases were just as difficult as previous cases, suggesting that performing euthanasia does not make it \"easier.\"",
"   </p>",
"   <p>",
"    A recent study in the Netherlands found similar results examining the experience of primary care physicians, namely feeling tension before performing euthanasia, loss during the procedure, and relief afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/78\">",
"     78",
"    </a>",
"    ]. The report concluded that &ldquo;although it is a very rare occurrence, euthanasia has a major impact on primary care providers. Their relationship with the patient, their loneliness, the role of the family, and pressure from society are the main issues that emerged&rdquo;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF PERFORMING EUTHANASIA AND PAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The public perception about euthanasia and PAS is that they are quick, painless, and guaranteed ways to die. Initial reports from Oregon suggested that \"there were no reported adverse events, although one patient who was still conscious 30 minutes after taking the lethal medication was given more of the medication to take\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/79\">",
"     79",
"    </a>",
"    ]. However, these reports were met with incredulity; no medical procedure, not even phlebotomy, is flawless. Subsequently, descriptions of complications began to appear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/66,77,80,81\">",
"     66,77,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Netherlands, three types of problems have been reported. Minor technical problems such as inability to insert an IV occur in 5 and 10 percent of euthanasia and PAS cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/77\">",
"     77",
"    </a>",
"    ]. Serious complications, such as vomiting up the medications, occur in 3 and 7 percent of euthanasia and PAS cases, respectively. Finally, in 5 percent of euthanasia cases and 15 percent of PAS cases, the patient either did not die or took a very long time to die. In 18 percent of PAS cases, physicians had to intervene to administer a lethal medication, converting them into euthanasia. Other reports, based on physician self reporting, have suggested complication rates of approximately 15 percent among PAS cases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from Oregon and Washington state [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/60,64\">",
"     60,64",
"    </a>",
"    ] confirm that complications do occur. Since 1998 in Oregon, 4.5 percent of PAS administrations had the side-effect of regurgitation, and, it is claimed, that only one patient (out of a total of 460) awoke after taking prescribed medication. In Washington state in 2009, one PAS procedure (out of 36) had the side effect of regurgitation, while 2 of the 36 patients awoke after taking prescribed medication.",
"   </p>",
"   <p>",
"    These data suggest that far from being quick and flawless, euthanasia and PAS (like all other medical interventions) are associated with potential complications. PAS appears to be associated with more complications than euthanasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INVOLUNTARY EUTHANASIA IN NEONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision of when to start and withhold care for severely affected neonates with a poor prognosis is one of the most difficult facing the pediatrician and neonatologist. Even more difficult would be deciding whether and when euthanasia should be considered in the care of the infant who is faced with severe suffering and no hope for improvement. Although neonatal euthanasia is neither a legal nor accepted practice in the United States, there are reported cases of neonatal euthanasia in the Netherlands and Belgium. In approximately 8 percent of deaths that occurred in Dutch infants under one year of age (about 87 deaths), the decision to stop life-sustaining treatments was followed by the \"use of drugs with the explicit intention to hasten death\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/82\">",
"     82",
"    </a>",
"    ]. In 1 percent of all infant deaths (about 11 cases per year), drugs were administered with the intention of ending the infant's life when the infant was not dependent upon life-sustaining interventions.",
"   </p>",
"   <p>",
"    A survey of data on infant euthanasia from the Netherlands between January 1997 and June 2004 examined 22 cases of deliberate termination of life in newborns reported to the public prosecutor for assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/83\">",
"     83",
"    </a>",
"    ]. The survey found that &ldquo;all cases concerned newborns with spina bifida and hydrocephalus, and in all cases, at least two doctors were consulted outside the medical team. In 17 of 22 cases, a multidisciplinary spina bifida team was consulted. All parents consented to the termination of life, and in four cases, parents explicitly requested it&rdquo;. All cases were found by the prosecutor to be in accordance with good practice.",
"   </p>",
"   <p>",
"    In Belgium, in approximately 7 percent of infant deaths \"lethal doses or lethal drugs were administered\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/84\">",
"     84",
"    </a>",
"    ]. The use of lethal medications was significantly more common among neonates under seven days of age, in whom 13 percent of deaths involved lethal medications. In these early cases, many of the infants were born prematurely, and had intracranial hemorrhages, lung hypoplasia, or severe congenital malformations.",
"   </p>",
"   <p>",
"    The use of euthanasia in neonates and infants has led the Dutch to formalize the practice in what is called The Groningen Protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. This protocol requires:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certainty about the diagnosis and prognosis",
"     </li>",
"     <li>",
"      The presence of \"hopeless and unbearable\" suffering",
"     </li>",
"     <li>",
"      A second physician (not directly involved in the management of the patient) must confirm the diagnosis, prognosis and suffering",
"     </li>",
"     <li>",
"      Informed consent provided by both parents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, this protocol is explicitly for infants who are not on life-sustaining interventions, but who have \"a hopeless prognosis and experience what parents and medical experts deem to be unbearable suffering.\" The authors of the protocol acknowledge \"it is difficult to define [such suffering] in the abstract\". They give as an example of the type of patient for whom the protocol was intended, children with the most serious form of spina bifida.",
"   </p>",
"   <p>",
"    For many, the Groningen Protocol represents the very slippery slope they warned about when they opposed legalization of euthanasia and PAS. For others it constitutes humane treatment of patients who are suffering. It certainly is extending the practice of euthanasia to groups that were explicitly excluded in the initial debate about permissibility of euthanasia. Furthermore, it constitutes sanction for nonvoluntary euthanasia.",
"   </p>",
"   <p>",
"    Several issues surrounding this practice have not been addressed by the Dutch. The individual who has the \"most to lose\" is \"never asked\", and therefore, the burden of the decision falls on the surrogate decision makers (the parents) and the child's physician. In contrast to adults, for whom a request for euthanasia prompts an assessment of their mental state and reasons for requesting euthanasia or PAS, such evaluations are not made of the surrogate decision makers. While it is assumed that the parents have the best interests of their child at heart, their opinions and reasoning may be at odds with pediatricians and neonatologists in their roles as patient advocates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Euthanasia and physician-assisted suicide (PAS) are two different concepts. The term euthanasia without a qualifying phrase means voluntary active euthanasia; that is, the physician intentionally ends the patient's life at the patient's request and with the patient's full informed consent. Euthanasia is not legal in any state in the United States. PAS refers to the physician's act of providing medication, a prescription, information, or other interventions to a patient with the understanding that the patient intends to use them to commit suicide. In the United States, this is currently legal only in the states of Oregon, Montana, and Washington State. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Over the last decade there has been a substantial amount of empirical research conducted on euthanasia and PAS in the United States. Many unexpected findings have been revealed that have significantly influenced the public debate (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Attitudes and practices of patients'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of requests for euthanasia or PAS come from patients who have cancer.",
"     </li>",
"     <li>",
"      Public support for euthanasia and PAS is closely linked with the underlying reasons why patients want these interventions. Surveys suggest that the general public supports these interventions only for patients in excruciating unrelieved pain. Pain does not appear to be the primary factor motivating patients to request euthanasia and PAS.",
"     </li>",
"     <li>",
"      Depressive symptoms, hopelessness, and other psychological factors are consistently associated with interest in PAS and euthanasia. However, depressed patients are also more likely to change their minds about wanting PAS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      euthanasia.",
"     </li>",
"     <li>",
"      Despite the fact that these practices are legal in limited jurisdictions (the Netherlands, Belgium, Luxembourg, Switzerland, and three US states [for PAS but not euthanasia]), euthanasia and PAS are practiced globally, albeit at a very low rate. Less than 1 percent of all dying Americans and less than 4 percent of those dying in the Netherlands have these interventions. Rates in other European countries are also below 1 percent (",
"      <a class=\"graphic graphic_table graphicRef58741 \" href=\"UTD.htm?25/20/25932\">",
"       table 7",
"      </a>",
"      ). These low rates suggest that euthanasia and PAS are not seen as methods to improve end of life care for the vast majority of decedents. The current emphasis is on improved symptom control and palliative care for terminally ill patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Responding to a request for PAS or euthanasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians should pursue several avenues when they receive a request for euthanasia or PAS (",
"    <a class=\"graphic graphic_table graphicRef62176 \" href=\"UTD.htm?27/34/28204\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56848 \" href=\"UTD.htm?3/57/3996\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/12/24778/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physician should not take the interest in or explicit request for euthanasia or PAS as final. He or she should inquire about what motivates the request and its timing, and ask if concrete steps have been taken beyond the request, without taking a moral stance. Some patients may be confused about legal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ethical distinctions. Treatment withdrawal, withholding of food and fluids, and aggressive management of symptoms such as pain (even if there is a possibility that death may be hastened by the use of sufficient medication doses to provide symptom relief) do not constitute physician-assisted suicide and are legal. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Practices of American physicians'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physicians should determine what social relationships and supports the patient has, and encourage interactions with family and others. Reassurance should be provided if one of the patient's concerns is that the physician will not be available or might abandon them.",
"     </li>",
"     <li>",
"      While physical symptoms such as pain, fatigue, and dyspnea, have not been consistently associated with interest in and requests for euthanasia or PAS, they should be evaluated and treated as part of high-quality end-of-life care. Hospice and palliative care services may be very helpful in addressing these symptoms for patients who are staying at home. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"       \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"       \"Overview of managing common non-pain symptoms in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Depression and anxiety should be specifically addressed. Consultation with a psychiatrist or psychologist may be indicated to rule out potentially reversible causes of severe symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"       \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"       \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      These interventions may not improve the situation to the point that the patient will no longer desire euthanasia or PAS. As many as 40 percent of patients requesting euthanasia or PAS have already been receiving hospice, suggesting that requests can persist despite efforts at good end of life care. In such circumstances, the physicians must make a personal decision about whether he or she will participate in euthanasia or PAS and whether the patient is an appropriate case.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/1\">",
"      A piece of my mind. It's over, Debbie. JAMA 1988; 259:272.",
"     </a>",
"    </li>",
"    <li>",
"     Kass, L. Neither for love nor money: why doctors must not kill. Public Interest 1989; No.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/3\">",
"      Singer PA, Siegler M. Euthanasia--a critique. N Engl J Med 1990; 322:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/4\">",
"      Quill TE. Death and dignity. A case of individualized decision making. N Engl J Med 1991; 324:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/5\">",
"      Emanuel EJ. Euthanasia. Historical, ethical, and empiric perspectives. Arch Intern Med 1994; 154:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/6\">",
"      Amundsen DW. The physician's obligation to prolong life: a medical duty without classical roots. Hastings Cent Rep 1978; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/7\">",
"      Emanuel EJ. The history of euthanasia debates in the United States and Britain. Ann Intern Med 1994; 121:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/8\">",
"      Verkerk M, van Wijlick E, Legemaate J, de Graeff A. A national guideline for palliative sedation in the Netherlands. J Pain Symptom Manage 2007; 34:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/9\">",
"      Lo B, Rubenfeld G. Palliative sedation in dying patients: \"we turn to it when everything else hasn't worked\". JAMA 2005; 294:1810.",
"     </a>",
"    </li>",
"    <li>",
"     Derived from the EPEC (Education for Physicians on End-of-life Care) project curriculum, module 5: Physician-Assisted Suicide (available online at www.epec.net/EPEC/Webpages/ph.cfm, accessed February 5, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/11\">",
"      Meier DE, Emmons CA, Wallenstein S, et al. A national survey of physician-assisted suicide and euthanasia in the United States. N Engl J Med 1998; 338:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/12\">",
"      Wolfe J, Grier HE, Klar N, et al. Symptoms and suffering at the end of life in children with cancer. N Engl J Med 2000; 342:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/13\">",
"      van der Maas PJ, van der Wal G, Haverkate I, et al. Euthanasia, physician-assisted suicide, and other medical practices involving the end of life in the Netherlands, 1990-1995. N Engl J Med 1996; 335:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/14\">",
"      van der Heide A, Onwuteaka-Philipsen BD, Rurup ML, et al. End-of-life practices in the Netherlands under the Euthanasia Act. N Engl J Med 2007; 356:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/15\">",
"      Bilsen J, Cohen J, Chambaere K, et al. Medical end-of-life practices under the euthanasia law in Belgium. N Engl J Med 2009; 361:1119.",
"     </a>",
"    </li>",
"    <li>",
"     Washington v. Glucksberg 117 S. Ct. 2258 (1997).",
"    </li>",
"    <li>",
"     Vacco v. Quill 117 S. Ct. 2293 (1997).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/18\">",
"      Kamisar Y. On the meaning and impact of the physician-assisted suicide cases. Minn Law Rev 1998; 82:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/19\">",
"      Burt RA. Disorder in the court: physician-assisted suicide and the Constitution. Minn Law Rev 1998; 82:965.",
"     </a>",
"    </li>",
"    <li>",
"     Krischer v. McIver 697 So. 2d 97 (Fla. 1997).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/21\">",
"      Doerflinger RM. An uncertain future for assisted suicide. Hastings Cent Rep 1999; 29:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/22\">",
"      Alpers A, Lo B. Physician-assisted suicide in Oregon. A bold experiment. JAMA 1995; 274:483.",
"     </a>",
"    </li>",
"    <li>",
"     Maine lawmakers reject bill allowing doctor-assisted suicide. New York Times Feb. 12, 1998; 25.",
"    </li>",
"    <li>",
"     Ayers, BD. A rejection on suicide in Michigan. New York Times Nov. 4, 1998; B1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/25\">",
"      Kissane DW, Street A, Nitschke P. Seven deaths in Darwin: case studies under the Rights of the Terminally Ill Act, Northern Territory, Australia. Lancet 1998; 352:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/26\">",
"      Hurst SA, Mauron A. Assisted suicide and euthanasia in Switzerland: allowing a role for non-physicians. BMJ 2003; 326:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/27\">",
"      Rurup ML, Smets T, Cohen J, et al. The first five years of euthanasia legislation in Belgium and the Netherlands: description and comparison of cases. Palliat Med 2012; 26:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/28\">",
"      Watson R. Luxembourg is to allow euthanasia from 1 April. BMJ 2009; 338:b1248.",
"     </a>",
"    </li>",
"    <li>",
"     Roper Center for Public Opinion Research, Storrs, Connecticut collates many polls on this matter.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/30\">",
"      Blendon RJ, Szalay US, Knox RA. Should physicians aid their patients in dying? The public perspective. JAMA 1992; 267:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/31\">",
"      Emanuel EJ, Fairclough DL, Daniels ER, Clarridge BR. Euthanasia and physician-assisted suicide: attitudes and experiences of oncology patients, oncologists, and the public. Lancet 1996; 347:1805.",
"     </a>",
"    </li>",
"    <li>",
"     Gallup. Public divided over moral acceptability of doctor-assisted suicide. May 31, 2007. Available online at file://www.gallup.com/poll/27727/public-divided-over-moral-acceptability-doctorassisted-suicide.aspx (Accessed on January 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/33\">",
"      Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA 2000; 284:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/34\">",
"      Silveira MJ, DiPiero A, Gerrity MS, Feudtner C. Patients' knowledge of options at the end of life: ignorance in the face of death. JAMA 2000; 284:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/35\">",
"      Heilig S. The SFMS euthanasia survey: results and analysis. SF Med 1989; 61:24,34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/36\">",
"      Overmyer M. National survey: physicians' views on the right to die. Physicians Manage 1991; 31:40.",
"     </a>",
"    </li>",
"    <li>",
"     Washington State Medical Association. Initiative 199 WSMA Membership Survey. (Seattle Wash.: Washington State Medical Association March 1991).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/38\">",
"      Crosby C. Internists grapple with how they should respond to requests for aid in dying. Internist 1992; 33:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/39\">",
"      Caralis PV, Hammond JS. Attitudes of medical students, housestaff, and faculty physicians toward euthanasia and termination of life-sustaining treatment. Crit Care Med 1992; 20:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/40\">",
"      Slome L, Moulton J, Huffine C, et al. Physicians' attitudes toward assisted suicide in AIDS. J Acquir Immune Defic Syndr 1992; 5:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/41\">",
"      Fried TR, Stein MD, O'Sullivan PS, et al. Limits of patient autonomy. Physician attitudes and practices regarding life-sustaining treatments and euthanasia. Arch Intern Med 1993; 153:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/42\">",
"      Anderson JG, Caddell DP. Attitudes of medical professionals toward euthanasia. Soc Sci Med 1993; 37:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/43\">",
"      Shapiro RS, Derse AR, Gottlieb M, et al. Willingness to perform euthanasia. A survey of physician attitudes. Arch Intern Med 1994; 154:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/44\">",
"      Cohen JS, Fihn SD, Boyko EJ, et al. Attitudes toward assisted suicide and euthanasia among physicians in Washington State. N Engl J Med 1994; 331:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/45\">",
"      Doukas DJ, Waterhouse D, Gorenflo DW, Seid J. Attitudes and behaviors on physician-assisted death: a study of Michigan oncologists. J Clin Oncol 1995; 13:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/46\">",
"      Bachman JG, Alcser KH, Doukas DJ, et al. Attitudes of Michigan physicians and the public toward legalizing physician-assisted suicide and voluntary euthanasia. N Engl J Med 1996; 334:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/47\">",
"      Lee MA, Nelson HD, Tilden VP, et al. Legalizing assisted suicide--views of physicians in Oregon. N Engl J Med 1996; 334:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/48\">",
"      Back AL, Wallace JI, Starks HE, Pearlman RA. Physician-assisted suicide and euthanasia in Washington State. Patient requests and physician responses. JAMA 1996; 275:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/49\">",
"      Slome LR, Mitchell TF, Charlebois E, et al. Physician-assisted suicide and patients with human immunodeficiency virus disease. N Engl J Med 1997; 336:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/50\">",
"      Portenoy RK, Coyle N, Kash KM, et al. Determinants of the willingness to endorse assisted suicide. A survey of physicians, nurses, and social workers. Psychosomatics 1997; 38:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/51\">",
"      Wolfe J, Fairclough DL, Clarridge BR, et al. Stability of attitudes regarding physician-assisted suicide and euthanasia among oncology patients, physicians, and the general public. J Clin Oncol 1999; 17:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/52\">",
"      Willems DL, Daniels ER, van der Wal G, et al. Attitudes and practices concerning the end of life: a comparison between physicians from the United States and from The Netherlands. Arch Intern Med 2000; 160:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/53\">",
"      Emanuel EJ, Fairclough D, Clarridge BC, et al. Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med 2000; 133:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/54\">",
"      Curlin FA, Nwodim C, Vance JL, et al. To die, to sleep: US physicians' religious and other objections to physician-assisted suicide, terminal sedation, and withdrawal of life support. Am J Hosp Palliat Care 2008; 25:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/55\">",
"      Seale C. Legalisation of euthanasia or physician-assisted suicide: survey of doctors' attitudes. Palliat Med 2009; 23:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/56\">",
"      Prokopetz JJ, Lehmann LS. Redefining physicians' role in assisted dying. N Engl J Med 2012; 367:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/57\">",
"      Deliens L, van der Wal G. The euthanasia law in Belgium and the Netherlands. Lancet 2003; 362:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/58\">",
"      Breitbart W, Rosenfeld BD, Passik SD. Interest in physician-assisted suicide among ambulatory HIV-infected patients. Am J Psychiatry 1996; 153:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/59\">",
"      Suarez-Almazor ME, Newman C, Hanson J, Bruera E. Attitudes of terminally ill cancer patients about euthanasia and assisted suicide: predominance of psychosocial determinants and beliefs over symptom distress and subsequent survival. J Clin Oncol 2002; 20:2134.",
"     </a>",
"    </li>",
"    <li>",
"     Office of Disease Prevention and Epidemiology. Department of Human Services, State of Oregon. Twelfth Annual report on Oregon's Death with Dignity Act, March 10, 2005. file://oregon.gov/DHS/ph/pas/docs/year12.pdf (Accessed on February 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/61\">",
"      Ganzini L, Johnston WS, McFarland BH, et al. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med 1998; 339:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/62\">",
"      Chin AE, Hedberg K, Higginson GK, Fleming DW. Legalized physician-assisted suicide in Oregon--the first year's experience. N Engl J Med 1999; 340:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/63\">",
"      Hedberg K, Hopkins D, Kohn M. Five years of legal physician-assisted suicide in Oregon. N Engl J Med 2003; 348:961.",
"     </a>",
"    </li>",
"    <li>",
"     Washington State Department of Health. 2009 Death with Dignity Act Report. February 2010. Report available online at file://www.doh.wa.gov/dwda/forms/dwda_2009.pdf (Accessed on January 03, 2011).",
"    </li>",
"    <li>",
"     Regionale toetsingcommissies euthanasie. Annual report 2009. Aailable online at file://www.euthanasiecommissie.nl/en/review-committees/annualreport/default.asp (Accessed on January 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/66\">",
"      Emanuel EJ, Daniels ER, Fairclough DL, Clarridge BR. The practice of euthanasia and physician-assisted suicide in the United States: adherence to proposed safeguards and effects on physicians. JAMA 1998; 280:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/67\">",
"      Wilson KG, Scott JF, Graham ID, et al. Attitudes of terminally ill patients toward euthanasia and physician-assisted suicide. Arch Intern Med 2000; 160:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/68\">",
"      Ganzini L, Goy ER, Dobscha SK. Oregonians' reasons for requesting physician aid in dying. Arch Intern Med 2009; 169:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/69\">",
"      Meier DE, Emmons CA, Litke A, et al. Characteristics of patients requesting and receiving physician-assisted death. Arch Intern Med 2003; 163:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/70\">",
"      van der Lee ML, van der Bom JG, Swarte NB, et al. Euthanasia and depression: a prospective cohort study among terminally ill cancer patients. J Clin Oncol 2005; 23:6607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/71\">",
"      Ganzini L, Goy ER, Dobscha SK. Prevalence of depression and anxiety in patients requesting physicians' aid in dying: cross sectional survey. BMJ 2008; 337:a1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/72\">",
"      Ganzini L, Nelson HD, Lee MA, et al. Oregon physicians' attitudes about and experiences with end-of-life care since passage of the Oregon Death with Dignity Act. JAMA 2001; 285:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/73\">",
"      Onwuteaka-Philipsen BD, van der Heide A, Koper D, et al. Euthanasia and other end-of-life decisions in the Netherlands in 1990, 1995, and 2001. Lancet 2003; 362:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/74\">",
"      Onwuteaka-Philipsen BD, Brinkman-Stoppelenburg A, Penning C, et al. Trends in end-of-life practices before and after the enactment of the euthanasia law in the Netherlands from 1990 to 2010: a repeated cross-sectional survey. Lancet 2012; 380:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/75\">",
"      Deliens L, Mortier F, Bilsen J, et al. End-of-life decisions in medical practice in Flanders, Belgium: a nationwide survey. Lancet 2000; 356:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/76\">",
"      van der Heide A, Deliens L, Faisst K, et al. End-of-life decision-making in six European countries: descriptive study. Lancet 2003; 362:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/77\">",
"      Groenewoud JH, van der Heide A, Onwuteaka-Philipsen BD, et al. Clinical problems with the performance of euthanasia and physician-assisted suicide in The Netherlands. N Engl J Med 2000; 342:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/78\">",
"      van Marwijk H, Haverkate I, van Royen P, The AM. Impact of euthanasia on primary care physicians in the Netherlands. Palliat Med 2007; 21:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/79\">",
"      Ganzini L, Nelson HD, Schmidt TA, et al. Physicians' experiences with the Oregon Death with Dignity Act. N Engl J Med 2000; 342:557.",
"     </a>",
"    </li>",
"    <li>",
"     Office of Disease Prevention and Epidemiology. Department of Human Services, State of Oregon. Seventh Annual report on Oregon's Death with Dignity Act, March 10, 2005. egov.oregon.gov/dhs/ph/pas/docs/year7.pdf (Accessed on February 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/81\">",
"      Nuland SB. Physician-assisted suicide and euthanasia in practice. N Engl J Med 2000; 342:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/82\">",
"      Vrakking AM, van der Heide A, Onwuteaka-Philipsen BD, et al. Medical end-of-life decisions made for neonates and infants in the Netherlands, 1995-2001. Lancet 2005; 365:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/83\">",
"      Verhagen AA, Sol JJ, Brouwer OF, Sauer PJ. [Deliberate termination of life in newborns in The Netherlands; review of all 22 reported cases between 1997 and 2004]. Ned Tijdschr Geneeskd 2005; 149:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/84\">",
"      Provoost V, Cools F, Mortier F, et al. Medical end-of-life decisions in neonates and infants in Flanders. Lancet 2005; 365:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/85\">",
"      Verhagen E, Sauer PJ. The Groningen protocol--euthanasia in severely ill newborns. N Engl J Med 2005; 352:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/12/24778/abstract/86\">",
"      Verhagen AA, Sauer PJ. End-of-life decisions in newborns: an approach from The Netherlands. Pediatrics 2005; 116:736.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2203 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24778=[""].join("\n");
var outline_f24_12_24778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRACTICAL GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETHICAL ARGUMENTS FOR AND AGAINST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LEGAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30038480\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ATTITUDES OF THE AMERICAN PUBLIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11516540\">",
"      Deep divisions of opinions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Framing effects in response to questionnaires",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Distinction between euthanasia and PAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ATTITUDES OF PHYSICIANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Predictors of physician support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ATTITUDES AND PRACTICES OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Practices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PRACTICES OF AMERICAN PHYSICIANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physician response to requests for euthanasia or PAS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - How should physicians handle such requests?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - A five-step approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PRACTICES IN THE NETHERLANDS AND BELGIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      IMPACT OF PERFORMING EUTHANASIA OR PAS ON PHYSICIANS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS OF PERFORMING EUTHANASIA AND PAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INVOLUNTARY EUTHANASIA IN NEONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Responding to a request for PAS or euthanasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2203|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/41/11934\" title=\"figure 1\">",
"      Support for euthanasia and PAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/51/22332\" title=\"table 1\">",
"      Definitions euthanasia PAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/60/26573\" title=\"table 2\">",
"      Framing effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/33/18971\" title=\"table 3\">",
"      Variation in public support PAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/34/28204\" title=\"table 4\">",
"      Response to euthanasia requests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/57/3996\" title=\"table 5\">",
"      NCCN guidelines PAS request",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/13/39132\" title=\"table 6\">",
"      Euthanasia PAS Netherlands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/20/25932\" title=\"table 7\">",
"      Euthanasia PAS Europe",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./palliative-sedation?source=related_link\">",
"      Palliative sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_12_24779="Incidence inborn errors";
var content_f24_12_24779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of some inborn errors of metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Biotinidase deficiency",
"       </td>",
"       <td>",
"        1 in 72,000 to 1 in 126,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital adrenal hyperplasia",
"       </td>",
"       <td>",
"        1 in 12,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital hypothyroidism",
"       </td>",
"       <td>",
"        1 in 3,600 to 1 in 5,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"       <td>",
"        1 in 2,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Galactosemia",
"       </td>",
"       <td>",
"        1 in 60,000 to 1 in 80,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homocystinuria",
"       </td>",
"       <td>",
"        1 in 50,000 to 1 in 150,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"       <td>",
"        1 in 250,000 to 1 in 400,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"       <td>",
"        1 in 10,000 to 1 in 25,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease",
"       </td>",
"       <td>",
"        1 in 2,800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis",
"       </td>",
"       <td>",
"        1 in 1,000 to 1 in 8,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tyrosinemia",
"       </td>",
"       <td>",
"        1 in 19,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24779=[""].join("\n");
var outline_f24_12_24779=null;
var title_f24_12_24780="Disorders of fatty acid oxidation";
var content_f24_12_24780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F86411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F86411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders of fatty acid oxidation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorders",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acylcarnitine profile abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine uptake defect",
"       </td>",
"       <td>",
"        &darr; Free (C0) carnitine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short chain acyl-CoA dehydrogenase (SCAD) deficiency",
"       </td>",
"       <td>",
"        &uarr; Butyryl (C4) carnitine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short chain hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency",
"       </td>",
"       <td>",
"        &uarr; 3-hydroxybutyryl (C4-OH) carnitine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medium chain acyl-CoA dehydrogenase (MCAD) deficiency",
"       </td>",
"       <td>",
"        <p>",
"         &uarr; Octanoyl (C8) carnitine",
"        </p>",
"        <p>",
"         &uarr; Decanoyl (C10) carnitine",
"        </p>",
"        &uarr; Decenoyl (C10:1) carnitine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency",
"       </td>",
"       <td>",
"        <p>",
"         &uarr; Tetradecenoyl (C14:1) carnitine",
"        </p>",
"        <p>",
"         &uarr; Tetradecanoyl (C14) carnitine",
"        </p>",
"        <p>",
"         &uarr; Tetradecendioyl (C14:2) carnitine",
"        </p>",
"        &uarr; C12 C12:1 &amp; C16, frequently",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         &uarr; Hydroxypalmitoyl (C16-OH) carnitine",
"        </p>",
"        <p>",
"         &uarr; Hydroxyhexadecenoyl (C16:1-OH) carnitine",
"        </p>",
"        <p>",
"         &uarr; Hydroxysteryl (C18-OH) carnitine",
"        </p>",
"        &uarr; Hydroxyoleyl (C18:1-OH) carnitine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trifunctional protein (TFP) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine palmitoyltransferase II (CPTII) deficiency",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         &uarr; Palmitoyl (C16) carnitine",
"        </p>",
"        <p>",
"         &uarr; Steryl (C18) carnitine",
"        </p>",
"        &uarr; Oleyl (C18:1) carnitine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine-acylcarnitine translocase (CACT) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine palmitoyltransferase I (CPTI) deficiency",
"       </td>",
"       <td>",
"        &uarr; Free (C0) carnitine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple acyl-CoA dehydrogenase deficiency (glutaric acidemia type II)",
"       </td>",
"       <td>",
"        &uarr; In multiple non-hydroxylated acylcarnitines",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    List of common fatty acid oxidation disorders and associated acylcarnitine abnormalities. Note that the first newborn screen is most useful for diagnosis and that acylcarnitine profiles may be normal for milder phenotypes when not acutely ill. Additionally for some of the longer chain disorders (eg, VLCAD &amp; CPTII) further testing, such as DNA mutation analysis, may be required to establish a diagnosis definitively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24780=[""].join("\n");
var outline_f24_12_24780=null;
var title_f24_12_24781="Protein structure ghrelin";
var content_f24_12_24781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Protein structure of ghrelin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 210px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the octanoyl group on the serine residue at position three. This fatty acid modification is necessary for biological activity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24781=[""].join("\n");
var outline_f24_12_24781=null;
var title_f24_12_24782="Mallory Weiss clot Endosc";
var content_f24_12_24782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mallory-Weiss tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy shows a Mallory-Weiss tear with an adherent clot at the apex of the tear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24782=[""].join("\n");
var outline_f24_12_24782=null;
var title_f24_12_24783="Drugs that affect sleep in children";
var content_f24_12_24783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected drugs with effects on sleep and wakefulness in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sleep and wakefulness effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alteration of sleep pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selective serotonin reuptake inhibitors (SSRIs)*",
"       </td>",
"       <td>",
"        Depression, anxiety, panic disorder",
"       </td>",
"       <td>",
"        Fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram",
"       </td>",
"       <td>",
"        Insomnia, daytime sleepiness, akathisia. Exceptions: paroxetine and fluvoxamine are relatively sedating.",
"       </td>",
"       <td>",
"        SSRIs may decrease total sleep time and increase awakenings, particularly during initiation of treatment. May also prolong latency to and decrease overall REM sleep",
"        <sup>",
"         [1-4]",
"        </sup>",
"        . Abrupt withdrawal of short acting SSRIs may worsen insomnia.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Serotonin and norepinephrine reuptake inhibitors (SNRIs)*",
"       </td>",
"       <td>",
"        ADHD, autism, depression, pain",
"       </td>",
"       <td>",
"        Venlaflaxine, duloxetine",
"       </td>",
"       <td>",
"        Insomnia, daytime sleepiness, akathisia.",
"       </td>",
"       <td>",
"        SNRIs may decrease total sleep time and increase awakenings, particularly during initiation of treatment. May also prolong latency to and decrease overall REM sleep",
"        <sup>",
"         [1-4]",
"        </sup>",
"        . Abrupt withdrawal of short acting SNRIs may worsen insomnia.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Serotonin-2 receptor antagonists/reuptake inhibitors (SARIs)",
"       </td>",
"       <td>",
"        Depression, adjunct to SSRI or SNRI to improve sleep",
"       </td>",
"       <td>",
"        Trazodone, nefazodone, mirtazapine",
"       </td>",
"       <td>",
"        Sedation, increased sleep time.",
"       </td>",
"       <td>",
"        SARIs may increase total sleep time and increase deep (N3) sleep",
"        <sup>",
"         [2-4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Aminoketones*",
"       </td>",
"       <td>",
"        ADHD, depression, fatigue",
"       </td>",
"       <td>",
"        Bupropion",
"       </td>",
"       <td>",
"        Insomnia, agitation.",
"       </td>",
"       <td>",
"        Aminoketones may alter REM density and activity, and cause abnormal dreams",
"        <sup>",
"         &bull;",
"        </sup>",
"        .",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Tricyclic and tetracyclics*",
"       </td>",
"       <td rowspan=\"2\">",
"        Depression, pain, enuresis",
"       </td>",
"       <td>",
"        More sedating: amitriptyline, doxepin, nortriptyline, clomipramine",
"       </td>",
"       <td>",
"        Sedation, daytime sleepiness. Increased total sleep time in non-depressed patients.",
"       </td>",
"       <td>",
"        When dosed in evening these drugs can shorten sleep latency, decrease awakenings, prolong REM latency and reduce REM sleep",
"        <sup>",
"         [2,3]",
"        </sup>",
"        . Clomipramine is a potent suppressor of REM sleep",
"        <sup>",
"         [4]",
"        </sup>",
"        . Antihistaminic and antimuscarinic side effects may cause daytime sedation and altered cognition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        More activating: desipramine, trimipramine, protriptyline",
"       </td>",
"       <td>",
"        Insomnia, daytime sleepiness, akathisia (motor restlessness).",
"       </td>",
"       <td>",
"        These drugs may prolong REM latency and suppress REM sleep (potentially beneficial in depressed patients). They also may cause increased wakefulness and decreased total sleep time, particularly during the intitial weeks of treatment",
"        <sup>",
"         [2,4]",
"        </sup>",
"        . Antihistaminic and antimuscarinic side effects may cause daytime sedation and altered cognition.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Monoamine oxidase inhibitors (MAOIs)*",
"       </td>",
"       <td>",
"        Refractory depression, Parkinson disease",
"       </td>",
"       <td>",
"        Isocarboxazid",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , phenelzine",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , moclobemide, tranylcypromine",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , selegiline, rasagiline",
"       </td>",
"       <td>",
"        Insomnia, daytime sleepiness.",
"       </td>",
"       <td>",
"        MAOIs cause nearly complete suppression of REM sleep, which is potentially beneficial in severely depressed patients. They also cause increased awakenings and decreased total sleep time",
"        <sup>",
"         [2,4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Seizures, anxiety, muscle relaxant, nausea/vomiting",
"       </td>",
"       <td>",
"        Lorazepam, diazepam",
"       </td>",
"       <td>",
"        Daytime sedation. Worsening of sleep-related breathing disorders. Rebound insomnia upon abrupt withdrawal.",
"       </td>",
"       <td>",
"        Benzodiazepines cause reduced sleep latency, increase total sleep time, reduce awakenings, suppress deep (N3) sleep and alter REM density",
"        <sup>",
"         [4]",
"        </sup>",
"        . Long-acting agents are associated with more day-time hangover. Short-acting agents are associated with rebound insomnia when withdrawn.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Stimulants",
"       </td>",
"       <td>",
"        ADHD, narcolepsy",
"       </td>",
"       <td>",
"        Methylphenidate, dextroamphetamine",
"       </td>",
"       <td>",
"        Insomnia. Increased wakefulness. Rare reports of disturbed sleep, nightmares, hallucinations.",
"       </td>",
"       <td>",
"        These stimulants prolong latency of sleep onset, reduce total sleep time and decrease deep (N3) sleep time",
"        <sup>",
"         [4,6]",
"        </sup>",
"        . The negative effects on sleep may be caused by the direct stimulant effect of these medications as well as rebound of ADHD symptoms as the dose wears off.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Selective norepinephrine reuptake inhibitor",
"       </td>",
"       <td>",
"        ADHD",
"       </td>",
"       <td>",
"        Atomoxetine",
"       </td>",
"       <td>",
"        Somnolence or insomnia. Increased wakefulness. Sleep disturbance, abnormal dreams. Among pediatric patients in clinical trials somnolence reported more frequently than insomnia.",
"       </td>",
"       <td>",
"        Among pediatric patients with ADHD, atomoxetine caused less delay in sleep latency and less reduction in total sleep time than methylphenidate",
"        <sup>",
"         [6]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Anticonvulsants",
"       </td>",
"       <td rowspan=\"2\">",
"        Epilepsy, bi-polar disorder, migraine prophylaxis, neuropathic pain",
"       </td>",
"       <td>",
"        Phenytoin, valproate, carbemazepine, topiramate, gabapentin",
"       </td>",
"       <td>",
"        Somnolence. Daytime sleepiness.",
"       </td>",
"       <td>",
"        This group tends to decrease sleep latency and REM sleep (except gabapentin); they also may increase deep (N3) sleep",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigene, tiagabine, felbamate, levetiracetam",
"       </td>",
"       <td>",
"        Increased wakefulness. Administer early in day.",
"       </td>",
"       <td>",
"        This group may increase deep (N3) sleep and improve sleep efficiency (levetiracetam)",
"        <sup>",
"         &bull;",
"        </sup>",
"        .",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Antipsychotics (first generation)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Bipolar disorder, psychomotor agitation, schizophrenia",
"       </td>",
"       <td>",
"        Haloperidol, thioridazine, chlorpromazine",
"       </td>",
"       <td>",
"        Daytime sedation especially chlorpromazine and thioridazine.",
"       </td>",
"       <td>",
"        This drug class tends to decrease sleep latency, cause fewer awakenings and increase total sleep time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics (second generation)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Aripirazole, clozapine, olanzapine, quetiapine risperidone, ziprasidone",
"       </td>",
"       <td>",
"        Daytime sedation. Aripiprazole is least sedating. Clozapine, quetiapine and olanzapine are most sedating.",
"       </td>",
"       <td>",
"        Olanzapine, ziprasidone and risperidone suppress REM sleep, increase deep (N3) sleep and improve sleep continuity",
"        <sup>",
"         [1,4]",
"        </sup>",
"        ; they may counteract detrimental effects of certain SSRIs on sleep",
"        <sup>",
"         [1]",
"        </sup>",
"        . Sleep improvements are attributed to 5HT-2A/2C receptor blockade.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Alpha-2 agonists",
"       </td>",
"       <td>",
"        Hypertension, ADHD, pain, migraine prophylaxis",
"       </td>",
"       <td>",
"        Clonidine, methyldopa",
"       </td>",
"       <td>",
"        Daytime sedation.",
"       </td>",
"       <td>",
"        These drugs cause decreased latency of sleep onset and partial suppression of REM sleep",
"        <sup>",
"         [4,5]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Beta-antagonists",
"       </td>",
"       <td>",
"        Hypertension, heart failure",
"       </td>",
"       <td>",
"        Proranolol",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , metoprolol, nadolol, atenolol",
"       </td>",
"       <td>",
"        Disturbed sleep, insomnia, nightmares, hallucinations",
"        <sup>",
"         [5]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Beta-antagonists tend to suppress REM sleep. The lipophilic beta-antagonists (eg, propranolol, labetalol) may cause more sleep disturbance than hydrophilic agents (eg, atenolol)",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Beta-agonists (inhaled)",
"       </td>",
"       <td>",
"        Inhaled bronchodilator",
"       </td>",
"       <td>",
"        Inhaled albuterol (salbutamol), salmeterol",
"       </td>",
"       <td>",
"        Long acting forms appear to improve sleep in asthmatics.",
"       </td>",
"       <td>",
"        The long-acting forms of these drugs tend to increase sleep time including deep (N3) sleep in asthmatics, due to control of nocturnal asthma symptoms",
"        <sup>",
"         [4,5]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Methylxanthines",
"       </td>",
"       <td>",
"        Bronchodilation, antiinflammatory (asthma)",
"       </td>",
"       <td>",
"        Theophylline, aminophylline",
"       </td>",
"       <td>",
"        Insomnia. Increased wakefulness.",
"       </td>",
"       <td>",
"        Methylxanthines tend to delay sleep latency, increase awakenings, and decrease total sleep time. They do not improve total sleep time or sleep quality of asthmatics",
"        <sup>",
"         [4,5]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HMG CoA reductase (hydroxymethylglutaryl CoA reductase) inhibitors or statins",
"       </td>",
"       <td>",
"        Hypercholesterolemia",
"       </td>",
"       <td>",
"        Simvastatin, lovastatin, pravastatin",
"       </td>",
"       <td>",
"        Reports of disturbed sleep and nightmares.",
"       </td>",
"       <td>",
"        These effects are limited to case descriptions and are not well documented.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Glucocorticoids",
"       </td>",
"       <td>",
"        Immunosuppression, anti-inflammatory, anti-emetic",
"       </td>",
"       <td>",
"        Dexamethasone, prednisone, prednisolone",
"       </td>",
"       <td>",
"        Insomnia, increased wakefulness and fatigue.",
"       </td>",
"       <td>",
"        Glucocorticoids tend to decrease total sleep time, and may decrease deep (N3) sleep time. REM sleep suppression is reported with certain glucocorticoids",
"        <sup>",
"         &bull;",
"        </sup>",
"        .",
"        <sup>",
"         [5]",
"        </sup>",
"        These effects are dose-related and PM dosing may cause greater sleep disturbance.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Antihistamines (first generation)",
"       </td>",
"       <td rowspan=\"2\">",
"        Allergic rhinitis, pruritus, anti-emetic",
"       </td>",
"       <td>",
"        Diphenhydramine, hydroxyzine, doxylamine, promethazine",
"       </td>",
"       <td>",
"        Daytime sleepiness may result in decreased night sleep time, increased awakenings.",
"       </td>",
"       <td>",
"        These drugs are associated with decreased sleep latency and fewer night awakenings in adolescents and adults, but may cause paradoxical excitation in young children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines (second generation)",
"       </td>",
"       <td>",
"        Loratadine, cetirizine, fexofenadine",
"       </td>",
"       <td>",
"        Few effects on sleep or wakefulness at moderate doses. Daytime sleepiness at higher dosing.",
"       </td>",
"       <td>",
"        Effects on sleep are minimized because there is little CNS penetration with usual dosing for seasonal allergies. Cetirizine may be more sedating.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Opioid analgesics",
"       </td>",
"       <td>",
"        Analgesia",
"       </td>",
"       <td>",
"        Morphine, hydromorphone, oxycodone, methadone",
"       </td>",
"       <td>",
"        Daytime sleepiness and fatigue. Dose related worsening of sleep related respiratory disorders. Insomnia and disturbed sleep if abrupt withdrawal.",
"       </td>",
"       <td>",
"        These drugs increase night awakenings and decrease deep (N3) and REM sleep. Chronic methadone has fewer effects on sleep",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Decongestants",
"       </td>",
"       <td>",
"        Cold and allergy symptoms",
"       </td>",
"       <td>",
"        Phenylephrine, pseudoephedrine",
"       </td>",
"       <td>",
"        Insomnia, anxiety, agitation.",
"       </td>",
"       <td>",
"        These drugs cause decreased total sleep time and increased awakenings. Systemic decongestants are generally not recommended in pediatric patients.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Specific effects of medication on sleep and wakefulness in children will vary depending on drug dose, time of administration, time-released formulation, age of child, and relevant co-morbidity such as depression, anxiety, ADHD, psychoses or underlying sleep disorder. Much of the information in this table is based on data from adults, and scant information is available about effects in children.",
"    <div class=\"footnotes\">",
"     ADHD: attention deficit/hyperactivity disorder; REM sleep: rapid eye movement sleep; N3 sleep: deep non-REM sleep, also known as slow wave sleep, considered important for restorative function of sleep.",
"     <br>",
"      * Agents in these classes may precipitate or exacerbate night-time movement disorders (eg, bruxism, restless legs). Effects on sleep and wakefulness can differ between depressed and non-depressed patients. For additional information, see UpToDate topic: Initial treatment of depression in adults, table \"Side effects of antidepressant medications.\"",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Conflicting or limited data.",
"       <br>",
"        &Delta; Agents associated with more prominent sleep effects. No data for linezolid.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         For additional information see UpToDate topic reviews: First-generation antipsychotic medications; and Second-generation antipsychotic medications: Pharmacology, administration and comparative side effects.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Sharpley AL, et al. Olanzapine increases slow-wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005; 66:450.",
"       </li>",
"       <li>",
"        Wilson S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005; 65:927.",
"       </li>",
"       <li>",
"        Holshoe JM. Antidepressants and sleep: a review. Perspect Psychiatr Care 2009; 45:191.",
"       </li>",
"       <li>",
"        Roux FJ, Kryger MH. Medication effects on sleep. Clin Chest Med 2010; 31:397.",
"       </li>",
"       <li>",
"        Novak M, Shapiro CM. Drug-induced sleep disturbances: focus on nonpsychotropic mediations. Drug Saf 1997; 16:133.",
"       </li>",
"       <li>",
"        Gruber R. Sleep characteristics of children and adolescents with attention deficit-hyperactivity disorder. Child Adolesc Psychiatric Clin N Am 2009; 18:863.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_12_24783=[""].join("\n");
var outline_f24_12_24783=null;
             